Papel de C3G y p38α en la regulación de la migración, invasión tumoral en carcinoma de colon. Función de fibulina 3 by Priego Bendeck, Neibla
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE FARMACIA 
Departamento de Bioquímica y Biología Molecular II 
TESIS DOCTORAL
Papel de C3G y p38α en la regulación de la migración, 
invasión  y crecimiento tumoral en carcinoma de colon. 
Función de fibulina 3 
Role of C3G and p38α in the regulation of migration, 
invasion and tumoral growth in colon carcinoma.
 Function of fibulin 3 
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
PRESENTADA POR 
Neibla Priego Bendeck 
Directora 
Almudena Porras Gallo 
Madrid, 2016 
© Neibla Priego Bendeck, 2016 
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE FARMACIA 
DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA 
MOLECULAR II 
PAPEL DE C3G Y p38 EN LA REGULACIÓN 
DE LA MIGRACIÓN, INVASIÓN Y 
CRECIMIENTO TUMORAL EN CARCINOMA 
DE COLON. FUNCIÓN DE FIBULINA 3 
ROLE OF C3G AND p38 IN THE 
REGULATION OF MIGRATION, INVASION 
AND TUMORAL GROWTH IN COLON 
CARCINOMA. FUNCTION OF FIBULIN 3 
TESIS DOCTORAL 
NEIBLA PRIEGO BENDECK 
Madrid, 2016 
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE FARMACIA 
DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA 
MOLECULAR II 
El presente trabajo ha sido realizado en el Departamento de 
Bioquímica y Biología Molecular II de la Facultad de Farmacia de la 
Universidad Complutense de Madrid, bajo la dirección de la Dra. 
Almudena Porras Gallo.  
Este trabajo ha sido posible gracias a la financiación del Ministerio 
de Educación, Cultura y Deporte mediante la concesión de beca de 
Formación del Profesorado Universitario (FPU) para realizar la 
Tesis doctoral. Asimismo, el trabajo ha sido financiado a través de 
los proyectos del Ministerio de Ciencia e Innovación SAF-2010-
20198-C02-01 y SAF-2013-48210-C2-2-R.  
OPTA AL GRADO DE DOCTOR CON MENCIÓN EUROPEA: 
Neibla Priego Bendeck
  
 
 
A mi familia 
  
  
 
 
AGRADECIMIENTOS 
 
 Me di cuenta de lo que quería hacer “de mayor” escuchando la explicación de cómo se 
sintetiza una proteína. Desde ese momento y hasta el día de hoy, en el que escribo los 
agradecimientos de mi Tesis doctoral, he disfrutado aprendiendo y trabajando en el 
laboratorio. Durante esta etapa de doctorado, he tenido la suerte de conocer a muchas 
personas y de poder contar con otras que siempre han estado y siempre estarán ahí. 
A todos ellos, quiero darles las gracias. 
Tengo que empezar agradeciendo a mi directora de tesis, Almudena. Muchas gracias 
por haber confiado en mí durante estos años. Gracias por preguntarme qué tenía 
pensado hacer al terminar la carrera, aún me acuerdo de cuando entré por primera vez 
en tu despacho. Y muchas gracias por abrirme las puertas de tu laboratorio. Gracias 
por tu dedicación y por todo lo que me has enseñado. Por tus consejos, por ayudarnos 
tanto y sacar lo mejor de nosotros. Gracias por hacer de este un buen grupo en los 
buenos y en los malos tiempos. 
Gracias a todos los profesores del departamento, ha sido un placer haber podido 
trabajar aquí. Gracias a Arancha, a Blanca, a Marga y como no a César por toda su 
paciencia con las cuantis. Sois un gran grupo, gracias por toda vuestra ayuda estos 
años. En especial a Fernando Escrivá por ser tan buen profesor y por su amabilidad y 
ayuda. A María Jesús Miró, por abrirme las puertas del departamento por primera vez 
para realizar la beca de excelencia, nunca pensé que la palabra apoptosis iba a ser 
tan importante. Por supuesto a Pilar y a Manuel, por su ayuda y su dedicación diaria al 
departamento y a todos los que hemos pasado por él. 
Me gustaría agradecer a las personas que me enseñaron desde el primer día, a Rebe, 
a Ana y en especial a María. A Dani por llegar al labo y cambiarlo todo, mil veces 
gracias. Eres un gran compañero y un gran amigo. Y a Celia por todos los buenos 
momentos, las risas, el apoyo, los desahogos y tu gran ayuda siempre. Siempre voy a 
recordar con mucho cariño los días buenos y los días en los que no nos salía nada, 
pero entre los tres, terminábamos sacando la parte divertida a cualquier situación. 
Gracias a nuestras vecinas, a AnnaLisa y a Laura. Muchas gracias por hacerme sentir 
tan bien día a día, por la ayuda y el cariño. Por todos los buenos ratos dentro y fuera 
del laboratorio. Y a todas las personas que han pasado por el grupo de hígado, Nerea, 
María, nuestra italiana, te echamos de menos Silvia, y sobre todo a Dora y a Ami por 
enseñarme. Y por supuesto a Diego, me alegro de como te van las cosas, te lo 
mereces. Gracias a todas las personas que han pasado por el 15, Sara, Jakub, Edu y 
a los más peques por esta última etapa: Sara, Isa, José Luis y Roberta. Espero de 
corazón que este primer contacto, os haya estimulado para seguir en esto porque 
merece la pena y creo que vais por buen camino todos. 
Al grupo de “las Margas” con las que no llegué a coincidir mucho, pero siempre 
estaban ahí para ayudar. A los compis del 21, los que estuvieron y los que están. A 
Silvia, Gemma y Elena. A Oscar y Almu, gracias por estar siempre dispuestos a echar 
una mano. A Alberto por ser un modelo de investigador y a Carlos porque contagia su 
amor por la ciencia. A Ana que es una currante, estoy segura de que todo el esfuerzo 
va a tener una gran recompensa. A Lily por ayudarme en momentos difíciles y siempre 
escucharme. Gracias por nuestras charlas en cultivos. A Nuri, un ejemplo, espero que 
te vaya todo genial. A Vane, espero que todo salga muy bien, y a Sabe que es un sol, 
 ya no queda nada chicas. A Diana, a Bea y a Yoli. También quiero agradecer a Alberto 
Morán el estar siempre disponible y por haberme preguntado un día si conocía a 
alguna amiga que estuviera buscando trabajo en oficina de farmacia. A las chicas de 
cáncer por haberme ayudado tantísimo, Tamara, Irene y Jackie (compañera de fatigas 
en cultivos) y a los compis del otro lado del pasillo, a Juan, a Ester y a Elisa.  
Y a todas las personas que permiten que las cosas funcionen día a día en el 
departamento. Gracias a Lourdes por todo lo que le he dado la lata estos años y a 
Manoli por alegrarnos los días grises.  
Tengo que agradecer la oportunidad de hacer una estancia en el Centro de 
Investigación del Cáncer de Salamanca. Muchísimas gracias a Carmen por acogerme 
con tanto cariño en su grupo y por enseñarme. Gracias también a Chema por toda su 
ayuda y dedicación. A Ana, que fue mucho más que una compañera de laboratorio. 
Gracias por haberte convertido en mi gran amiga, por tantas y tantas horas de charla. 
Y gracias por seguir siéndolo. Tengo un viaje pendiente este año. A las Saras. A Sara 
Ortiz, mi profe, que aunque estuvo poco tiempo conmigo, tuvo mucha paciencia y me 
enseño mucho. Gracias además por ser una anfitriona genial en las noches de 
Salamanca. Y a Sara Gutiérrez, una gran compañera. Muchas gracias por todo y 
suerte en tu etapa como mamá. Gracias Víctor, Patri, Arturo y Jose Antonio, da gusto 
trabajar con personas como vosotros. Gracias a todas las personas que trabajan en el 
CIC, por hacernos las cosas tan fáciles, en especial a la gente que trabaja en el 
servicio de microscopía. Gracias a mis compis de piso, a Alfonso y a Bob, fue una 
sorpresa encontrar a unos compañeros como vosotros a los que puedo llamar amigos. 
Y gracias en especial a la gran familia de Quimera, a mi Rober, a Vero, a Pili, a Sara, a 
Isa, a Eva…hicisteis que mi experiencia fuera increíble, gracias de corazón. Gracias 
también a Bea por todas esas comidas en el CIC y por descubrirme lo bonito que es 
ver bailar tango. 
También tuve la gran oportunidad de realizar una estancia en Bélgica, otra experiencia 
que no voy a olvidar. Gracias en especial a Juanjo. Gracias por aceptar que fuera 
contigo a Lovaina, por ayudarme y darme alas en el laboratorio, he aprendido mucho 
contigo. Por ser un anfitrión de los que no quedan y por todos los buenos momentos 
durante la estancia.  
Thanks to my Belgium family, Marcella and Rob. Thank you for being so nice and 
friendly since the very beginning. You have helped me a lot. Many thanks to all the 
people I met in the Department of Imaging and Pathology. Thank you for teaching me, 
being patient and always helpful. For all the good moments, sport days and Harry 
Potter nights. Thanks Nathalie, Julie, Linde, Sarah, Emilie, Francesca, An, Daphne, 
Bart, Peter, Sophie, Olivier, An-kathrien and Kathleen. 
Gracias a la gente que he podido conocer gracias a los congresos y a los viajes 
durante estos años. A Juan, Enrique y Bea, sé que me dejo a mucha gente. Y a 
Nienke por las conversaciones en los momentos de bajón que siempre conseguían 
hacerme reír.  
A mis chicos del máster, a Celia, a Juan y a Julia. Gracias por las cañas de desahogo 
y por las risas, pasara lo que pasara, hemos conseguido no tirar la toalla. Y a mi 
 doctora, a Ire, una gran amiga, aunque estos años hayas estado lejos. Siempre puedo 
contar contigo, gracias por entenderme tan bien. 
Gracias a Alberto y a su familia que fue un poquito la mía también. Gracias por 
ayudarme a conocerme a mí misma y a aprender a querer. Sobre todo gracias por 
traer a mi vida a un grupo de personas maravillosas y a las que agradezco que 
decidieran seguir formando parte de mi camino. Gracias a mis Chipies porque, pese a 
no vernos todo lo que nos gustaría, siempre han estado ahí para mí, dándome apoyo y 
consejo cuando más lo he necesitado. Sois geniales chicas.  
Gracias a mis amigos, a mis botis. Algo tan simple como la inicial de un apellido puede 
resultar en una amistad de diez años. Sin vosotros, mucho de esto no habría sido 
posible. Porque habéis estado ahí en lo bueno, en lo malo y en lo peor. Pero también 
habéis estado en los momentos geniales y hay muchísimos. Gracias Ana por tantos 
momentos buenos, merecieron el tiempo de espera. Porque pasar por Talavera 
siempre me saca una sonrisa. Muchísima suerte en esta etapa, es un placer volver a 
tenerte cerquita. Gracias Patri, porque aun me acuerdo de las clases de inmuno 
juntas, de las horas interminables tomando apuntes y de las risas después de clase. 
Estoy segura de que vas a ser tan buena científica, como amiga y como amiga, te 
mereces un Nobel. Te deseo toda la felicidad del mundo en esta etapa con Rafa. 
Gracias Miguel por ser tan buen amigo, por tus llamadas, por los viajes, los gofres y 
las risas. Gracias por encontrar a Patri, vais a ser muy felices. Gracias Cris, 
compañera de aventuras por el mundo, gracias por hacernos ver que si quieres algo 
hay que ir a por ello y que el esfuerzo tiene recompensa. Gracias por tu amistad. 
Gracias María Astu, son muchos años y muchos momentos, gracias por conocer 
Madrid mejor que ningún madrileño, por intentar poner orden porque somos un 
desastre y por cuidarnos. Gracias Pablo porque siempre sabes transmitirnos tu buen 
rollo, gracias por ser tan generoso con nosotros y gracias por quererla. Os echamos 
de menos. Gracias Mery porque siempre has sido una gran amiga, porque me has 
querido como soy. Porque me has escuchado quejarme muchísimas veces cuando he 
tenido un mal día y porque nos hemos reído a carcajadas muchísimas veces más. 
Gracias Kilian por ser parte de nuestra familia de botis, me alegro mucho de haber 
estado presente cuando apareció “el muchacho”. Gracias también a los que ya no 
vemos tanto, pero estuvieron ahí durante la carrera, porque Farmacia no es fácil y todo 
se hace menos complicado con gente buena a tu lado. Gracias Bea, Felipe, Elena y 
Argeme. Gracias también a todos los compis de prácticas y de fatigas durante esos 
años. 
Gracias a mis chicas de la uni. Tengo mucha suerte de teneros pese a todo. Son ya 
muchos años de viajes, de noches de fiesta, de días de salir de tranquis a tomar algo y 
que se vaya de las manos y sobre todo de momentos en los que he necesitado contar 
con vosotras y os he tenido a mi lado. Gracias a Pili, que va a ser la novia más guapa, 
a Delfi porque es única, a Lau por todos los días en que llegábamos tardísimo a comer 
por quedarnos hablando en el metro de Argüelles, a Ojitos porque siempre saca un 
rato de donde no lo tiene para estar con nosotras, a nuestra Alemani, estoy segura de 
que te va a ir genial de nuevo en España, a Noe por ser tan buena compi de cuarto, a 
Patri y nuestros momentos “Sandro Rey” y a mi súper profe de autoescuela, Sari. 
También a Moni y a Mery, con las que he compartido tantos buenos momentos. 
 Muchas gracias a esas amigas que han crecido conmigo. Porque ellas me conocen, 
en lo bueno y en lo malo y me aceptan y por eso las quiero tanto. Gracias a Sarah, por 
los juegos en el recreo y en casa de una y de la otra. Gracias por el reencuentro y por 
haber querido que estuviera presente en tu unión con Peter. Gracias por haber estado 
y por estar en mi vida. Gracias a Thais porque es la definición de amiga. Porque se 
puede contar contigo, gracias por saber siempre qué decir cuando tengo un problema. 
Y muchas gracias Verito. Gracias por haberme acompañado en este camino que a 
veces se ha hecho tan largo. Gracias por tus ánimos y por acordarte de mí cuando te 
necesito. Para mí siempre vamos a ser tú y yo en las vistis escuchando El Canto del 
Loco.  
Gracias en especial a ti, Javi. Has sido una parte muy importante en este empujón 
final.  Gracias por los consejos y por tu ayuda. Gracias por aguantarme cuando no me 
aguanto ni yo, por sacarme mis mejores sonrisas y por hacerme tan feliz. 
Sobre todo gracias a mi familia: a mis tías y tíos y a mis primas y primos, a los que 
estáis cerca y a los que estáis lejos. Porque soy como soy por vosotros, mi familia. 
A mi tía María Elena, un ejemplo de mujer fuerte y a mis primos Pepe y Carlos. A mi 
prima Elena, siempre con esa sonrisa enorme que se contagia. También al primo Borja 
y a las nuevas adquisiciones Anja, Nito y Carlotita, por alegrarme con vuestras fotos 
muchas mañanas de laboratorio. A mi tía Estrella, a Antonio y a Isra, mi compañero de 
juegos y empujones. A la tía María Jesús y a Manolo, gracias por llenar vuestra casa 
de cariño y paciencia estos últimos años. A la tía Sara que tanto me cuida, a Ceci, 
Jesús, Miguel y Eva, siempre me acuerdo con muchísimo cariño de vosotros. Y en 
especial a Ana porque estoy segura de que se está convirtiendo en una gran mujer. A 
la tía Ester y a Paco, siempre lejos, pero cerca y ahora quizá un poco más. 
A mi tía Lola en el recuerdo porque me encanta mirar sus fotos en blanco y negro. A 
mi primo Fran, por esos veranos en Londres aprendiendo a cocinar y chapurreando 
inglés. Gracias por cuidarnos en la distancia, incluso en los malos momentos. Gracias 
a mi tío Juan, la persona más culta que creo que podré conocer jamás, gracias por 
ayudarme durante todos estos años y por quererme. Gracias a Ana y a Paula por los 
buenos momentos que nos habéis hecho pasar. 
Gracias a mis abuelas a las que he perdido por el camino para llegar hasta aquí, pero 
que siguen conmigo porque me acuerdo de ellas cada día.  
Gracias Anita. Gracias por ser así. Por ser tan buena (no hay otra palabra) y por 
cuidarnos tanto. Gracias por pensar siempre en todos, por ser tan generosa. Te 
mereces ser muy feliz. Eres una parte fundamental de mi vida y un apoyo 
incondicional, sin ti mucho de esto no habría sido posible. Gracias a tu familia por todo.  
Y gracias a mis padres, Carlos y Rosa, sin ellos no habría podido llegar hasta aquí. 
Muchas gracias papá. Tú me has conducido hasta aquí. Gracias por obligarme a 
tirarme por el tobogán cuando me daba miedo y gracias por guiarme 20 años después, 
aunque nos costara muchas discusiones. Estos años han sido muy difíciles. Muchos 
 cambios que dan miedo. Mucha mala suerte. Pero también mucha buena suerte. Lo 
más bonito que me has podido decir, es que estás orgulloso de mi.  
Muchas gracias mamá. No hay forma de agradecer todo lo que has hecho por mí 
durante este tiempo. Por las conversaciones telefónicas interminables, por tus 
esfuerzos para que llegue hasta aquí, por apoyarme, por hacerme sentir tan querida y 
por dejarme quererte tanto.  
  
  
 
 
 
 
ABREVIATIONS  
  
5A2dC: 5-Aza-2´-deoxicytidine  
ADAM: -disintegrin and metalloproteinase 
Akt:  AK strain Transforming; v-Akt murine thymoma viral oncogene homolog 1 
APC: Adenomatous Polyposis Coli protein 
ASK1: Apoptosis Signal Regulating Kinase 1  
AT: Anaphylatoxin 
ATF-1/2/6: Activating Transcription Factor 1/2/6  
Bax: BCL2-Associated X protein  
Bcr: Breakpoint Cluster Region protein 
BiP: Binding immunoglobulin Protein 
C/EBP: CCAAT-enhancer-binding proteins  
C3G: Crk SH3-domain-binding Guanine-nucleotide-releasing factor 
c-Abl: Belson murine leukemia viral oncogene homolog (mammal) 
CAFs: Cancer Associated Fibroblasts 
CASP5: Caspase 5, Apoptosis-Related Cysteine Peptidase 
cbEGF: Calcium-binding EGF (Epidermal Growth Factor)  
CCP: Complement Control Protein  
Cdc42: Cell division cycle 42-related protein kinase  
c-DNA: Complementary DNA  
CHOP: C/EBP homologous protein  
CML Chronic Myeloid Leukemia  
CO2: Carbon dioxide 
COX-2: Cyclooxigenase-2  
CpG: Cytosine-phosphate-Guanine 
CRC: Colorectal Cancer 
CSAIDs: pyridinyl imidazole anti-inflammatory drugs  
CT: Threshold Cycle 
CTNNB1: Catenin (cadherin-associated protein), beta 1 
CXCL12: Chemokine (C-X-C motif) Ligand 12 
CXCR4: Chemokine (C-X-C motif) Receptor 4 
Dab2: Disabled-2  
DCC: Deleted in Colorectal Carcinoma protein 
DMEM: Dulbecco’s Modified Eagle Medium  
DMSO: Dimethyl sulfoxide  
DNA: Deoxyribonucleic acid  
DNMTs: DNA Methyl Transferases  
DNRap1: Dominant negative Rap1  
DTCs: Disseminated Tumour Cells  
DTT: Dithiothreitol  
ECM Extracellular Matrix  
EDTA: Ethylenediaminetetraacetic acid  
eEF2: Eukaryotic Elongation Factor 2 
EFEMP-1: EGF-containing fibulin-like extracellular matrix protein 1  
EGF: Epidermal Growth Factor  
EGFR: Epithelial Growth Factor (EGF) receptor 
EGTA: Ethylene Glycol-bis (2-aminoethylether)-N,N,N’,N’ tetraacetic acid 
EMT: Epithelial-Mesenchymal Transition  
ERKs: Extracellular Signals Regulated Kinases  
  
ES: Embryonic Stem  
FA: Focal Adhesion  
FAK: Focal Adhesion Kinase  
FAP: Familial Adenomatous Polyposis  
FBS: Fetal Bovine Serum  
FC-domain: Fibulin-like domain  
FGF: Fibroblast Growth Factor  
FoxC2: Forkhead Box C2 
FoxO: Forkhead Box O  
GADD153: Growth arrest and DNA damage inducible 153 protein 
GAPs: GTPase-Activating Proteins 
GC-rich regions: Guanine-Cytosine-rich regions  
GEF: Guanine Nucleotide Exchange Factor  
GH: Growth Hormone  
GK: Guanylate Kinase 
GLUT4: Glucose Transporter Type 4  
Gly: Glycine 
Grb2: Growth Factor Receptor-bound Protein 2  
GSK3β: Glycogen Synthase Kinase 3β  
H2O2: Hydrogen peroxide  
HBP1 High mobility group-box protein 1  
Hck: hemopoietic cell kinase  
HGF: Hepatocyte Growth Factor  
HIF-1: Hypoxia Inducible Factor  
HNPCC: Hereditary Nonpolyposis Colorectal Cancer  
Hsp27: Heat-shock protein 27  
HuR: Human antigen R  
ID4: Inhibitor of DNA binding 4 
IGF-1/2: Insulin-like Growth Factor 1/2 
IL-1/IL-3/ IL-4/ IL-6/IL-8: Interleukin-1/3/4/6/8 
IRF8: Interferon Regulatory Factor 8  
JNK: c-Jun N-terminal Kinases  
KDa: Kilo Dalton  
LPS: Lipopolysaccharide  
LSC: Lung Stem Cells  
MAP: MUTYH-Associated Polyposis  
MAPK: Mitogen Activated Protein Kinases  
MBD: Methyl-CpG-Binding Domain  
MEF2: Myocyte Enhance Factor 2 
MEFs: Mouse Embryonic Fibroblasts  
Met:  Met Tyrosine Kinase Receptor  
MET: Mesenchymal–Epithelial Transition  
MITF1: Microphthalmia-Associated Transcription Factor 1 
MK2/MAPKAP-K2: MAPK-Activated Protein Kinases 2  
MKK: MAP Kinase Kinase  
MKKK: MAPK Kinase Kinase  
MKP: MAP Kinase Phosphatases  
MLK: Mixed Lineage Kinase  
  
MMPs: Matrix Metalloproteases 
MNK1: MAP Kinase Interaction Protein Kinase  
mRNA: Messenger Ribonucleotic Acid  
MSCs: Mesenchymal Stem Cells 
MSK: Mitogen and Stress activated Kinase  
mTORC1: Mammalian Target of Rapamycin Complex 1  
NFAT: Nuclear Factor of Activated T-cells  
NF-kB: Nuclear Factor Kappa-light-chain-enhancer of activated B cells 
NP40: Nonidet P-40  
PBS: Phosphate Buffered Saline  
PCR: Polymerase Chain Reaction  
PDGF: Platelet-Derived Growth Factor  
PDXs: Patient Derived Xenografts  
PDZ:  Post Synaptic Density protein (PSD95), Drosophila Disc Large tumor suppressor 
(Dlg1) and Zonula Occludens-1 protein (ZO-1)  
PFA: Paraformaldehyde  
PI3K: Phosphatidylinositol 3-Kinase  
PMSF: Phenylmethanesulfonylfluoride  
PP2A/C: Protein Phosphatase 2A/C  
PSD95: Postsynaptic Density Protein 95 
PTHLH: Parathyroid Hormone-Like Hormone  
PTP: Protein Tyrosine Phosphatase  
Rac: Ras-Related C3 botulinum toxin  
Rap1: Ras-related protein 1  
Ras: Rat Sarcoma virus  
REM: Ras-Exchange-Motif  
Rheb: Ras Homolog Enriched in Brain  
Rho: Ras Homolog  
Rit: Ras-like protein in tissues 
ROS: Reactive Oxygen Species  
RT: Room Temperature 
RT-qPCR: Quantitative PCR  
SAP-1, SAP-90, SAP-95, SAP-97: Secreted Aspartyl Proteinase-1, -90, -95, -97 
SDF-1: Stromal Cell-Derived Factor 1 
SDS: Sodium Docecyl Sulphate  
S.E.M.: Standard Error of the Mean 
Ser: Serine  
SFRP: Secreted Frizzled-Related Protein 
SH2/3: Src Homology 2/3  
shRNA: short hairpin RNA 
SIP1: Smad Interacting Protein 1 
SOD: Superoxide Dismutase  
TAB-1: TAK1-binding protein 1  
TAK-1: Transforming growth factor beta-activated protein kinase 1  
TBS: Tris Buffered Saline 
TCR: T-Cell Receptor  
TGFβ: Tumour Growth Factor beta  
Thr: Threonine  
  
TIMPs: Inhibitors of Metalloproteases  
TNF: Tumour Necrosis Factor alpha  
TRAF6: TNF receptor-associated factor 6, E3 ubiquitin protein ligase 
TWEAK: Tumor necrosis factor-like weak inducer of apoptosis 
Tyr: Tyrosine  
WASP: The Wiskott–Aldrich Syndrome protein 
Wip1: WASP-Interacting Protein 1 
ZEB 1/2: Zinc finger E-box binding homeobox 1/2 
ZO-1/2/3: Zona Occuldens proteins -1/2/3 
 1 
 
 
 
 
 
INDEX 
 
1 
 PAGE 
INTRODUCTION 
1. COLORECTAL CANCER ...................................................................................... 3
2. p38 MAPKs ............................................................................................................ 5
2.1 GENERALITIES .................................................................................................. 5 
2.2 FUNCTIONS ....................................................................................................... 8 
2.2.1 Inflammation ................................................................................................. 9 
2.2.2 Differentiation ................................................................................................ 9 
2.2.3 Stemness ...................................................................................................... 9 
2.2.4 Development ................................................................................................. 9 
2.2.5 Proliferation ................................................................................................... 9 
2.2.6 Cell death...................................................................................................... 9 
2.2.7 Adhesion ..................................................................................................... 10 
2.2.8 Migration and invasion ................................................................................ 10 
2.2.9 Senescence ................................................................................................ 10 
2.2.10 Cancer: ..................................................................................................... 10 
2.3 p38 MAPK IN CANCER ..................................................................................... 11 
2.4 p38 MAPK CROSS-TALK WITH OTHER SIGNALING PATHWAYS ................. 13 
3. C3G ..................................................................................................................... 15
3.1 GENERALITIES ................................................................................................ 15 
3.2 FUNCTIONS ..................................................................................................... 17 
4. FIBULINS ............................................................................................................ 19
4.1 GENERALITIES ................................................................................................ 19 
4.2 FIBULIN 3 ......................................................................................................... 20 
5. CELL ADHESION, MIGRATION AND INVASION. GENERALITIES .................... 21
5.1 EXTRACELLULAR MATRIX AND MATRIX METALLOPROTEASES  (MMPs)  23 
5.2 ROLE OF p38 MAPKs IN ADHESION, MIGRATION AND INVASION ............... 26 
5.3 ROLE OF C3G IN ADHESION, MIGRATION AND INVASION .......................... 27 
6. EPITHELIAL-MESENCHYMALTRANSITION ...................................................... 28
7. STROMAL REGULATION IN CANCER ............................................................... 31
8. EPIGENETIC REGULATION AND DNA-METHYLASES ..................................... 32
8.1 EPIGENETIC: DNA METHYLATION ................................................................. 32 
8.2 DNA METHYLTRANSFERASES (DNMTs) ....................................................... 33 
1 
GROUP BACKGROUND 
1. FUNCTION OF p38 PATHWAY IN CELL DEATH. CROSSTALK WITH C3G .... 37
2. ROLE OF p38 MAPK IN THE REGULATION OF APOPTOSIS IN THE HUMAN
COLON CARCINOMA HCT116 CELL LINE ............................................................... 39 
3. FUNCTION OF p38 MAPK IN CELL ADHESION AND MIGRATION. NEW
TARGETS OF p38 .................................................................................................... 40 
AIMS .......................................................................................................................... 42 
MATERIALS AND METHODS 
1. CELL LINES ........................................................................................................ 44
1.1 Fibulin 3 knock-down: ........................................................................................ 44 
1.2 C3G permanent knock-down: ............................................................................ 45 
1.3 Rap1 permanent knock-down: ........................................................................... 45 
1.4 Re-expression of DNMT3A: ............................................................................... 45 
2. CELL CULTURE CONDITIONS AND PRESERVATION ...................................... 46
2.1 Cell culture conditions ....................................................................................... 46 
2.2 Freezing, cryopreservation and thawing of cells ................................................ 46 
2.3 Cell treatments    ............................................................................................... 46 
3. PROTEIN ANALYSIS .......................................................................................... 47
3.1 Preparation of cell extracts ................................................................................ 47 
3.2 Protein quantification ......................................................................................... 47 
3.3 Western-blot analysis ........................................................................................ 47 
3.3.1 Proteins electrophoresis .............................................................................. 47 
3.3.2 Proteins transfer.......................................................................................... 48 
3.3.3 Proteins immunodetection ........................................................................... 49 
4. ANALYSIS OF mRNA EXPRESSION .................................................................. 50
4.1 Total RNA isolation ............................................................................................ 50 
4.2 c-DNA synthesis ................................................................................................ 50 
4.3 Quantitative PCR ............................................................................................... 50 
5. ADHESION, MIGRATION AND INVASION ASSAYS........................................... 51
5.1 Adhesion assay ................................................................................................. 51 
5.2 Wound healing assay ........................................................................................ 52 
5.3 Invasion assay................................................................................................... 52 
6. QUANTIFICATION OF MMP2 AND MMP9 ACTIVITIES BY ZYMOGRAPHY ...... 53
7. ANALYSIS OF CELL VIABILITY AND APOPTOSIS ............................................ 53
7.1 Analysis of cell viability ...................................................................................... 53 
7.2 Analysis of anoikis ............................................................................................. 53 
1 
8. TUMORIGENESIS STUDIES .............................................................................. 54
8.1 Anchorage dependent growth ............................................................................ 54 
8.2 Anchorage independent growth ......................................................................... 54 
8.3 Xenografts assays ............................................................................................. 54 
8.4 Sphere formation assays ................................................................................... 54 
9. CONFOCAL MICROSCOPY ANALYSIS ............................................................. 55
9.1 F-actin staining .................................................................................................. 55 
9.2 Immunofluoresccence analysis of E-cadherin and ZO-1 subcellular localization 55 
10. ANALYSIS OF TUMORS FROM XENOGRAFTS ................................................. 55
10.1  Immunohistochemistry analysis ...................................................................... 56 
10.2  Inmunofluorescence analysis ......................................................................... 56 
10.3 Tunel assay ..................................................................................................... 57 
11. STATISTICAL ANALYSIS ..................................................................................... 57
RESULTS 
1. p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION THROUGH
METHYLATION OF DNA REGULATORY SEQUENCES. ROLE IN MIGRATION, 
INVASION AND TUMOR GROWTH ........................................................................... 59 
1.1 p38 MAPK down-regulates fibulin 3 expression in HCT116 cells ..................... 59 
1.2 p38 MAPK down-regulates fibulin 3 expression through methylation of DNA 
regulatory sequences .............................................................................................. 60 
1.3 Fibulin-3 knock-down inhibits migration and invasion of HCT116 cells .............. 63 
1.4 Mechanisms involved in the regulation of cell migration and invasion by Fibulin 3 
in HCT116 cells. Role of p38/β .............................................................................. 66 
1.5 Role of Fibulin 3 in the tumorigenic capacity of HCT116 cells ............................ 68 
2. C3G REGULATES CELL ADHESION, MIGRATION AND INVASION THROUGH
DOWN-REGULATION OF p38 MAPK ACTIVITY BY A MECHANISM NOT 
MEDIATED BY RAP1. INVOLVEMENT IN TUMOR GROWTH .................................. 71 
2.1 C3G inhibits cell migration and invasion of HCT116 cells through down-regulation 
of p38 activity by a mechanism not mediated by Rap1. Function in cell adhesion . 72 
2.2 Role of MMPs as mediators of C3G effects on cell invasion .............................. 78 
2.3 Mechanisms involved in the regulation of migration and invasion by C3G and 
p38 ........................................................................................................................ 80 
2.4 Role of C3G in the regulation of the tumorigenic capacity of HCT116 cells ....... 86 
2.5 Mechanisms involved in the regulation of tumor growth by C3G and p38 ........ 92 
1 
 DISCUSSION 
1. p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION THROUGH DNA
METHYLATION. ROLE IN MIGRATION, INVASION AND TUMOR GROWTH ......... 100 
2. C3G REGULATES CELL ADHESION, MIGRATION AND INVASION THROUGH
DOWN-REGULATION OF p38 MAPK ACTIVITY BY A MECHANISM NOT 
MEDIATED BY RAP1. INVOLVEMENT IN TUMOR GROWTH ................................ 104 
3. GENERAL DISCUSSION .................................................................................. 109
CONCLUSIONS ....................................................................................................... 112 
REFERENCES ......................................................................................................... 115 
ABSTRACT .............................................................................................................. 151 
REUMEN .................................................................................................................. 158 
APPENDIX ............................................................................................................... 165 
 1 
 
INDEX OF TABLES AND FIGURES 
                                                                                                                                PAGE 
INTRODUCTION 
 
1. COLORECTAL CANCER 
FIGURE 1: PROGRESSION OF COLORECTAL CANCER .......................................... 5 
 
2. p38 MAPK         
FIGURE 2: p38 MAPK SIGNALING PATHWAY ............................................................ 7 
FIGURE 3: ROLES OF p38 MAPKS IN TUMOR PROGRESSION ............................. 13 
 
3. C3G  
FIGURE 4: C3G STRUCTURE  .................................................................................. 16 
FIGURE 5: C3G INTERACTING PARTNERS AND FUNCTIONS ............................... 18 
 
4. FIBULINS     
FIGURE 6: FIBULINS STRUCTURE  ......................................................................... 19 
 
5. MIGRATION, INVASION, ADHESION AND MMPs      
FIGURE 7: DOMAIN STRUCTURE OF THE MAMMALIAN MMP FAMILY ................. 25 
 
6. EMT      
FIGURE 8: SCHEMATIC REPRESENTATION OF EMT PROCESS STEPS .............. 28 
TABLE 1: EMT MARKERS  ........................................................................................ 30 
 
8. EPIGENETIC REGULATION AND DNA-METHYLASES           
FIGURE 9: DNA METHYLATION OF CPG ISLANDS AT PROMOTERS IMPAIRS 
TRANSCRIPTIONAL ACTIVATION ............................................................................ 33 
FIGURE 10: SCHEMATIC REPRESENTATION OF THE STRUCTURE OF HUMAN 
DNMTs ....................................................................................................................... 34 
 
GROUP BACKGROUND 
 
FIGURE 11: REGULATION OF APOPTOSIS BY C3G AND RAP1 THROUGH p38 
MAPK ......................................................................................................................... 37 
FIGURE 12: p38 PROTECTS FROM H2O2-INDUCED CELL DEATH ....................... 38 
FIGURE 13: CISPLATIN-INDUCED p53/ ROS/p38 MAPK CASCADE ..................... 39 
 
MATERIALS AND METHODS 
 
TABLE 2: CHARACTERISTICS OF HCT116 CELL   .................................................. 44 
TABLE 3: SDS-PAGE AND ANDERSON GELS COMPOSITION ............................... 48 
TABLE 4: PRIMARY AND SECONDARY ANTIBODIES USED FOR WESTERN-BLOT 
 ................................................................................................................................... 49 
TABLE 5: PRIMERS SEQUENCES USED IN QUANTITAVE PCR  ........................... 51 
FIGURE 14: SCHEMATIC PROTOCOL OF INVASION ASSAY THROUGH MATRIGEL
 ................................................................................................................................... 52 
 1 
 
RESULTS 
 
p38 MAPK down-regulates fibulin 3 expression through methylation of DNA regulatory 
sequences. Role in migration, invasion and tumor growth 
 
1.1 p38 MAPK down-regulates fibulin 3 expression in HCT116 cells 
FIGURE 15: p38 MAPK IS A NEGATIVE REGULATOR OF FIBULIN 3 EXPRESSION 
IN HCT116 CELLS ..................................................................................................... 60 
 
1.2 p38 MAPK down-regulates fibulin 3 expression through methylation of DNA 
regulatory sequence 
FIGURE 16: p38 DOWN- REGULATES FIBULIN 3 EXPRESSION THROUGH DNA 
METHYLATION .......................................................................................................... 61 
FIGURE 17: DNMT3A EXPRESSION CORRELATES WITH FIBULIN 3 DOWN-
REGULATION. REGULATION BY p38… ................................................................. 62 
 
1.3 Fibulin-3 knock-down inhibits migration and invasion of HCT116 cells 
FIGURE 18: FIBULIN 3 KNOCK-DOWN INHIBITS MIGRATION OF HCT116 CELLS 
EXPRESSING p38 ................................................................................................... 64 
FIGURE 19: FIBULIN 3 KNOCK-DOWN INHIBITS MIGRATION OF HCT116 CELLS 
EXPRESSING p38 ................................................................................................... 65 
FIGURE 20: EFFECT OF FIBULIN 3 KNOCK-DOW REDUCES INVASION IN HCT116 
CELLS EXPRESSING p38 
 ................................................................................................................................... 66 
 
1.4 Mechanisms involved in the regulation of cell migration and invasion by 
Fibulin 3 in HCT116 cells. Role of p38/β 
FIGURE 21: EFFECT OF FIBULIN 3 KNOCK-DOWN ON MMP2 AND 9 ACTIVITIES 67 
FIGURE 22: INHIBITION OF MMPs PREVENTS INVASION OF HCT116 CELLS ..... 67 
FIGURE 23: EFFECT OF FIBULIN 3 KNOCK-DOWN ON p38 SIGNALING PATHWAY
 ................................................................................................................................... 68 
FIGURE 24: FIBULIN 3 KNOCK-DOWN INHIBITS FOCUS FORMATION ................. 69 
FIGURE 25: FIBULIN 3 AND p38 KNOCK-DOWN INHIBIT ANCHORAGE 
INDEPENDENT GROWTH OF HCT116 CELLS 
 ................................................................................................................................... 70 
FIGURE 26: FIBULIN 3 AND p38 KNOCK-DOWN INHIBIT IN VIVO HCT116 CELLS 
TUMOR GROWTH 
 ................................................................................................................................... 71 
 
C3G regulates cell adhesion, migration and invasion through down-regulation of p38 
MAPK activity by a mechanism not mediated by Rap1. Involvement in tumor growth 
 
2.1 C3G inhibits cell migration and invasion of HCT116 cells through down-
regulation of p38 activity by a mechanism not mediated by Rap1. Function in 
cell adhesion 
FIGURE 27: C3G LEVELS IN DIFFERENT COLORECTAL CANCER CELL LINES 
 ................................................................................................................................... 72 
FIGURE 28: EFFECT OF C3G KNOCK-DOWN ON DIFFERENT SIGNALING 
PATHWAYS ............................................................................................................... 73 
FIGURE 29: C3G KNOCK-DOWN ENHANCES MIGRATION OF HCT116 CELLS 
THROUGH A MECHANISM DEPENDENT ON p38 ................................................. 74 
FIGURE 30: C3G KNOCK-DOWN ENHANCES MIGRATION OF HCT116 CELLS 
THROUGH A MECHANISM NOT MEDIATED BY RAP1 ............................................ 75 
FIGURE 31: EFFECT OF C3G, p38 AND RAP1 KNOCK-DOWN ON ADHESION ... 76 
 1 
 
FIGURE 32: C3G SILENCING PROMOTES INVASION OF HCT116 CELLS BY A 
MECHANISM MEDIATED BY p38 ............................................................................ 77 
FIGURE 33: C3G SILENCING PROMOTES INVASION OF HCT116 CELLS BY A 
MECHANISM NOT MEDIATED BY RAP1 
 ................................................................................................................................... 78 
 
2.2 Role of MMPs as mediators of C3G effects on cell invasion 
FIGURE 34: EFFECT OF C3G AND p38 KNOCK-DOWN ON DIFFERENT MMPs 
EXPRESSION ............................................................................................................ 79 
FIGURE 35: EFFECT OF C3G, p38 AND RAP1 KNOCK-DOWN ON MMP2/9 
ACTIVITIES 
 ................................................................................................................................... 80 
 
2.3 Mechanisms involved in the regulation of migration and invasion by C3G and 
p38 
FIGURE 36: EFFECT OF C3G KNOCK-DOWN IN E-CADHERIN LEVELS AND 
SUBCELLULAR LOCALIZATION IN HCT116 CELLS. FUNCTION OF p38 MAPK 
 ................................................................................................................................... 81 
FIGURE 37: EFFECT OF C3G KNOCK-DOWN IN ZO-1 PROTEIN LEVELS AND 
SUBCELLULAR LOCALIZATION IN HCT116 CELLS. FUNCTION OF p38 MAPK 
 ................................................................................................................................... 82 
FIGURE 38: EFFECT OF C3G KNOCK-DOWN IN N-CADHERIN EXPRESSION IN 
HCT116 CELLS. FUNCTION OF p38 MAPK 
 ................................................................................................................................... 83 
FIGURE 39: EFFECT OF C3G AND p38 KNOCK-DOWN ON THE EXPRESSION OF 
TRANSCRIPTION FACTORS INVOLVED IN EMT ..................................................... 84 
FIGURE 40: EFFECT OF C3G KNOCK-DOWN ON ACTIN-ORGANIZATION IN 
HCT116 CELLS .......................................................................................................... 85 
 
2.4 Role of C3G in the regulation of the tumorigenic capacity of HCT116 cells 
FIGURE 41: C3G AND p38 MAPK PROMOTE ANCHORAGE DEPENDENT 
GROWTH OF HCT116 CELLS ................................................................................... 87 
FIGURE 42: RAP1 INHIBITS ANCHORAGE DEPENDENT GROWTH OF HCT116 
CELLS 
 ................................................................................................................................... 88 
FIGURE 43: C3G AND p38 MAPK PROMOTE TUMOR GROWTH IN VITRO OF 
HCT116 CELLS .......................................................................................................... 89 
FIGURE 44: RAP1 DOES NOT PROMOTE TUMOR GROWTH IN VITRO OF HCT116 
CELLS 
 ................................................................................................................................... 90 
FIGURE 45: C3G AND p38 MAPK PROMOTE TUMOR GROWTH IN VIVO OF 
HCT116 CELLS .......................................................................................................... 91 
 
2.5 Mechanisms involved in the regulation of tumor growth by C3G and p38   
FIGURE 46: EFFECT OF C3G AND p38 KNOCK-DOWN ON CELL VIABILITY ...... 93 
FIGURE 47: ANALYSIS OF E-CADHERIN AND ZO-1 ................................................ 94 
FIGURE 48: ANALYSIS OF CELL DEATH ................................................................. 95 
FIGURE 49: ANALYSIS OF INFILTRATED CELLS IN TUMORS ............................... 96 
FIGURE 50: EFFECT OF C3G AND p38 KNOCK-DOWN ON DIFFERENT 
STROMAL REGULATION FACTORS EXPRESSION ................................................. 97 
FIGURE 51: EFFECT OF C3G AND p38 KNOCK-DOWN ON SPHERE FORMATION
 ................................................................................................................................... 98 
 
 
 1 
 
DISCUSSION 
 
FIGURE 52: p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION 
REGULATING CELL MIGRATION, INVASION AND TUMOR GROWTH IN HCT116 
CELLS  
 ................................................................................................................................. 103 
FIGURE 53: ROLE OF C3G/p38 CASCADE IN THE CONTROL OF CELL 
MIGRATION, INVASION AND TUMOR GROWTH OF HCT116 CELLS ................... 108 
FIGURE 54: CROSSTALK BETWEEN p38, FIBULIN 3 AND C3G IN THE 
REGULATION OF MIGRATION, INVASION AND TUMOR GROWTH IN HCT116 
CELLS ...................................................................................................................... 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
 
 
 
 
INTRODUCTION  
 
INTRODUCTION 
2 
 
 
1. COLORECTAL CANCER 
 
Cancer is a class of complex diseases that includes more than 100 types and it is 
characterized by an uncontrolled cell growth and survival. Tumorigenesis in humans 
involves several alterations in cell physiology that drive to malignant transformation, 
which is characterized by self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of programmed cell death, limitless replicative potential, 
sustained angiogenesis and metastatic tissue invasion (Hanahan and Weinberg 2000). 
Colorectal cancer (CRC) represents the third most common cancer type and the 
second leading cause of cancer-related death in the western world. It remains a major 
cause of cancer mortality in the developed world, due largely to its propensity to 
metastasize.  
CRC results from the accumulation of both acquired genetic and epigenetic changes 
that transform normal glandular epithelium into adenocarcinoma (Lao and Grady 2011). 
It includes a broad spectrum of forms according to the stage, going from non-neoplastic 
to neoplastic polyps (adenomatous polyps and adenomas) and invasive CRC. The 
most common type is the adenocarcinoma which accounts for 95% of cases, although 
other rarer types such as lymphoma and squamous cell carcinoma can also develop. 
They are predominantly epithelial-derived tumors (Sameer 2013). 
Sporadic colorectal carcinomas, devoid of any familial or inherited predisposition, 
account for approximately 70% of colorectal cancers and are generated probably as a 
result of dietary and environmental factors as well as normal aging (Sameer 2013). 
Inherited colorectal carcinomas represent approximately 5 to 10% of colorectal 
cancers. The most common ones are familial adenomatous polyposis (FAP), an 
autosomal dominant syndrome characterized by more than 100 colorectal adenomas. 
FAP is due to a pathogenic mutation in Apc. Another inherited polyposis syndrome is 
MUTYH-associated polyposis (MAP), an autosomal recessive cause of multiple 
colorectal adenomas originated by mutations in the DNA glycosylase MUTYH, which is 
involved in the repair of mispaired bases. MUTYH protects against mutations in 
different genes such as Apc and K-ras, critical in colorectal cancer. Other type of 
inherited CRC is the hereditary nonpolyposis colorectal cancer (HNPCC), also called 
Lynch syndrome, which is caused by mutations in DNA repair genes, MLH1 and MSH2 
(Haggar and Boushey 2009, Worthley and Leggett 2010, Sameer 2013). The least 
understood CRC is known as familial colorectal carcinomas and accounts up to 25% of 
colorectal cancers (Sameer 2013). 
There are several risk factors for developing CRC, for example, a low fiber and high fat 
diet, obesity or heavy alcohol consumption. Inflammatory intestinal conditions such as 
those occurring in Chrohn’s disease and inflammatory bowel disease favor CRC 
development (Haggar and Boushey 2009). 
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Morson described the polyp-cancer sequence in which adenocarcinomas arise from 
pre-existing adenomatous polyps (Morson 1974). Then, Vogelstein proposed a model 
whereby colorectal cancer proceeds through a series of morphological steps due to 
specific genetic alterations, as shown in figure 1. The premises of this model are that 
the mutational activation of oncogenes and/or the inactivation of tumor suppressor 
genes result in colorectal carcinogenesis and at least four or five genes of a cell must 
undergo somatic mutations so as to get malignantly transformed. The model 
emphasizes the central role of the adenomatous polyp as the precursor lesion and 
provides evidence that in the majority of colorectal cancers the primary event is the 
aberrant activation of the APC/β-catenin pathway, followed by ras/raf mutations and 
loss of p53 function at later stages. However, nowadays only 7% of CRCs have been 
shown to bear mutations in all of these three genes. The genetic changes that occur in 
the origin of the tumor result in uninhibited cell growth, proliferation and clonal tumor 
development. The additive and accumulative effect of these somatic mutations has 
been shown to be the cause of sporadic colorectal cancer. The model also states that 
the characteristics of the tumor are dependent upon the accumulation of multiple 
genetic mutations rather than the sequence of mutations of the genes involved 
(Pancione et al. 2012, Sameer 2013). 
Three different pathogenic pathways have been implicated in the development of 
colorectal cancer. And recently an alternative serrated pathway has been proposed. 
The traditional models for these tumors are: 
1-Predominant chromosomal instability pathway: Approximately 70%-85% of 
CRCs develop through chromosomal instability pathway. It results from the 
accumulation of numerical or structural chromosomal abnormalities by loss of 
heterozygosity, homozygous deletion, chromosomal rearrangements and aneuploidy 
(Hanahan and Weinberg 2000, Worthley and Leggett 2010, Lao and Grady 2011, 
Sameer 2013). It generally occurs within inherited tumors, such as familial 
adenomatous polyposis (FAP), but it has also been associated with the majority of 
sporadic CRCs (Lao and Grady 2011). 
The chromosomal instability  pathway is associated with the sequential deregulation of 
tumor suppressor genes and oncogenes such as Apc, K-ras, dcc/Smad4 and p53 
(Pancione, Remo et al. 2012). Inactivation of Apc leads to activation of the 
Wingless/Wnt pathway, a common mechanism for initiating the polyp to cancer 
progression sequence (Worthley and Leggett 2010, Lao and Grady 2011). Other 
frequent mutations involve K-ras or B-raf, which occurs in approximately 55–60% of 
CRCs, leading to aberrant ERKs activation that induces proliferation and survival. p53 
gene (TP53) is also frequently mutated or lost, being a late event in the transition 
adenoma to adenocarcinoma. Mutations in genes that regulate transforming growth 
factor β (TGFβ) signaling pathway are also important (Worthley and Leggett 2010, Lao 
and Grady 2011). 
2-Pure microsatellite instability pathway: Microsatellite instability is responsible for 
the Lynch syndrome and 15–20% of sporadic tumors and it also occurs in patients with 
ulcerative colitis (Worthley and Leggett 2010, Pancione et al. 2012, Sameer 2013). 
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Microsatellites are short nucleotide repeat sequences scattered throughout the 
genome. DNA polymerase is particularly susceptible to making errors when copying 
these sequences leading to microsatellite instability. It is mainly caused by inactivation 
of DNA mismatch repair genes: hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1 and 
2 (Worthley and Leggett 2010, Lao and Grady 2011). Therefore, there is a dramatic 
increase in genetic errors in genes implicated in colorectal carcinogenesis such as 
tgfbr2, bax, casp5, ctnnb1, Apc, igf2, and e2f4 (Worthley and Leggett 2010). 
3-The CpG island methylator phenotype pathway: The subtype of colorectal cancer 
called CpG island methylator phenotype is associated with a high frequency of 
methylated genes (Lao and Grady 2011). It accounts for approximately 15% of 
sporadic cases and they are usually characterized by an advanced pathology and a 
poor clinical outcome (Worthley and Leggett 2010, Lao and Grady 2011). It includes 
sporadic microsatellite instability cancers that occur sporadically in the context of MLH1 
promoter methylation and its consequent transcriptional silencing. Such cancers exhibit 
both CpG island methylator phenotype and microsatellite instability pathways, and are 
usually considered as part of the CpG island methylator phenotype pathway (Worthley 
and Leggett 2010). 
Epigenetic alterations involve global DNA hypomethylation (related with aging), as well 
as hypermethylation of classic tumor suppressor genes leading to their transcriptional 
repression. These epigenetic changes would promote CRC initiation (from adenoma to 
cancer), although some methylation changes might also contribute to CRC 
progression. So, at initial stages, apc, cxcl12/sdf-1 or vim are methylated and silenced, 
while timp3, Id4 and Irf8 are likely more methylated in metastatic CRC than in 
adenomas (Worthley and Leggett 2010, Lao and Grady 2011). 
The CRC development model was revised by Issa (Issa 2008), who proposed a new 
route, the serrated pathway. According to it, distinct multiple pathways would be 
possible with different molecular mechanisms and variable prognosis, instead of a 
linear progression of single events. Thus, an alternative mechanism associated with a 
worse prognosis was proposed, where CRC would originate mainly from villous, but 
also from serrated adenomas and would be very heterogeneous. Serrated adenomas 
are characterized by a CpG island methylator phenotype low phenotype, predominant 
K-ras and occasional B-raf mutations, but without chromosomal instability (Lao and 
Grady 2011). Moreover, changes in the patterns of mRNAs and noncoding RNAs 
expression, as well as the consequent effect on protein expression and 
posttranslational modifications could play a role in CRC tumorigenesis (Sameer 2013). 
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 Figure 1-Progression of colorectal cancer. Progression from normal epithelium through adenoma to 
colorectal carcinoma is characterized by accumulation of alterations in particular genes (i.e. Apc, K-ras, 
Smad2/4, p53), which affects different signaling pathways. Adapted from Takayama et al. 1998 and 
Davies et al. 2005. 
 
 
 
 
 
 
2. p38 MAPKs 
2.1 GENERALITIES 
p38 MAPKs belong to the superfamily of MAPKs. MAPK pathways are evolutionarily 
conserved kinase modules that link extracellular signals to the machinery that controls 
fundamental cellular processes such as growth, proliferation, differentiation, migration 
and apoptosis (Dhillon et al. 2007). 
MAPKs are activated upon dual phosphorylation of threonine and tyrosine residues in a 
conserved Thr-X-Tyr motif (where X is any amino acid) in the activation loop of kinase 
subdomain VIII by a MAP kinase kinase (MKK), which in turn is activated when 
phosphorylated by a MAPK kinase kinase (MKKK). MAPK phosphatases reverse the 
phosphorylation and return MAPKs to their inactive state (Chang and Karin 2001, 
Dhillon et al. 2007, Kyriakis and Avruch 2012) 
In mammals, there are more than a dozen of MAPK genes codifying for different 
MAPKs. The best known subfamilies of MAPKs are ERKs (Extracellular signal-
regulated kinases): ERK1/2, mainly activated by growth factors, and the stress MAPKs, 
which were initially described as kinases activated mainly by stress. These include 
JNKs (c-Jun N-terminal Kinases): JNK-1, JNK-2 and JNK-3, and p38 MAPKs: p38, 
p38β, p38γ and p38δ. Other MAPKs are ERK3/4, ERK5 or ERK7/8, which belong to 
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the non-classical subfamily and have distinct regulation and functions (Dhillon et al. 
2007, Raman et al. 2007). MAPKs are activated by specific MAPKKs: MEK1/2 for 
ERK1/2, MKK3/4/6 for p38 (detailed below), MKK4/7 (JNKK1/2) for JNKs, and MEK5 
for ERK5. At the same time, each MAPKK can be activated by more than one 
MAPKKK, increasing the complexity and diversity of MAPK signaling (Chang and Karin 
2001, Kyriakis and Avruch 2012).  
There are four p38 MAPKs isoforms in mammals: , β, δ and γ, which are 60% 
identical in their amino acid sequence. The four p38 MAPKs are encoded by different 
genes and show specific and overlapping functions and substrate specificity in vitro. 
They can be differentially regulated by the three known p38 MAPK kinases and they 
have different patterns of tissue expression (Nebreda and Porras 2000). It therefore 
appears that the four p38 MAPKs are likely to be involved in specific cellular 
processes. Furthermore, p38 MAPK isoforms also differ in their sensibility to the 
inhibitors SB203580, SB202190 and BIRB796, and in their substrate specificity 
(Cuadrado and Nebreda 2010, Kyriakis and Avruch 2012). 
The first member of the p38 MAPK family was independently identified by four groups. 
It was identified for the first time as a 38 KDa protein kinase that was tyrosine 
phosphorylated in response to LPS (lipopolysaccharide) stimulation. They showed that 
p38 and its yeast homolog HOG1 had sequences, adjacent to critical phosphorylation 
sites, that distinguish these proteins from most other MAP kinase family members (Han  
et al. 1994). Then, two other groups independently identified p38 as a MAPK kinase 
activated by stress and similar to HOG1 (Rouse et al. 1994), and as a kinase activated 
by IL-1 and inactivated by protein phosphatases (Freshney et al. 1994). p38 was also 
reported as a polypeptide receptor for a class of pyridinyl imidazole anti-inflammatory 
drugs (CSAIDs), related with cytokine production (Lee et al. 1994). In later years, three 
other p38 MAPK isoforms were described: p38β (Jiang et al. 1996), p38γ (Cuenda et 
al. 1997) and p38δ (Jiang et al. 1997, Muller et al. 2001). 
Although all p38 isoforms are widely expressed, p38 is the best characterized and 
ubiquitously expressed at significant levels. p38β is also ubiquitous, but it is expressed 
at lower levels. p38γ is most significantly expressed in skeletal muscle and p38δ is 
mainly found in testis, pancreas, kidney and small intestine (Cuenda and Rousseau 
2007). 
The p38 MAPKs are strongly activated in vivo in response to extracellular stimuli such 
as environmental stresses (UV light, heat or osmotic shock), inflammatory cytokines 
(TNF and IL-1), pathogen/damaged-associated molecular patterns from the immune 
response and less by serum and growth factors (Zarubin and Han 2005, Muslin 2008, 
Kyriakis and Avruch 2012).  
The canonical activation of p38 MAPKs, outlined in figure 2, occurs via dual 
phosphorylation of their Thr-Gly-Tyr motif by three MKKs. Activation by a specific MKK 
depends on the stimuli, but also on the cell type, as its level of expression varies. 
MKKs are in turn activated by phosphorylation by a MAPK kinase kinase (MKKK) such 
as MLKs, ASK1, TAK1 and some members of the MEKK family. Upstream them there 
are small G proteins from the Rho subfamily such as Rac1, Cd242, Rho and Rit, and 
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heterotrimeric G proteins. MKK6 can phosphorylate the four p38 MAPK isoforms, 
whereas MKK3 activates p38, p38δ and p38γ, but not p38β. In addition, p38 can be 
also phosphorylated by MKK4 in response to some stimuli such as ultraviolet radiation. 
This specificity of MKKs to activate individual MAPK isoforms is mediated, in part, by 
an interaction between the N-terminal region of MKKs and different docking sites of 
MAPKs, and also by the structure of the MAPK activation loop with the dual 
phosphorylation motif (Cuenda and Rousseau 2007, Cuadrado and Nebreda 2010). 
 
 
 
Figure 2-p38 MAPK signaling pathway. A variety of stimuli activate p38 MAPK through GTPases, 
receptor adapter proteins or cell cycle checkpoint proteins that transmit the stimulus to complex kinase 
cascades including a MAP3K that phosphorylates a MAPK2 that, in turn, phosphorylates p38 MAPKs. 
MKK6 is the major activator of all p38 MAPK isoforms, while MKK3 and MKK4 are more specific and can 
only activate some isoforms. Once activated, the different p38 MAPKs either phosphorylate cytoplasmic 
targets or translocate into the nucleus leading to the regulation of transcription factors (Porras and 
Guerrero 2010). 
 
Non-canonical mechanisms for p38 (and probably p38β) activation have also been 
described. For example, in T cells upon T cell receptor (TCR) activation, p38 is 
phosphorylated in Tyr 323, which leads to autophosphorylation in Thr 180 and Tyr 182 
(Salvador et al. 2005). Interaction of TAB-1 (Transforming growth factor-β-activated 
protein 1 (TAK1)-binding protein 1) with p38 also induces p38 auto-phosphorylation 
and activation (forming a TRAF6-TAB1-p38 complex) (Ge et al. 2002, Li et al. 2005). 
The magnitude and duration of p38 MAPKs signal are critical determinants of their 
biological effects. Activation of p38 MAPK occurs within minutes in response to most 
stimuli and is transient, being down-regulated by dephosphorylation. Many dual-
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specificity phosphatases from the MAPK phosphatase family (MKP, also named as 
DUSP, dual specificity phosphatase) can efficiently dephosphorylate p38 and p38β, 
but not p38γ or p38δ. In addition, other protein phosphatases, such as serine/threonine 
protein phosphotase type 2C (PP2C) and Tyr phosphatase (PTP), can inactivate all 
p38 MAPK isoforms (Zarubin and Han 2005, Cuenda and Rousseau 2007). 
Although p38 MAPKs have overlapping substrate specificity, some substrates appear 
to be preferentially phosphorylated by one or more isoforms. The first p38 substrate 
identified was the MAP kinase-activated protein kinase 2 (MAPKAPK2 or MK2). Other 
well-known p38 and p38β substrates are the kinases MNK1, PRAK, MSK1 and 
transcription factors like activating transcription factor 1, 2 and 6 (ATF-1/2/6), SRF 
accessory protein (Sap1), CHOP (growth arrest and DNA damage inducible gene 153, 
or GADD153), p53, C/EBPβ, myocyte enhance factor 2C (MEF2C), MEF2A, MITF1, 
DDIT3, ELK1, NFAT and high mobility group-box protein 1 (HBP1). Others identified 
substrates are cytoskeletal proteins, translational machinery components and other 
proteins such as tau, keratin 8, metabolic enzymes, glycogen synthase or cytosolic 
phospholipase A2 (Zarubin and Han 2005). 
p38γ and p38δ MAPK isoforms can phosphorylate typical p38 MAPK substrates such 
as the transcription factors ATF-2, Elk-1 or SAP-1, but they have specific ones such as 
1-syntrophin, SAP90/PSD95 and SAP97/Hd1g for  p38γ, and stathmin, tau and eEF2 
(eukaryotic elongation factor 2) kinase for p38δ (Cuenda and Rousseau 2007, 
Cuadrado and Nebreda 2010). 
 
2.2. FUNCTIONS 
p38 MAPKs are involved in the regulation of several cellular functions such as 
proliferation, differentiation, survival or migration, among others. 
To study p38 MAPKs physiological roles, the most important experimental approaches 
have been the use of chemical inhibitors and genetically modified mice. In vitro and in 
vivo assays have demonstrated that p38 and p38β are inhibited by the pyridinyl 
imidazole derived SB203580 and SB202190 compounds, but not p38γ and p38δ. 
BIRB796 can inhibit the four isoforms, although at different doses (Cuenda et al. 1997, 
Goedert et al. 1997, Kuma et al. 2005). 
To identify specific roles played by the different isoforms, knock-out mice have been 
generated. p38 knock-out mouse was the first one. It is embryonic lethal, so mice dye 
at midgestation due a placental defect, which shows the essential role of p38 for 
embryonic development (Adams et al. 2000, Mudgett et al. 2000). Using cardiac-
specific p38 knock-out mice, it has been also shown that p38 is a key negative 
regulator of cardiomyocyte proliferation (Engel et al. 2005). In contrast, p38β knock-out 
mice are viable (Beardmore et al. 2005) and only show a reduced bone mass 
phenotype (Greenblatt et al. 2010). Mice with combined deletion of p38 and p38β 
display diverse developmental defects at midgestation, including major cardiovascular 
defects and liver abnormalities. Using knock-in mice that express p38β under control of 
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the endogenous p38 promoter, it has also been demonstrated that heart development 
requires endogenous p38β expression (del Barco Barrantes et al. 2011). p38γ and 
p38δ and double p38γ/p38δ knock-out mice are viable and fertile and have no obvious 
disorders (Sabio et al. 2005). 
Based on both in vitro and in vivo studies, many different functions played by p38 
MAPKs have been identified and characterized so far, such as: 
1.  Inflammation: p38 plays essential roles in pro-inflammatory cytokines 
production (Kumar et al. 2003) and induction of the pro-inflammatory mediator COX-2 
(Cyclooxygenase-2) (Xu and Shu 2007). p38γ and p38δ are also crucial regulators of 
inflammation in collagen-induced arthritis (Criado et al. 2014), colitis-associated colon 
cancer (Del Reino et al. 2014) and skin inflammation during squamous cell 
development (Zur et al. 2015). In contrast, p38β does not seem to be required for acute 
or chronic inflammatory response (O'Keefe et al. 2007). 
2.  Differentiation: p38/β have been implicated in various cell differentiation 
processes such as 3T3-L1 fibroblasts adipocytic differentiation, PC12 cells neuronal 
differentiation, differentiation of C2C12 myoblasts to myotubes, ATDC5 cells 
chondrogenic differentiation or erythroid differentiation of SKT6 cells (Nebreda and 
Porras 2000). In this line, p38 has a fundamental role in muscle formation in vitro and 
in vivo (Perdiguero et al. 2007, Liu et al. 2012) and p38γ regulates muscle growth and 
regeneration (Gillespie et al. 2009). 
3.  Stemness: p38 signaling has also an important role in maintaining the functional 
microenvironment of stem cells to control lung homeostasis. Thus, the activation of p53 
and the regulation of the miR-17-92 are involved in the response to extracellular 
signals in lung stem cell fate decision (Oeztuerk-Winder et al. 2012). In this context, 
activation of p38 in fibroblasts, is involved in the response to SDF-1 produced by lung 
stem cells (LSCs) and induces cytokine expression in a paracrine feedback loop, which 
is necessary for proper LSC differentiation (Ruiz et al. 2014). Furthermore, p38 upon 
activation by chondrogenic cytokines in mesenchymal stem cells, is an essential 
mediator of shape-induced terminal differentiation of skin stem cells (Oeztuerk-Winder 
and Ventura 2012). 
4.  Development: p38 MAPKs are involved in the regulation of various 
developmental processes in Drosophila (Nebreda and Porras 2000). p38 is essential 
for mouse embryonic development (Adams et al. 2000, Mudgett et al. 2000), while 
other p38 MAPK isoforms are not (Beardmore et al. 2005, Sabio et al. 2005). 
5.  Proliferation: Depending on the cell type and stimulus, p38 MAPKs can have 
either a positive or a negative role in cell proliferation (Nebreda and Porras 2000). p38 
can inhibit cell cycle progression, both at the G1/S, and G2/M transition acting through 
different mechanisms (Perdiguero et al. 2007, Gillespie et al. 2009). p38γ and p38δ 
play also a role in proliferation, so that p38γ and p38δ double knock-out MEFs growth 
slightly quicker than wt cells (Cerezo-Guisado et al. 2011). In contrast, it has been 
suggested an in vivo role for p38δ promoting cell proliferation (Schindler et al. 2009). 
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6.  Cell death: p38 can play a dual role as a regulator of cell death, acting as a 
mediator of either cell survival or cell death through different mechanisms. The specific 
function of p38 MAPKs depends on the cell type, the stimuli and/or the activated 
isoform (Nebreda and Porras 2000, Wagner and Nebreda 2009). p38 sensitizes 
cardiomyocytes derived cell lines to apoptosis through up-regulation of pro-apoptotic 
proteins such as Fas and Bax and down-regulation of the activity of ERKs and Akt 
survival pathways (Porras et al. 2004, Zuluaga et al. 2007). p38 is also a negative 
regulator of embryonic stem (ES) cells survival (Guo and Yang 2006) and it is essential 
for cisplatin-induced apoptosis in human colon carcinoma HCT116 cell line (Bragado et 
al. 2007).  
p38 MAPKs also have an anti-apoptotic role in DNA-damaged fibroblasts (Heron-
Milhavet and LeRoith 2002), differentiating neurons (Okamoto et al. 2000), activated 
macrophages (Park et al. 2002) or pulmonary arterial endothelial cells (Zhang et al. 
2003, Zhang et al. 2005). 
In addition, p38 MAPKs are relevant in the coordination of cellular stress responses to 
reactive oxygen species (ROS), mediating cell death or survival. ROS-induced 
activation of p38 in the initial stages of tumor transformation promotes apoptosis 
(Dolado et al. 2007). In contrast, p38 can also mediate cell survival in response to 
oxidative stress through different mechanisms (Thornton et al. 2008, Gutierrez-Uzquiza 
et al. 2010, Joaquin et al. 2012). For instance, p38 up-regulates some anti-oxidant 
enzymes such as catalase (Sen et al. 2005) and SOD in response to low doses of 
H2O2 (Gutierrez-Uzquiza et al. 2010), as well as heme oxygenase-1 mRNA levels 
(Aggeli et al. 2006). 
7.  Adhesion: p38 negatively regulates cell adhesion in various cell lines such as 
ES cells (Guo and Yang 2006) and cardiomyocyte derived cell lines (Zuluaga et al. 
2007). In chronic myeloid leukemia (CML) cells, although p38 inhibits the expression 
and/or phosphorylation of some focal adhesion (FA) proteins, it favors cell adhesion 
(Maia et al. 2013). 
8.  Migration and invasion: p38 mediates cell migration and invasion of several 
cell types, including tumor cells (Cuenda and Rousseau 2007, Wagner and Nebreda 
2009), as it will be further explained later. 
9.  Senescence: p38 MAPKs have been described to play a role in senescence 
induction in response to telomere shortening (Haq et al. 2002, Bihani et al. 2004), 
oncogenes (Bulavin et al. 2003, Kwong et al. 2009, Kwong et al. 2013) or endothelial 
function (McMullen et al. 2005). 
10.  Cancer: p38 is involved in the regulation of different aspects of tumor 
progression and metastasis, either acting as a tumor promoter or suppressor. p38 
role in cancer will be detail below.  
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2.3  p38 MAPK IN CANCER 
p38 MAPK can act both, promoting or suppressing tumor growth playing different 
roles during tumor progression as shown in figure 3. In the initial stages of tumor 
development, p38 can act as a tumor suppressor. For instance, p38 plays a key role 
in lung tumorigenesis through inhibition of proliferation, differentiation induction and 
control of lung stem cells self-renewal (Ventura et al. 2007). Thus, p38 conditional 
deletion in adult mice favors not scheduled proliferation of progenitor cells and K-Ras 
G12V-induced tumorigenesis. p38 liver-specific deletion also enhances 
hepatocarcinoma development (Hui et al. 2007). In addition, p38 inhibits malignant 
transformation induced by oncogenic H-Ras through induction of apoptosis and/or, cell 
cycle arrest (Dolado et al. 2007, Grossi et al. 2014). In this line, inactivation or 
disruption of Wip1 phosphatase suppresses in vitro transformation and in vivo 
mammary carcinogenesis through activation of p38 MAPK-p53 pathway (Bulavin et al. 
2004). Moreover, loss of Gadd45a accelerates Ras-driven mammary tumor formation 
through a decrease in JNK and p38 kinase activation, leading to a reduced apoptosis 
and Ras-induced senescence (Tront et al. 2006).  
In contrast, other studies support a role for p38 MAPK as a tumor promoter. For 
example, activation of p38 MAPK has been correlated with bad prognosis in HER-2 
negative breast cancer or hepatocellular carcinoma and p38 MAPK act as a tumor 
promoter in follicular lymphoma, lung, thyroid, colorectal, ovarian, breast, gliomas and 
head and neck squamous cell carcinomas (Bakin et al. 2002, Junttila et al. 2007, Kim 
et al. 2003, Hsieh et al. 2007, Matrone et al. 2010). In addition, p38 MAPK pathway 
may contribute to the survival or proliferation of cancer cell lines from breast, prostate 
or skin (Grossi et al. 2014). p38 MAPK also promotes migration and invasion 
processes, features associated with cancer aggressiveness. For example, it enhances 
metastasis in breast and hepatocellular carcinomas (Igea and Nebreda 2015), which 
will be explained more in detail later. 
Other p38 MAPK isoforms have been involved in cancer regulation. For example, p38δ 
plays an essential role in skin carcinogenesis (Schindler et al. 2009) and both p38γ and 
δ isoforms are involved in the inflammatory response during squamous cell 
development (Zur et al. 2015). Moreover, p38γ/δ modulate inflammation and the 
procarcinogenic environment in colitis-associated colon cancer formation (Del Reino et 
al. 2014). In contrast, another study revealed a tumor suppressor role for p38γ and 
p38δ in mouse transformed fibroblasts (Cerezo-Guisado et al. 2011). 
In head and neck cancer, p38/β activation induces growth arrest through up-
regulation of p27 and down-regulation of CDKs, leading to tumor dormancy, which 
favors survival of disseminated tumor cells (Aguirre-Ghiso 2007, Bragado et al. 2013).  
p38/β also makes dormant HEp3 cells highly resistant to chemotherapy through 
upregulation of chaperone BiP/Grp78, which inhibits Bax activation (Ranganathan et al. 
2006). Moreover, p38 allows survival of dormant tumor cells through activation of 
Rheb/mTOR pathway (Schewe and Aguirre-Ghiso 2008).  
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p38 signaling has also an important role in maintaining the functional microenvironment 
for tumor stem cells. For example, low p38 MAPK activity and PI3K-Pdk1 signaling 
lead to selection of more malignant cells, with a less differentiated stem-like profile in 
lung adenocarcinomas (Voisset et al. 2013). 
There are several studies showing a relevant role for p38 MAPKs, especially p38, in 
colorectal cancer development and progression. 
p38 MAPK-mediates cell death in colorectal cancer cells in response to different pro-
apoptotic signals (Fassetta et al. 2006). In particular, p38 plays a role in the regulation 
of oxidative stress, which results from the high proliferative and/or metabolic rate of 
colorectal cancer cells (Simone 2007). In addition, in the HCT116 human colorectal 
cancer cell line, cisplatin apoptotic response requires p53/ROS-mediated p38 MAPK 
activation (Bragado et al. 2007). p38 activation also induces cell death in K-ras-
mutated human colon cancer cells by mechanisms involving the suppression of vitamin 
D receptor activity (Qi et al. 2004). 
However, p38 can also act as a tumor promoter in colorectal cancer. p38 is required 
for colorectal cancer cell homeostasis. Hence, p38 inhibition or genetic inactivation 
causes cell cycle arrest, autophagy and finally, cell death, although initially represents 
a survival pathway (Comes et al. 2007). Accordingly, p38 regulates the expression 
and/or localization of proteins required for autophagosome formation, which leads to 
inhibition of autophagy and survival of colorectal cancer cells (Grossi et al. 2014). 
p38 is also required to maintain colorectal cancer cell metabolism and its inhibition 
reduces tumor growth, both in vitro and in vivo (Chiacchiera et al. 2009, Chiacchiera et 
al. 2012). 
Results derived from a mouse model of colitis associated colon-cancer indicate that 
p38 MAPK plays a dual role, suppressing tumor initiation, while contributing to cell 
proliferation and survival later on (Gupta et al. 2014). According to this, chemical 
inhibition of p38 MAPK with PH797804 decreases colorectal cancer tumor growth in 
patient derived xenografts (PDXs) bearing a K-Ras mutation (Gupta et al. 2015). This 
involves a reduction in cell proliferation and survival through a mechanism mediated by 
down-regulation of CXCL-1/2 and IL-6, which leads to JNK activation (Gupta et al. 
2015). 
On the other hand, recent data has shown that a reduced p38 MAPK signaling, along 
with a high ERK2 activation, favors the generation of colon cancer metastasis in the 
lung from previously established liver metastatic lesions (Urosevic et al. 2014). This is 
mediated by the increased expression of PTHLH cytokine, which contributes to colon 
cancer cell extravasation (Urosevic et al. 2014). Moreover, the expression of Wnt/β-
catenin target genes in colorectal cancer cells induces epithelial-mesenchymal 
transition (EMT) and enhances cell migration and invasion in tissue culture by 
activating p38 MAPK pathway (Qi et al. 2015). 
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Figure 3-Roles of p38 MAPKs in tumor progression: p38 are involved in the EMT process of cells from 
the primary tumor, acquisition of invasive and migratory properties, resistance to anoikis, extravasation of 
migrating cells, pre-metastatic niche formation and tumor cell dormancy (del Barco Barrantes and Nebreda 
2012). 
 
 2.4  p38 MAPK CROSS-TALK WITH OTHER SIGNALING PATHWAYS  
There are different examples of interplay between p38 MAPKs signaling and other 
pathways, resulting in a complex network that contributes to explain their involvement 
in several biological cell functions in a context-dependent manner (Cuadrado and 
Nebreda 2010). For example, p38 MAPK negatively regulates the activity of the ERKs 
pathway, as a consequence, in the absence of p38 ERKs activation is increased 
(Porras et al. 2004). This p38 MAPK-mediated inactivation of ERKs appears to be 
PP2A dependent (Junttila et al. 2008). In a tumor context, a reciprocal compensatory 
role of p38 and MEK/ERK pathways is also possible. Thus, in colorectal cancer p38 
inhibition enhances the activation of other kinases cascades such as ERKs contributing 
to tumor growth. Therefore, inhibition of both p38 and MEK1 improves cancer therapy 
efficiency, reducing in vivo tumor growth (Grossi et al. 2014). 
There is also a cross-talk between JNKs and p38 MAPKs pathways. In fact, although 
multiple stimuli can simultaneously activate both pathways, their activation has 
antagonistic effects in many cases. p38 MAPKs can negatively regulate JNK activity at 
different levels. For example, at the level of MAP3Ks, either by phosphorylating MLK3 
or the TAK1 regulatory subunit TAB1 (Cuadrado and Nebreda 2010). In a different 
way, p38 controls myoblast proliferation by antagonizing the proliferation-promoting 
function of JNK (Perdiguero et al. 2007). p38 MAPK also down-regulates JNK activity 
by decreasing ROS in various tumor cell lines, including colorectal cancer cells (Pereira 
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et al. 2013). Therefore, either p38/β inhibition or p38 knock-down leads to ROS 
upregulation, which in turn activates the JNK pathway via inactivation of phosphatases, 
sensitizing these cancer cells to cisplatin-induced apoptosis (Pereira et al. 2013). 
The interaction between p38 MAPK and Akt has been widely described. Akt can 
inhibit the activation of p38 MAPK through phosphorylation of the upstream regulator, 
ASK1, on Ser 83 (Yuan et al. 2003). On the other hand, p38 negatively modulates Akt 
activity through activation of PP2A in the caveola, which is favored by the interaction 
between caveolin-1 and PP2A (Zuluaga et al. 2007). At a different level, there is also a 
connection between PI3K/Akt and p38 MAPK pathways. Thus, p38 MAPK was 
identified as an upstream regulator of mTORC1 activity in Drosophila melanogaster 
and in a transformed human cell line in response to different stimuli (Cully et al. 2010). 
Moreover, in quiescent tumor cells, activation of ATF6 via p38 up-regulates mTORC1 
activation, leading to survival of dormant cells (Schewe and Aguirre-Ghiso 2008).  
A link between p38 MAPK and Wnt/β-catenin pathways has also been reported, so 
that, p38 MAPK inactivates GSK3β by phosphorylation, leading to β-catenin 
accumulation (Thornton et al. 2008).  
There are also different connections between p38 MAPKs and small GTPases. For 
instance, a functional cross-talk between Rac and p38 MAPK has been largely 
reported. p38 can act as either an effector or activator of Rac, as well as an inhibitor. 
For example, in embryonic cardiomyocytes derived cell lines, p38 acts as either a 
positive or a negative regulator of Rac1 depending on the presence of growth factors 
(Zuluaga et al. 2007). On the other hand, to control cell motility, Rac induces p38 
activation in some cellular systems (Nobes and Hall 1995).  
There is a regulation of p38 MAPK by Rap1, which could be either positive or negative. 
Rap1 can inhibit Ras-induced p38 MAPK activation in a thymoma cell line (Stork and 
Dillon 2005), while FGF2 (Fibroblast growth factor 2)-induced p38 MAPK activation in 
endothelial cells is mediated by Rap1 (McDermott and O'Neill 2002). On the other 
hand, the combined actions of p38 MAPK and Rap1 are required for LPS 
(lipopolysaccharide)-induced chemotaxis breakdown (Yi et al. 2012). Moreover, our 
group has recently described a new functional interaction between the Rap1 GEF, C3G 
(RapGEF1), and p38 MAPK involved in the regulation of apoptosis in MEFs 
(Gutierrez-Uzquiza et al. 2010) and in the K562 chronic myeloid leukemia cell line 
(Maia et al. 2009). This C3G/p38 crosstalk also regulates adhesion in K562 cells (Maia 
et al. 2013), which will be further explained later on.  
An interplay between p38 MAPKs and Rho GTPase signaling also exists in some 
inflammatory and hyperpermeability responses. For example, upon stimulation by gram 
positive pathogens, there is an endothelial pulmonary dysfunction induced by different 
pattern of crosstalk between Rho, p38 MAPK and NFκB signaling (Wu et al. 2013). 
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3. C3G 
3.1  GENERALITIES  
C3G (Crk SH3-domain-binding guanine-nucleotide-releasing factor) is a guanine 
nucleotide exchange factor (GEF) for some members of Ras and Rho families of small 
GTPases, mainly the Ras family members: Rap1 (Gotoh et al. 1995) and R-Ras (Gotoh 
et al. 1997). In addition, C3G can activate other Ras family members such as TC21 
and the Rho family member TC10, leading to MAPK activation (Ehrhardt et al. 2002, 
Radha et al. 2011). Alternate names of C3G are RapGEF1, GRF2, DKFZ p781p1719 
or CRK SH3-BINDING GNRP. 
C3G can also act through GEF independent mechanisms. For instance, to suppress 
transformation induced by different oncogenes (Guerrero et al. 1998, Guerrero et al. 
2004) or to activate apoptosis through interaction with Hck (Shivakrupa et al. 2003).  
C3G was the first Rap GEF identified, originally isolated as an interacting partner of Crk 
and Grb2/ASH in the upstream pathway of Ras (Tanaka et al. 1994). The nucleotide 
sequence of the 4.1 kb C3G c-DNA contains a 3.2 kb open reading frame encoding a 
121 kDa protein. Antibodies against C3G recognize a 130-140 kDa protein (Tanaka et 
al. 1994). Human C3G protein is encoded by rapgef1 gene, which is located on 
chromosome 9q34.13, comprising 24 exons and spanning 163 kb (Takai et al. 1994).  
C3G is ubiquitously expressed. However, some tissue-specific differences in 
expression have been detected. In humans, adult skeletal muscle, placenta, fetal heart 
and brain present higher C3G levels than other tissues such as liver (Tanaka et al. 
1994). In mouse, C3G expression is high in brain, heart, liver and muscle and low in 
adipose tissue, kidney and spleen (Radha et al. 2011). 
Sequence comparison revealed 88% identity in the nucleotide sequence between 
mouse and human C3G cDNA (Zhai et al. 2001). In humans, two predominant C3G 
isoforms have been found, a and b, which arise from alternative splicing and differ in 
their N-terminus, where three amino acids of isoform a are replaced by 21 amino acids 
in isoform b (Radha et al. 2011). A truncated C3G isoform, named p87C3G, which 
lacks 305 residues from N-terminal region and interacts with Bcr-Abl, has been shown 
to be abundantly expressed in chronic myeloid leukemia (CML) cells and primary cells 
from CML patients (Gutierrez-Berzal et al. 2006). The expression levels of this isoform 
correlates with the stage of the disease as it decreases upon treatment-induced 
remission, suggesting a role for C3G in CML (Gutierrez-Berzal et al. 2006). In mice, 
two transcripts with or without a 114 bp insertion in 5´ region are expressed, which lead 
to the expression of two C3G isoforms in most tissues (Zhai et al. 2001). 
C3G protein can be divided into three modular domains clearly differentiated, both 
structurally and functionally, as it is outlined in figure 4. In the C-terminal region, there 
is a CDC25 homologous domain that, together with the REM (Ras-Exchange-Motif) 
domain, are responsible for its GEF activity. The central region contains five proline-
rich sequences that bind to Src Homology-3 (SH3) domains of Crk, p130Cas, Grb2, c-
Abl and Hck (Radha et al. 2011). The N-terminal region negatively regulates C3G GEF 
activity, since its deletion results in constitutive catalytic activity (Ichiba et al. 1999). In 
INTRODUCTION 
 
16 
 
this N-terminal region (from amino acids 144 to 230) there is a binding site for the 
cytoplasmic domain of E-cadherin, which is involved in the interaction of E-cadherin 
and C3G during cell-cell contacts formation (Hogan et al. 2004).  
 
Figure 4-C3G structure. Schematic diagram showing the domain organization of C3G protein. The C-
terminal catalytic region of C3G contains a domain homologous to CDC25, that together with the REM 
domain are responsible for its GEF activity. The N-terminal region has a domain that interacts with E-
cadherin. The central region has a protein interaction domain (also known as Crk-binding region, CBR) 
containing multiple proline-rich sequences that bind SH3 domains of Crk, Cas or c-Abl. The non-catalytic 
sequences negatively regulate the catalytic activity of C3G (Radha et al. 2011). 
 
The mechanisms regulating C3G expression and activation are still poorly understood. 
It is known that several stimuli such as T cell receptor stimulation (Reedquist et al. 
1996), hepatocyte growth factor (HGF) (Sakkab et al. 2000), growth hormone (Ling et 
al. 2003), platelet-derived growth factor (PDGF) (Yokote et al. 1998), nerve growth 
factor (NGF) (York et al. 1998), interferon-γ (Alsayed et al. 2000), integrins 
(Buensuceso and O'Toole 2000) or interleukin-3 (Arai et al. 2001) engage C3G-
mediated signaling. In addition, other GEFs could be involved in the regulation of C3G. 
For example, the Rac GEF DOCK-180 might down-regulate C3G, as its knock-down 
leads to an increased C3G expression (Wang et al. 2010). Furthermore, based on 
bioinformatic studies from our group (unpublished data) C3G expression might be 
regulated by different hematopoietic transcription factors, mainly some members of 
GATA family. However, this needs to be validated. There is an example of C3G 
regulation by the novo methylation of C3G regulatory sequences, which would lead to a 
decreased expression in cervical squamous carcinoma (Okino et al. 2006). 
The major C3G activating mechanism in response to the above mentioned stimuli is 
the multimolecular complex formation. It primarily occurs through membrane 
recruitment of Crk-C3G complex, which facilitates its interaction with the substrate 
Rap1 (Gotoh et al. 1995, Van den Bergh et al. 1997). The SH2 domain in Crk enables 
translocation of the Crk-C3G complex to tyrosine-phosphorylated molecules (Ichiba et 
al. 1997), such as receptor tyrosine kinases (Yokote et al. 1998). Interaction between 
C3G and Crk is influenced by Crk phosphorylation, which can be regulated by the 
tyrosine phosphatase PTP1B (Radha et al. 2011). Moreover, C3G activation has been 
shown to be mediated by tyrosine phosphorylation at Y504 and membrane targeting, 
enabled by its interaction with Crk in response to some stimuli. In this way, the negative 
regulatory action of N-terminal domain is impaired (Ichiba et al. 1999, Radha et al. 
2004). c-Src, Hck, Fyn and c-Abl are kinases known to phosphorylate C3G at Y504. In 
addition, to Y504, C3G can be phosphorylated in other tyrosine residues, which 
function remains unknown (Radha, et al. 2011). 
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3.2  FUNCTIONS 
C3G is involved in different signaling pathways, regulating many cellular functions 
(figure 5). Some of its actions are mediated by its GEF activity, while others depend on 
protein-protein interactions such as its suppressor activity against oncogenic-induced 
transformation in fibroblasts (Guerrero et al. 1998, Shivakrupa et al. 2003). 
C3G-/- homozygous mice died before embryonic day 7.5 due to a defect in integrin-
mediated cellular adhesion (Ohba et al. 2001). Moreover, studies using C3G knock-out 
mouse embryonic fibroblasts has revealed that C3G-dependent activation of Rap1 is 
required for adhesion and spreading. Other reports also support that C3G plays a 
relevant role in cell adhesion, spreading, migration and cell-cell junction assembly and 
disassembly (Radha et al. 2011), as it would be explained more in detail later. 
C3G is also important for regulation of proliferation in different cell types such as 
neuroblastoma cells (Radha et al. 2008). In agreement with this, C3G-deficient mice 
show an over-proliferation of the cortical neuroepithelium (Voss et al. 2006), having 
defects in cortex development. In addition, C3G is involved in the regulation of some 
differentiation processes such as adipocyte differentiation (Jin et al. 2000) or skeletal 
muscle differentiation (Sasi Kumar et al. 2015). 
C3G regulates vesicle traffic, too. For instance, C3G-mediated TC10 activation 
promotes GLUT4 (glucose transporter type 4) membrane translocation in response to 
insulin in muscle and adipose tissue through a mechanism dependent on cytoskeletal 
rearrangement (Chiang et al. 2001). 
C3G is also a regulator of cell death. It can induce apoptosis acting through Hck 
(Shivakrupa et al. 2003) or c-Abl (Radha et al. 2008). Moreover, C3G through the 
negative regulation of p38 activity mediates, either cell survival or death, depending 
on the stimulus and cell type (Maia et al. 2009, Gutierrez-Uzquiza et al. 2010). 
The function of C3G in cancer is quite controversial as it can act as either a tumor 
suppressor or promoter. As a tumor suppressor, C3G prevents malignant 
transformation induced by several oncogenes (Guerrero et al. 1998, Guerrero et al. 
2004). According to this, C3G expression was shown to be reduced in cervical 
squamous cell carcinoma (Okino et al. 2006). In contrast, an increased C3G 
expression was found in human non-small-cell lung cancer in comparison to the 
corresponding non-cancerous lung tissues (Hirata et al. 2004). In agreement with this, 
Crk-C3G-Rap1 pathway, downstream RET, has been involved in the process of 
transformation produced in papillary thyroid carcinoma (De Falco et al. 2007). The 
expression of p87C3G isoform in CML cells is also associated with the development of 
this type of cancer (Gutierrez-Berzal et al. 2006). Moreover, recent data suggest that 
C3G acting through Rap1, might promote migration and invasion of epithelial ovarian 
cancer cells (Che et al. 2015), which indicates that C3G could regulate key events in 
later stages of cancer progression. 
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Figure 5-C3G interacting partners and functions. Members of different signaling pathways that interact 
with the proline-rich Crk-binding region of C3G through their SH3 domain and implication in the regulation 
of cellular functions (Radha et al. 2011). 
 
4. FIBULINS 
4.1  GENERALITIES  
Fibulins are a family of extracellular matrix (ECM) secreted glycoproteins in the 50-200 
KDa range. In 1989, Argraves described Fibulin-1 for the first time as a protein that 
interacts with the Fibronectin Receptor β (Argraves et al. 1989) and later its main 
characteristics were reported (Argraves et al. 1990). Since then, six more family 
members have been identified in mammals (de Vega et al. 2009).  
The structure of fibulins is organized in three domains (figure 6), which have been 
implicated in mediating a number of protein-protein interactions. All fibulins share a 
globular C-terminal domain referred to as “fibulin-like” or “FC domain” (domain III).  
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Domain II represents the central portion and contains a variable number of EGF-like 
modules in a tandem array. Most of the EGF-like modules contain a consensus 
sequence for calcium binding and are known as calcium-binding EGF (cbEGF)-like 
modules. Domain I represents the N-terminus and its sequence vary among the family 
members (Obaya et al. 2012). 
 
 
 
Figure 6-Fibulins structure. Scheme showing the different domains of fibulins: the “fibulin-like” C-terminal 
domain, the central domain containing EGF-like modules in tandem and the variable N-terminus domain. 
Alternative splice variants of Fibulin 1 (A, B, C and D). Only 9 of the 48 immunoglobulin domains in Fibulin 
6 are present in the scheme (Argraves et al. 2003). 
 
Fibulin family members have been classified into two subgroups according to their 
domains organization. The first subgroup includes Fibulin 1 (100kDa) and Fibulin 2 
(195kDa), which are larger than the other members. They have an extra domain with 
three anaphylatoxin (AT) modules in domain I and more EGF-like modules in the 
central portion. The second subgroup includes the rest of the members, from Fibulin 3 
to Fibulin 7. They are smaller proteins ranging 50-60 kDa, except Fibulin 6, which is the 
largest member of the family (615 kDa) due to the presence of 44 immunoglobulin C-2 
domains in tandem and 6 thrombospondins type-I modules within domain I. Fibulin 7 
has a unique N-terminal domain I, bearing a sushi domain, also known as complement 
control protein (CCP) domain (de Vega et al. 2009). 
The different fibulins have a distinct tissue distribution; although some of them are 
expressed in the same places, being important their presence in blood vessels. The 
mechanisms that regulate fibulins expression are still poorly understood (Argraves et 
al. 2003). Evidence indicates that steroids regulate the expression of Fibulins 1, 2 and 
3 (Ishibashi et al. 2002, Hayashi et al. 2003, Okada et al. 2003).  
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To study the functional relevance of fibulins, different mouse models deficient in a 
specific fibulin gene have been generated and show specific phenotypes. Mice lacking 
Fibulin 1 do not survive long after birth, as they undergo severe bleeding in muscle, 
skin and perineural tissue (Kostka et al. 2001). In contrast, mice deficient in Fibulin 2 
are viable, fertile and show no apparent defects (Sicot et al. 2008). Fibulin 3 knock-out 
mice evidence alterations associated with premature aging and reduced lifespan, 
reproductive defects, loss of body mass and generalized atrophy in some tissues such 
as fat or muscle (McLaughlin et al. 2007). Fibulin 4 deficient mice exhibit lung and 
vascular disorders, dying perinatally (McLaughlin et al. 2006). Finally, mice lacking 
Fibulin 5 display highly disorganized elastic fibers (Yanagisawa et al. 2002). 
Fibulins exhibit a wide number of protein-protein interactions, particularly, with other 
extracellular matrix proteins. Indeed, fibulins might act as intramolecular bridges within 
the ECM, connecting various supramolecular structures in order to mediate certain cell 
signaling events (Gallagher et al. 2005). Fibulins have been shown to modulate a 
number of cellular functions such as cell morphology, growth, adhesion and motility. 
The dysregulation of particular fibulins occurs in a number of human disorders. For 
example, Fibulin 2 is increased in streptozotocin-induced diabetic glomerulosclerosis 
(Wada et al. 2001) or Fibulin 5 is increased in elastase-induced emphysema in mice 
(Kuang et al. 2003). In addition, Fibulin 4 might have a role in response to sepsis 
(Heine et al. 1999). Furthermore, different fibulins have been found to have a function 
in cancer due to their role in the regulation of adhesion, migration, invasion or other 
processes. So far, different studies conclude that both tumor suppressive functions and 
oncogenic activities can be elicited by fibulins (Obaya et al. 2012). 
Fibulin1 is down-regulated in colorectal cancer through promoter methylation (Xu et al. 
2015), which is associated with poor prognosis (Zhu et al. 2015). Fibulin 5 is also 
downregulated in lung cancer, where it acts as a tumor suppressor inhibiting MMP7 
(Yue et al. 2009) as well as in urothelial carcinoma (Hu et al. 2011) or hepatocellular 
carcinoma (Tu et al. 2014). It plays also an important role in the tumor 
microenviroment, inhibiting MMP9 production and invasion (Moller et al. 2011). Fibulin 
5 can also act as a tumor promoter in gastric cancer (Shi et al. 2014) or pancreatic 
tumors (Schluterman et al. 2010). Moreover, Fibulin 5 has been involved in the 
regulation of TGFβ-induced EMT in cervical cancer metastasis (Xiao et al. 2013) and in 
mammary epithelial cells (Lee et al. 2008). Fibulin 3 expression is also associated with 
cancer, as it will be shown below. 
 
4.2  FIBULIN 3  
Fibulin 3, also known as S1-5 or EFEMP-1, was isolated by subtractive screening of a 
c-DNA library derived from mRNA of senescent human diploid fibroblasts (HDF) 
established from a patient with Werner syndrome of premature aging (Lecka-Czernik et 
al. 1995).  
Fibulin 3 is expressed in bone and cartilage structures during development and is also 
present at high levels in retina and epithelial and endothelial cells throughout the body 
(de Vega et al. 2009). In adults, Fibulin 3 expression is prominent in some capillaries 
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and it is overexpressed in Werner syndrome and in senescent normal HDFs. Growth 
arrest in young normal cells also induces its expression, while high serum significantly 
decreases it (Lecka-Czernik et al. 1995). In addition to changes in Fibulin 3 levels 
occurring in some pathologies, the R345W mutation appears to cause age-related 
macular degeneration and is associated with Malattia Leventinese (Argraves et al. 
2003, Marmorstein et al. 2007).  
Concerning cancer, Fibulin 3 has both anti- and pro- oncogenic effects. Fibulin 3 is 
simultaneously overexpressed with MMP2, MMP9 and ADAMTS-5 in glioma cells 
promoting tumor invasion and survival (Hu et al. 2009). Fibulin 3 plays also a pro-
angiogenic role in gliomas through the activation of Notch signaling (Nandhu et al. 
2014). Moreover, Fibulin 3 has been associated with progression of pancreatic 
adenocarcinomas through interaction with epithelial growth factor (EGF) receptor, 
which leads to Akt activation (Camaj et al. 2009). 
Nevertheless, many studies have described an anti-tumoral role of Fibulin 3. For 
example, in non-small cell lung cancer, Fibulin 3 down-regulates MMP2 and MMP7 and 
the subsequent decrease in its invasiveness (Kim et al. 2012). Down-regulation of 
Fibulin 3 also contributes to lung cancer invasion and metastasis through activation of 
Wnt/β-catenin pathway (Chen et al. 2014). Moreover, Fibulin 3 levels decrease in 
nasopharyngeal carcinomas, where it has the ability to suppress cell migration and 
invasion by decreasing Akt activity (Hwang et al. 2010). This Fibulin 3 down-regulation 
observed in different types of cancer, including lung cancer (Kim et al. 2012), 
hepatocellular carcinoma (Nomoto et al. 2010) or colorectal cancer (Tong et al. 2011), 
correlates with promoter methylation. 
Fibulin 3 is also linked with the EMT process related to cancer progression. For 
instance, Fibulin 3 suppresses both EMT and self-renewal of lung cancer stem cells by 
modulating the IGF1R/PI3K/Akt/GSK3β pathway (Kim et al. 2014). During breast 
cancer progression, Fibulin-3 expression decreases, which impairs its inhibitory effect 
on TGFβ signaling in cancer and endothelial cells microenvironment, promoting EMT, 
migration, invasion and endothelial permeability (Tian et al. 2015). 
 
5. CELL ADHESION, MIGRATION AND INVASION. 
GENERALITIES 
Cell adhesion plays an important role during embryonic development and in several 
physiological and pathological processes in the adult, including cancer. It contributes to 
cellular organization in tissues, as well as to cell proliferation and survival. 
Cells in tissues interact both with the extracellular matrix and neighboring cells. Rather 
than simply playing a passive role in maintaining attachment and resisting external 
forces, it is becoming increasingly evident that cell-extracellular matrix and cell-cell 
adhesions are also sites of transmission of active signals (Maruthamuthu et al. 2011). 
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Epithelial cell-cell adhesions are maintained by three basic structures connecting 
adjacent cells: tight junctions (zonula occludens), adherent junctions (zonula adherens) 
and desmosomes (macula adherens) (Le Bras et al. 2012). 
Adherent junctions are made up by calcium-dependent homophilic binding of the 
extracellular cadherin domains, nectins and afadins. Adherent junctions are highly 
dynamic structures, which are remodeled by endocytosis and recycling of their 
components. Endocytic pathways are often misregulated in cancer. There are different 
endocytic pathways, non-clathrin and clathrin-mediated. The last one involves adaptor 
proteins such as Numb and Disabled-2 (Dab2) and participates in the regulation of 
members of adherens junctions during EMT (Le Bras et al. 2012). 
Nascent adhesions can either turn over rapidly, in ~60 seconds, or mature to larger 
focal complexes (approximately 1 μm in diameter) that reside in the lamellipodium-
lamellum interface and persist for several minutes. These complexes can continue to 
mature into larger focal adhesions that reside in large actin bundles or stress fibers (2 
μm wide and 3-10 μm long). As traction forces move the cell forwards, focal adhesions 
assemble and disassemble. For productive advance of the cell body, contraction must 
be coupled to de-adhesion (Gardel et al. 2010, Parsons et al. 2010). These adhesions 
contain integrins, talin, vinculin, -actinin, paxillin and FAK, among other proteins, and 
are enriched in phosphotyrosine because they form active signaling complexes 
(Parsons et al. 2010). 
Cell migration plays a key role in the development and maintenance of multicellular 
organisms under physiological and pathological conditions such as metastasis in 
cancer. For example, migration is required for skin and intestine cell renewal, so that 
new epithelial cells migrate from the basal layer or the crypts, respectively, to the top 
layer. Likewise, migration plays an essential role in tissue repair and immune response 
(Ridley et al. 2003). 
Under pathological conditions, migration is also involved in several diseases, like 
vascular diseases, osteoporosis, chronic inflammatory diseases or cancer, where it 
leads to invasion and the generation of metastasis (Franz et al. 2002, Ridley et al. 
2003). Metastasis is a complex process, encompassing local infiltration of tumor cells 
from the initial tumor into adjacent tissues, intravasation (transendothelial migration of 
cancer cells) into vessels, survival in the circulatory system and extravasation, leading 
to colonization and formation of the secondary tumor (van Zijl et al. 2011).  
There are different types of cell migration. Cells can migrate as individual cells by a 
mesenchymal movement, which involves directional migration with proteolysis at the 
leading edge or by an amoeboid movement with lack of direction and polarity (Le Bras 
et al. 2012). In addition, they can migrate in solid cell strand, sheets, files or clusters, 
which is called “collective” migration (Friedl and Wolf 2003, Rorth 2009).  
Cell migration results from a continuous cycle of coordinated and interdependent steps 
that involves the cytoskeletal machinery (Friedl and Brocker 2000). Movement of the 
cell body is dependent on contractility generated by actin and myosin II filaments. 
Migrating cells are polarized, and at the front, extensions (filopodia) of lamellipodia are 
driven by dynamic polymerization of actin (Franz et al. 2002).  
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The actin polymerization in the lamellipodium is regulated by the Rho GTPases, Rac 
and Cdc42 (Parsons et al. 2010). Maturation of focal complexes into focal adhesions 
involves activation of Rho, perhaps through the recruitment of a Rho GEF to 
adhesions, and Rho might inhibit Rac (Sanz-Morenoet al. 2008, Tomar and Schlaepfer 
2009). Rho activity promotes the assembly of contractile actomyosin structures that 
regulate traction and tension-mediated changes (Gardel et al. 2010). In addition to Rho 
GTPases, other molecules such as FAK, Src, paxillin, talin or p130Cas are involved in 
the regulation of cell protrusion, adhesion and contraction, controlling the interplay 
between the F-actin cytoskeleton and integrin-mediated adhesion (Gardel et al. 2010). 
 
5.1  EXTRACELLULAR MATRIX AND MATRIX METALLOPROTEASES (MMPs) 
Cell migration in vivo is dependent on the modification and degradation of extracellular 
matrix components by the actions of secreted proteases such as MMPs (Sternlicht and 
Werb 2001). The ECM is the non-cellular component present within all tissues and 
organs, and provides not only essential physical scaffolding for the cellular 
constituents, but also initiates crucial biochemical and biomechanical cues that are 
required for tissue morphogenesis, differentiation and homeostasis. It mediates 
protection by a buffering action and water retention and directs essential morphological 
organization and responses (Frantz et al. 2010). In cancer, ECM also determines the 
preferred metastatic organs. For example, based on the deposition of fibronectin or the 
expression of tissue inhibitors of metalloproteinases (TIMPs) (Tse and Kalluri 2007).  
ECM is composed of a large collection of biochemically distinct components including 
collagens, laminins, fibronectin, elastin, fibrillins, tenascin, nidogen, entactin, fibulins, 
fibrinogen, thrombospondins, proteoglycans or hyaluronans. Different isoforms and/or 
family members of these components can be present in different tissues. ECM 
provides mechanical support for cells through its binding to integrins (Gout and Huot 
2008, Halper and Kjaer 2014). The basal lamina, a specialized sheet that underlies 
epithelial cell sheets and tubes, is a particular type of ECM that is produced through 
cooperation of epithelial and stromal cells and plays a significant role in cancer (Gout 
and Huot 2008).  
During cell migration and invasion, ECM is degraded preparing the path for cells to 
migrate, invade and spread to distant areas. Matrix endopeptidases play a crucial role 
in this process.  
Metzincins are a heterogeneous superfamily of Zinc proteolytic proteins of the 
extracellular matrix. They are characterized by a consensus motif containing three 
histidines that bind zinc at the catalytic site, and a conserved HEXXHXXGXXH motif 
within the active site (Bergers and Coussens 2000, Gardel et al. 2010). The C-terminus 
domain variants are related to their location and their function within the cells and 
tissues (Bergers and Coussens 2000). Metzincins can be classified into different 
families on the basis of structural similarity. Among them, MMPs that were the first 
known zinc-dependent endopeptidases family, ADAMs (-disintegrin and 
metalloproteinase) and ADAMTS (-disintergin and metalloproteinase with 
thrombospondin motifs) families, have been shown to contribute to tumor progression 
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(Bergers and Coussens 2000, Gardel et al. 2010). MMPs are zinc-dependent 
endopeptidases which primary function is tissue remodeling by selective proteolytic 
degradation (Bourboulia and Stetler-Stevenson 2010). There are 23 human MMPs (24 
in mouse), which differ from each other in their structural domain architecture, 
substrate specificity and their temporal and tissue specific expression patterns 
(Radisky and Radisky 2010). It is becoming increasingly clear that MMPs do not simply 
degrade the matrix, but also generate new ligands (Franz et al. 2002). 
MMPs have distinct and overlapping substrate specificities and together they possess 
enzymatic activity against, virtually, all ECM components. Their common 
characteristics are: dependence on zinc and calcium ions and synthesis as inactive 
zymogens (or proMMPs) that are activated by limited proteolysis. They are either 
secreted or expressed as transmembrane proteins, inhibited by tissue inhibitors of 
metalloproteases (TIMPs) and transcriptionally responsive to cytokines, growth factors, 
hormones and ECM-derived signals (Gardel et al. 2010). 
MMPs can be classified by their cellular localization (17 soluble, secreted enzymes and 
6 membrane-associated enzymes), or their substrate specificity: collagenases (MMP1, 
8 and 13), gelatinases (MMP2 and 9), and MMPs that degrade a broad spectrum of 
ECM proteins called stromelysins (MMP3, 10 and 11) or matrilysins (MMP7). 
Nowadays, as the MMP family grew, a numbering system was adopted and MMPs are 
now grouped according to their domain structure (Radisky and Radisky 2010, Tallant et 
al. 2010).  
MMPs are constituted by a modular combination of inserts and domains, as indicated 
in figure 7. This includes, from N- to C-terminus: a signal peptide for secretion, a 
zymogenic pro-peptide, a zinc- and calcium-dependent catalytic domain, a linker region 
and a hemopexin-like domain for collagen binding, pro-MMP activation and 
dimerization (Tallant et al. 2010, Kessenbrock et al. 2011). Most MMPs also possess 
additional accessory domains that modulate catalytic activity, substrate recognition and 
cellular localization, which are unique for a number of MMP members (Radisky and 
Radisky 2010). 
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Figure 7-Domain structure of the mammalian MMP family. MMPs can be divided in secreted or 
anchored in cis to the cell surface and those containing a furin-recognition motif (9 MMPs, including all the 
membrane anchored enzymes) or not (Parks et al. 2004). 
 
Several MMPs are not constitutively transcribed, but are expressed after external 
induction by cytokines and growth factors (Tallant et al. 2010). They are expressed as 
inactive pro-enzyme, due to the interaction of a cysteine residue of the pro-domain with 
the zinc ion of the catalytic site, and disruption of this interaction by a mechanism 
called cysteine switch, make enzymes proteolytically active (Sternlicht and Werb 2001). 
The regulation of MMPs is mainly due to modulation of gene expression, 
compartmentalization and inhibition of its activity by the endogenous inhibitors, TIMPs. 
There are four TIMP family members (TIMP-1, -2,-3 and -4) that can inhibit all active 
MMPs, but not with the same efficiency (Bourboulia and Stetler-Stevenson 2010). 
MMPs are implicated in a variety of physiological processes, including wound healing, 
uterine involution and organogenesis, as well as in pathological conditions, such as 
inflammatory, vascular and auto-immune disorders and carcinogenesis (Gialeli et al. 
2011).  
During tumor progression, the proteolytic activity of MMPs is required for cancer cells 
to degrade physical barriers during local expansion and for intravasation at nearby 
blood vessels, extravasation and invasion at a distant location. Expression of MMPs in 
the tumor microenvironment is produced by cancer cells, but also by the neighboring 
stromal cells induced by the cancer cells in a paracrine manner. For example, 
fibroblasts and macrophages produce matrix-metalloproteases (MMPs) in many 
tumors, which allows ECM degradation, promoting cancer cell motility and invasion 
(Wagner and Nebreda 2009, Gialeli et al. 2011). 
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Increased MMP2 and MMP9 expression and activity are associated with tumor 
progression of breast, urogenital, brain, lung, skin and colorectal cancer, as well as in 
other malignancies (Klein and Bischoff 2011). Particularly, in colorectal cancer, several 
studies have shown that MMP2 and 9 play a role and could be used as prognosis 
markers and therapeutical targets. 
 
5.2  ROLE OF p38 MAPKs IN ADHESION, MIGRATION AND INVASION 
p38 MAPKs play an important role in cell adhesion, migration and invasion, all of them 
processes involved in tumor progression and metastasis (Wagner and Nebreda 2009, 
del Barco Barrantes and Nebreda 2012).  
p38 negatively regulates cell adhesion in embryonic stem cells (Guo and Yang 2006) 
and embryonic cardiomyocyte-derived cell lines (Zuluaga et al. 2007) through different 
mechanisms.  
p38 MAPK mediates cell migration in HeLa cells and MEFs (Rousseau et al. 2006) 
through the regulation of the actin cytoskeleton by MK2. The activation of p38 can 
also induce cell migration and cytoskeletal remodeling in tumor cells by increasing the 
phosphorylation of Hsp27 (heat-shock protein 27) (Laferriere et al. 2001). In HGF/Met-
triggered cortical neurons, Rac1/p38 cascade is also important for migration (Segarra 
et al. 2006). In colorectal cells, E-selectin binds and activates death receptor-3, 
triggering p38 and ERKs activation, which enhances transendotelial migration, survival 
and the generation of metastasis (Gout et al. 2006). Accordingly, p38 MAPKs play a 
key role in invasion. For example, in melanoma cells (Estrada et al. 2009) or ovarian 
cancer cells, p38 MAPK together with EGF and HGF, promote cell migration and 
invasion through regulation of MMP9 (Zhou et al. 2007). p38 pathway also increases 
MMP9 activity in breast cancer cells and promotes migration (Suarez-Cuervo et al. 
2004). Moreover, p38 induces the expression of MMP1, MMP2, MMP9 and MMP13 in 
bladder, breast, liver, skin, keratinocytes and prostate cancer (del Barco Barrantes and 
Nebreda 2012). In head and neck carcinoma, p38 and p38δ promote head and neck 
squamous cell carcinoma invasion, through the induction of MMP1 and MMP13 
expression (Junttila et al. 2007). In hepatocellular carcinoma, head and neck 
squamous carcinoma, pancreatic or glioma cell lines, p38 also promotes invasion of 
tumor cells (Wagner and Nebreda 2009, del Barco Barrantes and Nebreda 2012).  
p38 plays a central role in the regulation of disseminated tumor cells (DTCs) fate at 
secondary organs (Bragado et al. 2013), where p38 would be activated, leading to 
tumor cell dormancy. This allows DCTs to keep in a quiescent state until the 
microenvironment is favorable for proliferation (Sosa et al. 2014).  
p38γ also regulates invasion and metastasis acting as an activator and cofactor for c-
Jun-induced MMP9 expression (Loesch et al. 2010).  
Related to the invasion process, inhibition of p38 MAPK pathway blocks TGFβ-induced 
EMT and migration of non-tumor and tumor mammary epithelial cells (Bakin et al. 
2002). Moreover, activation of the TGFβ–TRAF6–p38 MAPK pathway promotes c-Jun-
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mediated Snail1 expression, which enhances the migratory and invasive capacity of 
human prostate cancer cells (Thakur et al. 2014). The role of p38 MAPK in the EMT 
process will be further explained later.  
To sum up, p38 MAPKs contribute to the different steps of the metastatic process: 
epithelial-mesenchymal transition (EMT), migration/invasion, anoikis resistance, 
extravasation, organ colonization and metastatic dormancy (del Barco Barrantes and 
Nebreda 2012). 
 
5.3  ROLE OF C3G IN ADHESION, MIGRATION AND INVASION 
C3G plays an important role as a mediator of cell adhesion and spreading activated by 
integrins. As a consequence, C3G deficiency in mouse embryonic fibroblasts (MEFs) 
impairs cell adhesion and delays cell spreading, while it enhances cell migration (Ohba 
et al. 2001, Voss et al. 2003). This function of C3G is partially mediated by its main 
target, Rap1 (Ohba et al. 2001, Kooistra et al. 2007, Huang et al. 2008, Pannekoek et 
al. 2009). However, C3G, when overexpressed can also promote c-Abl-induced 
filopodia formation during cell spreading through mechanisms independent of its 
catalytic activity (Radha et al. 2007). In mammal cells, C3G and/or Rap1, as well as 
other proteins such as Crk or p130Cas, form multiprotein complexes during integrin-
mediated focal adhesion (Bos 2005). So that, Rap1 and its GEFs and GAPs might be 
responsible for the spatial and temporal regulation of actin dynamics at sites of cell 
adhesion through their localization and interactions with other molecules inside the cell, 
like cadherins (Bos 2005). Moreover, Dr. Guerrero´s group in collaboration with our 
group has recently found that C3G and p38 act through a common pathway 
promoting cell adhesion in K562 chronic myeloid leukemia cell line, where both 
proteins interact forming a complex. However, C3G and p38 also display antagonistic 
roles in the regulation of the expression of some focal adhesion (FA) proteins in these 
cells. Thus, whereas C3G silencing inhibits their expression, p38 knock-down leads to 
an increase of some of these proteins (Maia et al. 2013).  
As previously mentioned, C3G regulates cell migration, but its particular function can 
vary depending on the cellular context. C3G deficient MEFs present an enhanced 
migration (Ohba et al. 2001), while in C3G mutant mice sympathetic preganglionic 
neurons migration is altered (Yip et al. 2012) and mouse embryos lacking C3G also 
exhibit a migration defect in cortical neurons (Voss et al. 2008). On the other hand, 
C3G overexpression results in opposite outcomes in different cell types, so it increases 
cell migration in glomerular epithelial cells in glomerulonephritis (Rufanova et al. 2009), 
but decreases cell migration in highly invasive breast carcinoma cells (Dayma and 
Radha 2011). 
C3G also regulates cell-cell interactions, where E-cadherin is important (Kooistra et al. 
2007, Pannekoek et al. 2009). C3G binds intracellular E-cadherin to activate Rap1 and 
induces E-cadherin translocation (Pannekoek et al. 2009). Moreover, because C3G 
competes with β-catenin in the binding to E-cadherin (Kooistra et al. 2007), β-catenin 
and E-cadherin functions can be additionally modulated by C3G, which might be also 
important to regulate cell migration. 
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Recent data also suggest that C3G, acting through Rap1, would promote invasion of 
epithelial ovarian cancer cells through increasing MMP2 and 9 secretion (Che et al. 
2015).  
 
6. EPITHELIAL-MESENCHYMALTRANSITION 
Epithelial-mesenchymal transition (EMT) together with its reverse process, 
mesenchymal-epithelial transition (MET), allows the dissemination of cells from solid 
tumors and the colonization of distant sites (Pereira et al. 2015). In the metastatic 
process, cells from the primary tumor that suffer an EMT process, access to the 
circulatory system and go to distant sites. To form a secondary solid tumor, cells 
extravasation requires recognition and adhesion to endothelial cells and matrix 
degradation to invade the secondary tissue (Tse and Kalluri 2007). Once finished 
colonization, cells are thought to redifferentiate via MET and regain the organization of 
cells present in the primary tumor (Pereira et al. 2015). 
EMT is a process that allows epithelial cells to acquire a fibroblastoid, motile and 
invasive phenotype. This involves a loss of polarity, downregulation of epithelial-
specific proteins (for example, adherens and tight-junction proteins like E-cadherin and 
zona occludens 1 (ZO-1), respectively) and expression of mesenchymal proteins (for 
example, N-cadherin or vimentin) and MMPs (figure 8). Moreover, EMT may invoke the 
expression of stemness markers (Zeisberg and Neilson 2009). EMT is important during 
embryogenesis, organogenesis and for tissue repair during adult life. EMT is also 
induced in carcinoma cells undergoing a phenotypic conversion to make them invasive 
(Grunert et al. 2003). 
 
 
 
Figure 8-Schematic representation of EMT process steps. EMT involves a functional transition of 
polarized epithelial cells into mobile mesenchymal cells.  Commonly used epithelial and mesenchymal cell 
markers are listed. Co-localization of these two sets of distinct markers defines an intermediate phenotype. 
 
 
INTRODUCTION 
 
29 
 
Several markers change their expression and/or localization during the EMT process. 
Some of them are listed in table 1. The switch from E-cadherin to N-cadherin 
expression is used as a marker of EMT. E-cadherin is the main responsible for 
adherent junctions between cells, forming a “molecular zipper”. It binds to either β-
catenin or γ-catenin and subsequently to -catenin in the cytoplasm, forming a complex 
with cellular cytoskeleton microfilament network (Tsanou et al. 2008). In the cytoplasm, 
β-catenin stabilizes cell junctions, meanwhile in the nucleus it activates the 
transcriptional activity of LEF-1/TCFs, which are required to induce EMT, mainly by 
increasing Snail1 expression (Zeisberg and Neilson 2009). 
Loss of E-cadherin-mediated adhesion may act as a promoter of tumor cell detachment 
from the primary site, concurrent invasion of adjacent normal tissue and dissemination 
to distant places (Tse and Kalluri 2007). 
The zona occludens proteins (ZO-1, ZO-2 and ZO-3) are tight junction associated 
proteins that belong to the family of membrane-associated guanlyate kinase (MAGUK) 
homologs. They have three PDZ (postsynaptic density/disc-large/ZO-1) domains, an 
SH3 domain, a GK (guanylate kinase) domain, an acidic domain and an actin binding 
region (Gonzalez-Mariscal et al. 2000). ZO-1 is a junctional adaptor protein that 
interacts with other tight junction components, such as proteins from JAM (junctional 
adhesion molecule) family and F-actin (Bazzoni et al. 2000, Fanning and Anderson 
2009, Fanning et al. 2012). It regulates cadherin-mediated intercellular junctions and F-
actin cytoskeletal distribution, as well as endothelial cell migration and angiogenic 
potential, so that, cells lacking ZO-1 show a reduced migration (Tornavaca et al. 2015). 
ZO-1 knock-out mice are embryonic lethal, due to its requirement for normal blood 
vessel formation in the yolk sac (Katsuno et al. 2008). Accordingly, ZO-1 depletion 
reduces endothelial sprouting (Tornavaca et al. 2015).  
Snail1/2 transcription factors are common downstream targets of signaling pathways 
regulating EMT. Snail not only suppresses E-cadherin expression, but it also increases 
that of mesenchymal markers such as fibronectin and vitronectin and decreases the 
expression of other epithelial markers like claudins, occludins and cytokeratins, apart 
from other effects (de Herreros et al. 2010). Twist is another transcription factor 
involved in EMT induction. It is a basic helix-loop-helix protein that is upregulated 
during early embryonic morphogenesis, tissue fibrosis and cancer metastasis. In 
metastasis, Twist can act independently of Snail to downregulate E-cadherin and 
upregulate Fibronectin and N-cadherin (Zeisberg and Neilson 2009). The ZEB family of 
transcription factors have an essential role regulating signaling mechanisms of the 
epithelial-mesenchymal transition during cancer progression. They are involved in the 
maintenance of cancer cells stemness and their expression is linked with increased 
aggressiveness, metastasis and angiogenesis in mice models and primary human 
tumors (Sanchez-Tillo et al. 2011). For instance, ectopic expression of ZEB proteins in 
mammary epithelial cells is sufficient to induce the dissociation of adherens junctions, 
presumably through suppressing the expression of genes encoding Plakophilin-2 and 
ZO-3 (Eger et al. 2005). Moreover, ZEB transcriptional factors also increase the 
expression of genes encoding matrix metalloproteases (Miyoshi et al. 2004). 
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Different micro-RNAs are up- or down-regulated in tumor processes, existing a double-
negative feedback loop between mi-RNAs and the transcription factors that drive EMT. 
Different micro-RNAs control E-cadherin or Vimentin expression, as well as that of 
transcription factors regulating EMT. These include Snail, which is regulated by the 
miR-30 and miR-34 family and ZEB 1 and 2 by the miR-200 family. Other genes 
targeted by mi-RNAs are those from cytoskeletal components, Wnt pathway and 
stemness (Findlayet al. 2014). 
 
Acquired or maintained markers Attenuated markers 
Cell-surface proteins 
     N-cadherin 
     5β1 integrin 
     Vβ6 integrin 
     Syndecan-1 
    E-cadherin 
    ZO-1 
Cytoskeletal markers 
     FSP1 
     -SMA 
     Vimentin 
     β-Catenin 
    Cytokeratins 8/18/19 
ECM proteins 
    1(I) collagen 
    1(III) collagen 
    Fibronectin 
    Laminin 5 
    MMP2 
    MMP9 
    1(IV) collagen 
    Laminin 1 
    Desmoplakin 
 
Growth Factors 
    TGFβ 
    FGF-1,-2,-8 
 
Transcription factors 
    Snail 1 (Snail) 
    Snail 2 (Slug) 
    ZEB 1/2 
    Twist 
    FOXC2 
 
MicroRNAs 
    miR10b 
    miR-21 
    miR-200 family 
 
 
Table 1-Main markers of cells undergoing EMT. 
 
 
Although TGFβ is an important suppressor of tumorigenesis due to its role inducing 
apoptosis and cell cycle arrest in the initial stages, it is an important EMT inducer, 
enhancing tumor progression and metastasis (Tse and Kalluri 2007). Smad-
independent signaling pathways activated by TGFβ such as RhoA, p38 MAPK and 
PI3K/Akt pathways are involved in EMT induction (Boyer et al. 1999, Bhowmick et al. 
2001, Strutz et al. 2002, Yu et al. 2002). p38 MAPK pathway also collaborates with 
Smad 2/3 in the regulation of TGFβ1-dependent expression of fibronectin and collagen 
I in pulmonary epithelial cells and its inhibition blocks twist expression (Kolosova et al. 
2011). Moreover, p38 MAPK, together with Smad, NF-κB and ZEB 2 mediate N-
cadherin up-regulation induced by TGFβ1 in combination with TWEAK (Itoigawa et al. 
2015). In contrast, other data indicate that p38 maintains E-cadherin expression in 
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human primary mesothelial cells by suppressing TAK1–NFκB signaling, which impairs 
EMT (Strippoli et al. 2010). Other studies support a role for p38 MAPK in the regulation 
of EMT in breast cancer cells through the control of the expression of miRNAs, Twist, 
Snail, Slug and ZEB 2 (Antoon et al. 2013).  
In colorectal cancer, Wnt/β-catenin signaling pathway and the switch from E- to N-
cadherin neo-expression are considered the major inducers of EMT and metastatic 
progression (Cavallaro et al. 2002, Thiery 2002, Rosivatz et al. 2004, Pancione et al. 
2012). Wnt pathway is activated in stem-like tumors and cell lines, which co-expressed 
markers of intestinal and colorectal stem cells and EMT genes (Merlos-Suarez et al. 
2011). Moreover, Snail is often amplified in colon cancer (Hidaka et al. 2000, Nakao et 
al. 2001). Although TGFβ1 can induce EMT in colon cancer cell lines bearing a wild 
type TGFβR2 (Pancione et al. 2012), most colorectal cancer cells appear to be 
resistant to the induction of EMT by TGFβ (Calon et al. 2015). However, the presence 
of the EMT signature in these tumors associates with a worse prognosis and less 
sensitivity to conventional chemotherapy (Pereira et al. 2015). 
 
7. STROMAL REGULATION IN CANCER 
Cancer cells interact with the host stromal microenvironment, which contributes to 
support tumor growth and to induce metastasis. The stroma is formed by the 
extracellular matrix and cellular components including fibroblasts (myofibroblasts), glial, 
epithelial, fat, immune, vascular, smooth muscle and immune cells (Zeisberg et al. 
2007, Gout and Huot 2008). 
Cells from the stroma influence the initiation and promotion of cancer by secreting 
cytokines and growth factors and/or by expressing their receptors, so that, contributing  
to stimulate tumor cell growth and recruitment of precursor cells. At the same time, 
cancer cells modulate the stroma signaling (Li et al. 2007, Zeisberg et al. 2007). 
Tumor cells recruit and activate fibroblasts through various mechanisms, becoming 
myofibroblasts or cancer associated fibroblasts (CAFs) (Condeelis and Pollard 2006, 
Gout and Huot 2008). Several cytokines and growth factors, including TGFβ, PDGF, IL-
4 and IGF-2, have been reported to induce this myofibroblastic process. Other required 
signals for this process are reactive oxygen species (ROS), matrix proteins and 
mechanical stress arising from integrin-dependent cell interactions (Conti and Thomas 
2011). CAFs are perpetually activated and express -SMA. CAFs can themselves 
initiate cancer in response to HGF or TGFβ and they can contribute to proliferation and 
progression of cancer cells through the production of growth factors, chemotactic 
factors, angiogenic factors and MMPs. Additionally, these signals also lead to the 
transformation of endothelial cells into CAFs (Condeelis and Pollard 2006). 
Other types of cells recruited to the primary tumor are tumor-associated macrophages 
that came from monocytes recruited into tumors in response to cancer-associated 
inflammation. They produce VEGF, HGF, MMP2 or IL-8 (Barbera-Guillem et al. 2002). 
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Many tumors gain the ability to produce TGFβ, to stimulate tumor growth and invasion 
in an autocrine way, promoting angiogenesis and avoiding the immune system (Siegel 
and Massague 2003, Li et al. 2007). In response to TGFβ, CAFs proliferate and 
secrete cytokines, which will have further effects in tumors. In colorectal cancer, 
mesenchymal stem cells (MSC) that integrate into the tumor stroma have been 
reported to induce an EMT process of these cancer cells, which is mediated by TGFβ 
(Mele et al. 2014). TGFβ in colorectal cancer cell lines enhances cell growth (Sun et al. 
2013). In addition, TGFβ produced by stroma increases the frequency of tumor- 
initiating cells and increases the efficiency of organ colonization during the initial phase 
of metastasis (Calon et al. 2012, Calon et al. 2015). 
The chemokine stroma-derived factor (SDF-1/CXCL12) is constitutively produced by 
mesenchymal and marrow-derived stromal cells. In cancer, SDF-1 acting through 
CXCR4 receptor promotes tumor growth, angiogenesis, tumor metastasis and 
contributes to the immunosuppressive response (Li et al. 2007, Kim 2012, Hu et al. 
2014). The SDF-1/CXCR4 pathway is also involved in colorectal cancer progression, 
inducing invasion and EMT through activation of the Wnt/β-catenin signaling pathway 
(Hu et al. 2014). Stromal cells are positive for SDF-1 and cancer cells also have a 
strong expression of SDF-1 and its receptor CXCR4 (Kim 2012).   
Stromal fibroblasts, macrophages, and epithelial cells secrete MMPs that hydrolyze the 
extracellular matrix proteins of the surrounding tissue. For example, fibroblasts can 
produce MMP2 and macrophages MMP9. MMPs inhibitors, such as TIMP-1 can be 
also produced by stromal cells (Li et al. 2007). 
 
8. EPIGENETIC REGULATION AND DNA-METHYLASES 
8.1  EPIGENETIC: DNA METHYLATION 
The term epigenetic has been defined as the inheritance of changes in gene function 
without any change in the DNA nucleotide sequence (Hammoud et al. 2013). 
Epigenetic regulation controls gene expression in response to environmental changes 
and developmental status (Golbabapour et al. 2011). 
Epigenetic modifications comprise DNA methylation, post-translational histone 
modifications and nucleosome positioning, chromatin remodeling and post-
transcriptional modification of certain non-coding RNAs, among other mechanisms 
(Portela and Esteller 2010, Tost 2010). Epigenetic regulation is considered a key 
mechanism to maintain normal development and tissue homeostasis, so abnormalities 
in this regulation have been detected in different pathologies, being remarkable those 
found in cancer (Tost 2010). 
The most widely studied epigenetic modification in human is cytosine methylation. DNA 
methylation occurs in the 5 position of the pyrimidine ring of cytosines in the context of 
the dinucleotide sequence CpG, clustered in CpG islands. However, DNA methylation 
does not occur exclusively at CpG islands (Portela and Esteller 2010). In general, CpG-
island methylation is associated with gene silencing. DNA methylation can inhibit gene 
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expression by different mechanisms. First, DNA methylation inhibits the association of 
the transcriptional machinery to promoter regions (figure 9). In addition, methylated 
DNA can promote the recruitment of methyl-CpG-binding domain (MBD) proteins, 
leading to the formation of histone modifying and chromatin-remodeling complexes 
(Bird and Wolffe 1999, Portela and Esteller 2010). In fact, chromatin assembled on 
methylated DNA associates with hypoacetylated histones and becomes 
transcriptionally silent (Bird and Wolffe 1999, Esteller 2002).  
In several types of cancer, hypermethylation of CpG islands in promoter regions of 
tumor suppressor genes has been described and it is considered an important 
mechanism for inactivation of these genes.  
. 
 
 
Figure 9-DNA methylation of CpG islands at promoters impairs transcriptional activation. DNA 
methylation can occur in different regions of the genome. Methylation of regulatory regions of the genome 
impairs transcription (Portela and Esteller 2010). 
 
 
8.2  DNA METHYLTRANSFERASES (DNMTs) 
DNA methylation is mediated by the DNMT family of enzymes that catalyze the transfer 
of a methyl group from S-adenosyl methionine to CpG (Robertson 2001). In mammals, 
five members of the DNMT family have been reported so far: DNMT1, DNMT2, 
DNMT3A, DNMT3B and DNMT3L. DNMT can be classified into de novo DNMTs 
(DNMT3A and DNMT3B) and maintenance DNMTs (DNMT1) (Golbabapour et al. 
2011). 
DNMT1 methylates both imprints and non-imprints genes (Golbabapour et al. 2011). 
DNMT1 has a preference toward hemimethylated DNA and is the most abundant 
methyltransferase in somatic cells. It is responsible for maintaining the methylation 
patterns following DNA replication (Robertson 2001). DNMT3 functions as a novo 
methyltransferase, with the same preference for unmethylated and hemimethylated 
DNA, and consists of two related proteins encoded by distinct genes, dnmt3a and 
dnmt3b. DNMT3A and DNMT3B are thought to be responsible for establishing the 
pattern of methylation in germ cells during embryonic development (Portela and 
Esteller 2010). DNMT2 and DNMT3L do not show methyltransferase activity. DNMT2 
seems to play a regulatory role in DNA methylation and it might methylate RNA instead 
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of DNA, but this remains unclear (Newell-Price et al. 2000, Golbabapour et al. 2011, 
Subramaniam et al. 2014). 
As outlined in figure 10, DNMTs are comprised of two regions: the conserved C-
terminal catalytic domain with 500 amino acids and the N-terminal region with a large 
multi-domain of variable size, which has regulatory functions. The catalytic domain 
shares a common structure called “Ado-Met dependent methyltransferase”, involved in 
cofactor binding and catalysis (Newell-Price et al. 2000). 
 
 
Figure 10-Schematic representation of the structure of human DNMTs. DNMT1, DNMT2, DNMT3A, 
3B and 3L structure is shown. The N-terminal region contains motifs of interaction with proteins or DNA 
and the C-terminal contains the conserved methyltransferases domains. PHD means plant homology 
domain (Subramaniam et al. 2014). 
 
 
DNMT3 (A and B) levels can be regulated, being of relevance its post-transcriptional 
regulation (Denis et al. 2011). It has been described that HuR protein, an RNA-binding 
protein that stabilizes and/or modulates the translation of target mRNAs, binds to the 
3´UTR of dnmt3b mRNA at an HuR-recognition motif. This interaction stabilizes 
dnmt3b mRNA, leading to an increase in DNMT3B protein levels in colorectal RKO 
cells (Lopez de Silanes et al. 2009). 
Human DNMTs levels, specially, those of DNMT3A and 3B, are often increased in 
several cancers such as colon, prostate, breast, liver and leukemia. In colon cancer, 
DNMT1 and DNMT3 modulate different histone modification complexes (Newell-Price 
et al. 2000) and there has been found several hypermethylated gene promoters such 
as MLH1, retinoblastoma, p16, rarrb, and sfrp promoters (Nosho et al. 2009). dnmt3b 
INTRODUCTION 
 
35 
 
expression in colorectal cancer is significantly associated with the CpG island 
methylator phenotype pathway (Nosho et al. 2009). Moreover, DNMT3B activation has 
been implicated in aberrant de novo methylation of CpG islands in this type of cancer 
(Okano et al. 1999, Kanai and Hirohashi 2007, Linhart et al. 2007), being also capable 
of inducing colon tumors in mice (Linhart et al. 2007). 
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1. FUNCTION OF p38 PATHWAY IN CELL DEATH. 
CROSSTALK WITH C3G 
p38 MAPKs can act mediating cell death or survival depending on different factors, 
such as the cell type, the stimulus and the p38 isoform. Some years ago, there were 
many studies indicating that p38 MAPKs promoted cell death, although a few 
suggested that p38 MAPKs could also play a pro-survival role (Nebreda and Porras 
2000). However, the precise function of p38 MAPKs regulating cell death was unclear.  
During the last years, our group focused their studies on the characterization of the 
function of p38 MAPK pathway in the regulation of cell death and its functional 
interaction with other pathways using embryonic cardiomyocytes and MEFs-derived 
cell lines from p38 deficient mice. Data from those studies have demonstrated that 
p38 plays a relevant role as a mediator of apoptosis in response to several stimuli 
through both, the up-regulation of some pro-apoptotic proteins (Porras et al. 2004) and 
the down-regulation of the activity of the survival pathways, ERKs (Porras et al. 2004) 
and Akt (Zuluaga et al. 2007). 
In collaboration with Dr. Carmen Guerrero’s group (Centro de Investigación del Cáncer 
de Salamanca), we also studied the potential crosstalk between p38 and C3G 
pathways. We have found a new functional relationship between C3G and p38 MAPK 
regulating cell death in MEFs (Gutierrez-Uzquiza et al. 2010) and in the K562 chronic 
myeloid leukemia (CML) cell line (Maia et al. 2009). In both cell models C3G regulates 
apoptosis through down-regulation of p38 activity. In K562 CML cells, C3G silencing 
enhances STI-571-induced apoptosis through the up-regulation of p38 activity by a 
mechanism dependent on Rap1 (Maia et al. 2009). In MEFs, C3G knock-down also 
through the up-regulation of p38 activity either promotes cell survival in response to 
oxidative stress or cell death upon serum-deprivation, but through a Rap1 independent 
mechanism as shown in figure 11 (Gutierrez-Uzquiza et al. 2010).  
                                
 
Figure 11-Regulation of apoptosis by C3G and Rap1 through p38 MAPK. Model showing the 
regulation of p38 by C3G and Rap1 in MEFs and their effects on the balance between apoptosis and cell 
survival. (A) Upon serum deprivation, C3G through the negative regulation of p38 mediates cell survival, 
while activation of Rap1 by other GEFs, leads to p38 activation inducing apoptosis. (B) Upon treatment 
with H2O2, C3G mediates apoptosis through inhibition of p38 activity and Rap1 (activated by other GEFs) 
induces cell survival through p38 (Gutierrez-Uzquiza et al. 2010). 
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Moreover, the group has revealed a novel pro-survival role for p38 in response to low 
or moderate doses of H2O2, which involves the induction of antioxidant enzymes such 
as superoxide-dismutase-2 (SOD-2) and catalase preventing from a high accumulation 
of ROS. As shown in figure 12, p38 allows cells to survive under mild levels of 
oxidative stress in MEFs. It was also found that mTOR/p70S6K activation is dependent 
on p38 activation in this oxidative microenvironment (Gutierrez-Uzquiza et al. 2012). 
This pro-survival role of p38 could be a key event in the control of tumor growth in 
different types of tumors, including the colorectal cancer. 
 
 
 
 
Figure 12-p38 protects from H2O2-induced cell death. MEFs (wt and p38 −/−) maintained in the 
presence of serum were treated with H2O2 when indicated. (A) p38 expression increases cell viability in 
cells treated with H2O2 (0.1 or 0.5 mM) for 24 h. (B) p38 reconstitution in p38−/− cells (Rec) rescues 
cells from cell death upon treatment with H2O2 (1 mM)  for 6 h. The data correspond to cell viability 
expressed as the percentage of control value in wt cells. p38 expression was determined by Western blot 
and normalized with tubulin. (C) Loss of p38 increases the number of apoptotic nuclei in cells treated with 
H2O2 (0.5 mM) for 3 h. *p<0.05 and ***p<0.001, p38 −/− versus wt MEFs upon treatment with H2O2 
(Gutierrez-Uzquiza et al. 2012). 
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2. ROLE OF p38 MAPK IN THE REGULATION OF APOPTOSIS 
IN THE HUMAN COLON CARCINOMA HCT116 CELL LINE 
To assess the role of p38 as a regulator of cell death in response to some 
chemotherapeutical compounds in the human colon carcinoma HCT116 cell line, 
permanent p38 knock-down cells were used. Data revealed that p38 is a key player 
in cisplatin-induced apoptosis. Hence, as shown in figure 13, in response to cisplatin, 
p53 is activated, increasing their levels, which leads to a p53-mediated ROS production 
that activates p38 MAPK. Through this cascade, p38 induces apoptosis and 
enhances the initial p53 activation, leading to a subsequent p38/p53 positive 
feedback loop (Bragado et al. 2007). 
Therefore, p38 is mediating cell death in HCT116 cells and we wondered if p38 
pathway could be a major regulator of other cellular processes in these cells identifying 
mechanisms for its actions. 
 
                                      
 
 
Figure 13-Cisplatin-induced apoptosis in HCT116 cells through the p53/ROS/p38 MAPK cascade. 
p53 increases in response to cisplatin, which leads to ROS accumulation leading to p38 MAPK-mediated 
apoptosis. p38 MAPK enhances p53 activation, which results in a p38 MAPK/p53 loop of amplification 
(Bragado et al. 2007). 
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3. FUNCTION OF p38 MAPK IN CELL ADHESION AND 
MIGRATION. NEW TARGETS OF p38 
p38 MAPKs also play a key role in the regulation of cell adhesion and migration. In 
agreement with this, our group showed that p38 through down-regulation of Rac-1 
activity negatively regulates cell adhesion in embryonic cardiomyocytes derived cell 
lines (Zuluaga et al. 2007). Moreover, in collaboration with Dr. Carmen Guerrero’s 
group, we found that C3G and p38 acting through a common regulatory cascade 
promote cell adhesion in the K562 CML cell line regulating focal adhesion proteins 
(Maia et al. 2013). However, C3G and p38 display antagonistic roles in the regulation 
of focal adhesion complex formation (Maia et al. 2013). These data, together with the 
function of C3G/p38 in the control of cell death, prompted us to investigate if C3G 
acting through p38 could be also regulating migration and invasion processes in 
MEFs (M.Arechederra´s Thesis) and in the human colon carcinoma HCT116 cell line. 
Results derived from this analysis in MEFs revealed that C3G inhibits migration and 
invasion through down-regulation of p38 activity. 
In addition, to uncover novel mechanisms of action of p38 MAPKs in cell adhesion and 
migration/invasion, we have previously performed DNA microarray analyses using wt 
and p38 knock-out MEFs (A. Gutiérrez´s Thesis). Data derived from these studies 
showed up changes in the expression of a number of genes and some of them 
encoded proteins involved in the regulation of these processes such as Fibulin 3. In 
fact, Fibulin 3 was highly up-regulated in p38 knock-out MEFs. These results were 
validated by RT-PCR and RT-qPCR in MEFs. Therefore, based on the strong negative 
regulation of Fibulin 3 by p38, it was studied how p38 MAPK regulated Fibulin 3 
expression and the implication of this p38/Fibulin 3 pathway in the regulation of cell 
migration and invasion in MEFs (M. Arechederra´s Thesis). In particular, p38 was 
shown to silence Fibulin 3 expression through methylation of regulatory sequences of 
the gene, which enhanced migration/invasion. In parallel, this was also studied in a 
tumor model, the human colon carcinoma HCT116 cell line.  
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General Aim: 
 
The main aim of this research project is to study the role played by C3G/p38 MAPK 
cascade in the control of migration, invasion and tumor growth in a human colon 
carcinoma model, as well as to determine if Fibulin 3 could be a target of p38 to 
control these processes.  
 
 
Specific Aims: 
 
1. To determine if p38 MAPK regulates fibulin 3 expression, how it does it and 
the role of Fibulin 3 as a potential mediator of p38 actions on cell migration, 
invasion and tumor growth. 
 
 
2. To analyze whether C3G could act through p38 MAPK to regulate migration, 
invasion and tumor growth, identifying the mechanisms involved. 
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1. CELL LINES 
In our studies, we have used the human colon carcinoma cell line HCT116 obtained 
from ATCC (CCL-247), which were authenticated by microsatellite markers analysis. 
HCT116 cells with permanent p38 knock-down, previously generated in our laboratory 
by transfection of a p38 shRNA inserted in pSuper.retro.puro vector 
(OligoEngineVEC-PRT-0001) (Bragado et al. 2007), were also used. Additionally, 
these cells were, either permanently or transiently, genetically modified. 
 
Organism Homo sapiens, human 
Tissue Colon ascendens 
Morphology Epithelial 
Culture Properties Adherent 
Disease 
Colorectal carcinoma. Derived from primary 
tumor 
Age Adult (48-year-old) 
Gender Male 
Stage Dukes´D 
Characteristics 
This cell line has a mutation in codon 13 
(G13D) of the Ras proto-oncogene, in exon 
20 (H1047R) of the p110 catalytic subunit of 
PI3K (PIK3CA) and premature truncations in 
codon 216 of the E-cadherin gene (CDH1). 
 
Other relevant mutations: Cyclin-dependent 
kinase inhibitor 2A (CDKN2A) and β-catenin 
(CTNNB1). 
 
wt for APC, B-RAF, PTEN and TP53. 
 
Positive for CpG island methylator phenotype 
and negative for chromosomal instability. 
 
Microsatellite instability. 
 
 
Table 2- Characteristics of HCT116 cell line. From Ahmed et al. 2013 and ATCC. 
 
 
1.1  FIBULIN 3 KNOCK-DOWN: 
Permanent fibulin 3 knock-down (in parental and p38 knock-down HCT116 cells) was 
performed by transfection with a human fibulin 3 shRNA (OriGeneTechnologies, 
TR30018) inserted in the pGFP-B-RS vector. To do it, cells at a confluence around 50-
60% were used. The medium was replaced by a fresh one (with serum) and the 
transfection was done using Metafectene-Pro reagent (Biontex, T040-0.2) following the 
commercial protocol. 48 h after transfection, cells were trypsinized and splitted to select 
clones expressing the shRNA using a blasticidin (2 µg/ml) containing medium. Different 
clones were picked, expanded and analyzed for fibulin 3 expression. As a control, cells 
transfected with the empty vector were also generated.  
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Transient fibulin 3 knock-down was also performed using a second human fibulin 3 
shRNA (Sigma, NM-004105). Cell assays were initiated 48 h after transfection. 
 
1.2  C3G PERMANENT KNOCK-DOWN: 
Permanent C3G knock-down (in parental and p38 knock-down HCT116 cells) was  
done by infection with  lentiviral particles containing a mixture of different human C3G 
shRNAs (Santa Cruz Biotechnology, sc-29863-V) or a control shRNA (Santa Cruz 
Biotechnology, sc-134220). Cells were seeded 12 h prior to the viral infection at a 
density that guaranteed 50-60% confluence the next day. Then, the medium was 
replaced and 75.000 infectious units of lentiviral particles were added in the presence 
of 10 µg/ml polybrene. Cells were incubated overnight and the medium was removed 
and a fresh one was added. After 48 h cells were selected with 2µg/ml puromycine. 
Different clones were picked, expanded and analyzed for C3G protein levels. 
C3G knock-down was also performed with an alternative infection with lentiviral 
particles containing a shRNA (5´GATCCCCCCACTATGATCCCGACTATTTC 
AAGAGAATAGTCGGGATCATAGTGGTTTTTGGAAA3´) kindly supplied by Dr. 
Guerrero´s group inserted in the pLVTHM vector containing GFP. GFP expressing cells 
were selected. 
 
1.3  RAP1 PERMANENT KNOCK-DOWN:  
Permanent Rap1 knock-down (in parental and p38 knock-down HCT116 cells) was 
performed using two different shRNAs against human Rap1 (Sigma, 
TRCN0000029784 and TRCN0000029788) inserted in the pLKO.1-puro plasmid. 
Transfection was done using Metafectene-Pro reagent, as described above. Cells were 
selected and maintained with 2µg/ml puromycine.  
 
1.4  RE-EXPRESSION OF DNMT3A: 
To re-express DNMT3A in HCT116 shp38 cells, transient transfections were 
performed using dnmt3a inserted in the pcDNA3 vector using Metafectene-Pro 
reagent, as described above. Experiments were performed 48-72 h after transfection. 
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2.  CELL CULTURE CONDITIONS AND PRESERVATION 
2.1  CELL CULTURE CONDITIONS 
HCT116 cells were grown in McCoy’s medium (Invitrogen, 16600-082) supplemented 
with 10% fetal bovine serum (FBS) (Gibco, 26140-079), 20 mM Hepes (pH 7.4) and 
antibiotics: penicillin (12 µg/ml), streptomycin (10 µg/ml), amphotericin B (0.25 µg/ml) 
and MycoZap (Lonza, VZA-2012). HCT116 cells with permanent p38, C3G and Rap1 
knock-down were grown in the same medium, in the presence of puromycin (2 µg/ml) 
(Sigma-Aldrich, P8833). HCT116 cells with permanent Fibulin3 knock-down were 
grown in the presence of blasticidin (2 µg/ml) (Invitrogen, R210-01). Antibiotics were 
removed from the medium 48h before performing the experiments. 
Cells were splitted when they reached 90% confluence by trypsinization. Cells were 
washed with phosphate-buffered saline (PBS) (Gibco, 70011) and Trypsin 0,25%-
EDTA 0,02% (Gibco, 25200-056) was added. Trypsin action was stoped with10% FBS 
supplemented medium. The cellular suspension was splitted out following the required 
conditions for each experiment. Cells were maintained at 37ºC with 5% CO2 in a 
humidified atmosphere. 
 
2.2  FREEZING, CRYOPRESERVATION AND THAWING OF CELLS  
Cells were stored in 10% DMSO-FBS in liquid nitrogen (-170 ºC). Cells were 
progressively frozen: -20 ºC (for 20-30 min), -80 ºC (for 12-16 h) and liquid nitrogen. 
Thawing was performed quickly at 37ºC and cells were placed in the appropriated 
culture medium. When cells were attached, medium was replaced by fresh medium to 
remove DMSO. 
 
2.3  CELL TREATMENTS  
 Cells were treated with the following compounds: 
Inhibitors:  
 p38/β inhibitor, SB203580 (Calbiochem, 559389), at 5 M (mainly for p38) or 
10 M (for p38 and β). 
 5-aza-2´-deoxicytidine (Sigma, 3656), at 0.5-1 M for 48 h (24 h of pretreatment 
and 24 h of treatment in the absent of FBS) to inhibit DNA methylation. 
 Broad spectrum MMPs inhibitor, marimastat, at 0,01 M. 
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Stimuli: 
 Serum: 10% FBS for 10 min after serum-deprivation (24h) for signalling 
experiments.  
 Hepatocyte growth factor (HGF): 40 ng/ml for different time periods (10, 20 and 60 
min) in serum deprived cells for signalling experiments or for 24-72h to promote 
migration and invasion. 
 Hydrogen peroxide (H2O2): 2 mM treatment for 4h to assess cell viability. 
 
3. PROTEIN ANALYSIS 
 
3.1  PREPARATION OF CELL EXTRACTS  
Depending on the assay, cell culture medium was collected into tubes and stored at -
80ºC until it was processed. Then, cells were washed twice with cold PBS and lysed 
with the following buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP40, 5 mM 
EGTA, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin,10 μg/ml 
leupeptin, 1 mM NaVO3 and 20 mM NaF. 
Cells were detached from the plate by scraping, collected in an Eppendorf tube and 
maintained on ice for 10 min. Every 5 min, tubes were shaken using a vortex. Then, 
cell lysates were centrifuged at 13000 rpm for 10 min at 4°C. The supernatant (total 
protein extracts) was transferred to a new tube and stored at -80°C. 
 
3.2  PROTEIN QUANTIFICATION  
Protein quantification was performed using the method described by Bradford in 1976. 
Five min after addition of Bradford reagent (diluted 1:5 in ultrapure water) to the 
samples, the absorbance at 595 nm was measured. For each experiment, a standard 
curve with known concentrations of bovine serum albumin (0 to 5 µg/µl) was used to 
extrapolate sample values.  
 
3.3 WESTERN-BLOT ANALYSIS 
3.3.1 Protein electrophoresis 
Protein electrophoresis was performed using SDS-polyacrylamide gels (SDS-PAGE) 
and non-SDS-polyacrylamide gels (Anderson gels) (Table 1). The last ones allow a 
better separation of phosphorylated proteins with similar electrophoretic mobility. 
Acrylamide concentrations were chosen according to the proteins size to be studied: 
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for proteins of a relatively small molecular weight (30-80 KDa), we used higher 
percentages of the separating gel (12-15%) and for proteins higher than 80-100 KDa, 
we used lower percentages of the separating gel (7.5%-10%). Protein samples were 
prepared by adding Laemmli buffer 4X (Tris-HCl pH 7.6, 10% (w/v) glycerol, 1% (w/v) 
SDS, 0.002% (w/v) bromophenol blue, 2 mM β-mercaptoethanol) to the protein 
extracts. Then, they were heated at 95ºC and loaded into the gel, as well as the 
molecular weight markers.  
Electrophoresis was developed at a constant amperage of 20 mA using the following 
running buffers: 
- For SDS-PAGE gels: 25 mM Tris-HCl (pH 8.3), 200 mM Glycine and 0.1% SDS. 
- For Anderson gels: 50 mM Tris-HCl (pH 8.3), 400 mM Glycine and 0.1% SDS. 
SDS-PAGE gels composition (Vf=10ml) 
 
Composition Separating Gel 
10% 
Separating Gel 
12% 
Separating Gel 
15% 
Stacking gel 
(Vf=5ml) 
30% Acrylamide/  
Bisacrylamide 
3.3 ml  4 ml  5 ml  0.83 ml  
H2O  4 ml  3.3 ml  2.3 ml  3.4 ml  
1.5 M Tris pH 8.8  2.5 ml  2.5 ml  2.5 ml  -  
1 M Tris pH 6.8  -  -  -  0.63 ml  
10% SDS (w/v)  100 μl 100 μl 100 μl 50 μl 
10% 
Ammoniumpersulfate  
100 μl 100 μl 100 μl 50 μl 
TEMED  4 μl 4 μl 4 μl 5 μl 
 
Anderson gels composition (Vf=10 ml) 
 
Composition Separating 
Gel 7.5% 
Separating Gel 
10% 
Separating Gel 
15% 
Stacking gel 
(Vf=5 ml) 
30% Acrylamide  2.52 ml  3.36 ml  5.03 ml  0.833 ml  
1% Bis-acrylamide  1.95 ml  1.31 ml  0.87 ml  0.667 ml  
H2O  3.02 ml  2.82 ml  1.59 ml  2.875 ml  
1.5 M Tris pH 8.8  2.52 ml  2.52 ml  2.52 ml  -  
1 M Tris pH 6.8  -  -  -  0.625 ml  
10% Ammonium 
persulfate  
50 μl 50 μl 50 μl 50 μl 
TEMED  5 μl 5 μl 5 μl 5 μl 
 
 
Table 3- SDS-PAGE and Anderson gels composition. 
 
 
 
3.3.2 Proteins transfer  
Proteins from the gels were transferred to a nitrocellulose membrane using a semi-dry 
equipment. The nitrocellulose membrane was activated by immersion into distilled 
water and it was assembled as follows from bottom to top: 3 Whatman papers, 
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nitrocellulose membrane, acrylamide gel and 3 Whatman papers, which were all 
previously soaked in transfer buffer (20% methanol, 50 mM Tris, 400 mM glycine and 
0.1% SDS). Then, an electrical current of 15 V for 30-45 min (depending on the 
number/size of gels) was applied. Transfer was confirmed by staining the membrane 
with a Ponceau S solution (0.5% in 1% acetic acid).  
 
3.3.3 Proteins immunodetection 
Membranes were washed several times with distilled water, and twice with Tween-Tris-
buffered saline (TTBS) (10 mM Tris-HCl, 150 mM NaCl, pH 7.5 (TBS) with 0.05% 
Tween-20). Then, they were incubated in the blocking solution (either 5% non-fat dry 
milk or 5% BSA in TTBS) for one hour at room temperature. After this time, they were 
rinsed with TTBS and incubated with the primary antibody in 5% non-fat milk-TTBS or 
BSA-TTBS (for phospho-proteins) 1 h at room temperature (RT) for non-
phosphorylated proteins or overnight at 4 ºC for phospho-proteins at the indicated 
dilution (Table 2). Then, membranes were washed 3 times with TTBS (5 min/each) and 
incubated for 1 h at RT with the secondary antibody at a dilution of 1:5000 in the same 
buffer as the primary antibody. Finally, they were washed 3 times with TTBS and 
incubated with a chemiluminescent solution (Pierce ECL from Thermo Scientific, 
32106) to visualize proteins in an X-ray film. 
 
Primary antibody Laboratory Dilution 
Secondary 
antibody 
Dilution 
p38 
Santa Cruz Biotechnology sc-
535 
1:1000 Rabbit 1:3000 
C3G (H-300) 
Santa Cruz Biotechnology sc-
15359 
1:1000 Rabbit 1:3000 
Fibulin 3 
Santa Cruz Biotechnology sc-
99177 
1:1000 Rabbit 1:3000 
Phospho-p38 MAPK 
Cell Signaling 
Technology 9211 
1:1000 Rabbit 1:2500 
Phospho-ERK1/2 Cell Signaling Technology 9101 1:1000 Rabbit 1:3000 
Phospho-Ser473-Akt Cell Signaling Technology 9271 1:1000 Rabbit 1:3000 
E-cadherin 
BD Transduction Laboratories 
610181 
1:1000 Mouse 1:3000 
N-cadherin 
BD Transduction Laboratories 
610920 
1:1000 Mouse 1:3000 
ZO-1 Invitrogen 33-9100 1:1000 Rabbit 1:3000 
DNMT3A Cell Signaling Technology 2160 1:500 Rabbit 1:3000 
HuR 
Santa Cruz Biotechnology sc-
5161 
1:1000 Rabbit 1:3000 
β-Actin Sigma 4-5441 1:1000 Mouse 1:5000 
 
 
Table 4- Primary and secondary antibodies used for Western-Blot. 
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4. ANALYSIS OF mRNA EXPRESSION 
 
4.1  TOTAL RNA ISOLATION 
Cells were washed twice with cold PBS and total RNA was isolated using RNeasy Mini 
Kit (Quiagen, 74104) following manufacturer instructions. DNase (Quiagen, 79254) 
treatment was included to avoid possible genomic DNA contaminations. Finally, RNA 
was eluted with ultrapure water and stored at -80ºC until its use. RNA concentration 
was determined by spectrophotometry absorbance measurement at 260 nm (one unit 
of absorbance at 260 nm corresponds to 40 μg of RNA per ml). To estimate RNA 
purity, the ratio between the absorbance at 260 and 280 nm was calculated. A ratio 
A260/A280 of 1.8-2 is accepted for pure RNA. 
 
4.2  c-DNA SYNTHESIS 
Total RNA (1-3 µg) was reverse-transcribed to generate the cDNA using the Super 
Script III RT kit (Invitrogen, 18080-040) following instructions from the manufacturer. 
Essentially, RNA mixed with oligo (dT) (0.5 mM) and random primers (2.5 µM), was 
incubated at 65 ºC for 5 min to ensure RNA denaturation and then, placed on ice for at 
least one min. cDNA synthesis mix (5X RT buffer, 20 Units of RNase inhibitor, 5 mM 
DTT and 200 Units of SuperScript III) was added to each sample and incubated at 
50ºC for 1h. The reaction was stopped by heating at 70 ºC for 15 min to inactivate the 
enzyme. c-DNA was stored at -20 ºC for its use for qPCR analysis. 
 
4.3  QUANTITATIVE PCR 
Real time PCR or quantitative PCR (qPCR) was performed using specific primers and 
Fast Start Universal SYBR Green Master (Rox) (Roche, 04913850001) to detect DNA 
in the 7900 Fast Real Time System (Life Technologies, 4329001). PCR reactions were 
done in triplicate using specific primers (Table 3). GAPDH was used as the normalizing 
gene, as its expression was constant under the experimental conditions, and different 
negative controls were used prepared with RNA or water instead of the cDNA. 
A qPCR curve has typically an exponential phase followed by a plateau phase. To 
interpret the fluorescence emission, a fluorescence threshold bigger than background 
signal is determined during the exponential phase of real-time PCR. To process the 
data, the fractional number of PCR cycles required to reach this threshold is defined as 
the cycle threshold, or Ct. The Ct measure needs to be in the exponential phase of 
amplification, where the curve is linear. 
To perform the analysis of the data, ΔCt value for each sample and primer is obtained 
as follows: Ct for a primer minus Ct for the normalizing control (GAPDH in this case) 
under a particular experimental condition. Then, the values are referred to the control 
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condition, obtaining the ΔΔCt value (sample ΔCt-control ΔCt=ΔΔCt). Finally, 
quantification of RNA levels was performed using the relative quantification (RQ), 
calculated as follows: RQ= 2-∆∆Ct. 
We consider a RQ significant when there is a minimum of two-fold change: RQ of more 
than 2 or less than 0,5.  
 
 
 
 
Table 5- Sequences of the primers used in quantitative PCRs. 
 
 
5. ADHESION, MIGRATION AND INVASION ASSAYS 
 
5.1  ADHESION ASSAY 
50,000 cells were seeded in 12 multiwell plates and left at 37 ºC for 30 min, 1 h or 2 h. 
Then, the culture medium was removed, cells were washed twice with PBS and 
incubated for 30 min at RT with a solution of 0.2% crystal violet (w/v in 2% ethanol, 
Sigma-Aldrich, C-0775). To remove crystal violet excess, plates were washed with 
distilled water and dried. Then, cells adhered to the plate were quantified. 
 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Human GAPDH CATCGAAGGTGGAAGAGTGG CATCAAGAAGGTGGTGAAGC 
Human Fibulin 3 TGGCGGCTTCCGTTGTTATCCA TGGGGCAGTTCTCGGCACAT 
Human TGFβ 1 GAGCCTGAGGCCGACTACTA CGGAGCTCTGATGTGTTGAA 
Human TGFβ RECEPTOR 1 CTTGTAAGCCAAGTTTTCACCC CTCCACATGCTTAGGGGTGT 
Human TNF GGCGCTCCCCAAGAAGACA AAGTGCAGCAGGCAGAAGAG 
Human CXCL12 (SDF-1) TCTGAGAGCTCGCTTGAGTG GTGGATCGCATCTATGCATG 
Human CXCR4 GCCTTATCCTGCCTGGTATTGTC GCGAAGAAAGCCAGGATGAGGAT 
Human MMP2 TCGCCCATCATCAAGTTCCC TTCTTTAGTGTGTCCTTAGCA 
Human MMP9 CGGTGATTGACGACGCCT ACCAAACTGGATGACGATGT 
Human MMP10 CATTGCTAGGCGAGATAGGGG CAGTCACAGAACATGCAGGA 
Human MMP13 TATGACTATGCGTGGCTGAA TGTGTCCCATTTGTGGTGTGG 
Human E-cadherin CAACGACCCAACCCAAGAA CACACACGVTGACCTCTAA 
Human N-cadherin GCGTGAAGGTTTGCCAGTGT AGCACAAGGATAAGCAGGATGA 
Human Snail 1 CTATGCCGCGCTCTTTCCTC CTGCTGGAAGGTAAACTCTGGA 
Human Twist 1 CAAAGAAACAGGGCGTGGGG CAGAGGTGTGAGGATGGTGCC 
Human Zeb 1 GGCATACACCTACTCAACTACGG TGGGCGGTGTAGAATCAGAGTC 
Human Zeb 2 AATGCACAGAGTGTGGCAAGGC ATCTGGCGTTCCAGGGACTCAT 
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5.2  WOUND HEALING ASSAY 
Cell migration was evaluated using wound healing assays. Confluent cells were pre-
treated with mitomycin C (25 μg/ml) (Sigma-Aldrich, M0503) for 30 min to inhibit cell 
growth. Then, they were washed with PBS and a straight scratch was done. Cells were 
washed again and a fresh medium supplemented with 2% FBS was added (control 
conditions) and cells were allowed to migrate for 12–72 h at 37 °C and 5% CO2 under 
these conditions or in the presence of HGF (40 ng/ml) to promote cell migration. 
Migration was followed over time by a phase-contrast microscope coupled to a digital 
camera. Photographs were taken at different time points (0 h, 12 h, 24 h, 48 h and 72 
h) and the percentage of wound healing closure was quantified using TScratch 
program and referred to 0 h value. 
 
5.3 INVASION ASSAY 
To study the invasive capacity of the cells through matrigel, Boyden chambers with 
transwells inserts (8 μm filter, BD, 353097) coated with matrigel (444 µg/cm2) (BD 
Biosciences, 356234) were used. 50.000 cells were seeded in the upper chamber in a 
serum-free medium. Depending on the assay, cells were treated with SB203580 or 
marimastat inhibitors. In the lower chamber, HGF (40 ng/ml) was added to the medium 
to act as chemoattractant and cells were left in the incubator for 24 h at 37 °C and 5% 
CO2. Then, the medium and matrigel from the upper chamber were removed and cells 
present in the lower chamber were fixed with 4% paraformaldehyde, washed several 
times with PBS and stained with 0.2% crystal violet w/v. Inserts were washed with 
distilled water and dried. To count the cells, a phase-contrast microscope was used. 
 
 
 
 
 
 
Figure 14- Schematic representation of invasion assay through matrigel. 
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6.  QUANTIFICATION OF MMP2 AND MMP9 ACTIVITIES BY 
ZYMOGRAPHY 
MMP2 (gelatinase A) and MMP9 (gelatinase B) activities were determined by 
zymography. 80% confluent cells were serum-deprived for 24-48h and the culture 
medium was collected. To establish the volume of medium to be used, total protein or 
RNA levels were measured to normalize. Samples were prepared using a non-reducing 
loading buffer 4X (250 Mm Tris-HCl pH 6.8, 25% glycerol, 2.5% SDS and 1 mg/ml 
Bromophenol blue) and under non-reducing conditions. Then, they were loaded in a 
8% SDS polyacrylamide gel, polymerized in the presence of 0.1% gelatin.  
The electrophoresis was carried out at constant voltage of 80 V for 3-4 h. Then, gels 
were washed with 2.5% Triton X-100 for 30 min to remove SDS, rinsed with substrate 
buffer (0.2 M NaCl, 5mM CaCl2, 1% Triton X-100, 0.02% NaN3, 50 mM Tris pH 7.5) 
and incubated in this buffer at 37°C overnight to allow protein renaturation and MMP 
activation. To visualize gelatin degradation areas as clear bands, the gel was stained 
with Coomassie Brilliant Blue (BioRad, 161-0400). 
 
7. ANALYSIS OF CELL VIABILITY AND APOPTOSIS 
 
7.1 ANALYSIS OF CELL VIABILITY  
HCT116 cells (40.000) were seeded in 24 multiwell plates in triplicate. At a confluence 
of 70%, cells were deprived and treated with 2 mM H2O2 for 4 h. The medium was 
removed, cells were washed twice with PBS and incubated with crystal violet (0.2% w/v 
in 2% ethanol solution) for 20 min. Then, cells were washed several times with distilled 
water until the excess staining was eliminated. The plate was air-dried, the stained 
cells were lysed in 1% SDS and absorbance at 560 nm was measured. Results are 
expressed as the percentage of viable cells as compared to control cells (100%). 
 
7.2 ANALYSIS OF ANOIKIS  
To quantify cell viability and apoptosis, HCT116 cells were maintained detached for 6 h 
(under soft shaking to prevent adhesion) and then were replated for 4h, the number of 
cells was counted and the nuclei morphology was analyzed. Nuclei were stained by 
incubation for 30 min (in the dark) with 0,25μg/ml propidium iodure in PBS containing 
50 μg/ml RNasa. Previously, cells were washed twice with cold PBS, fixed at RT for 30 
min using a solution of cold methanol:acetic acid (dilution 3:1) and washed again with 
PBS. Finally, cells were embedded in Vecta shield mounting medium (Vector 
laboratories, 101098-042) to visualize the preparations. Total number of nuclei and the 
number of apoptotic nuclei (condensed and/or fragmented) were counted. 
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8. TUMORIGENESIS STUDIES 
 
8.1 ANCHORAGE DEPENDENT GROWTH  
To measure anchorage-dependent growth, HCT116 cells (300) were seeded in a 6 cm 
dish in duplicate. After 8-10 days, the medium was removed and cells foci were fixed 
and stained with a 0.2% crystal violet w/v in 2% ethanol solution. The total number of 
foci was quantified using Image J program and their size using Open CFU program.  
 
8.2 ANCHORAGE INDEPENDENT GROWTH  
To measure anchorage independent growth in soft-agar, cells were cultured in 24 
multiwell dishes in triplicate, containing two agar layers. 3000 cells were resuspended 
in 0.7% agar (BD, 214530) diluted in complete medium and poured onto a 0.5 % layer 
of agar (diluted in medium). To prevent agar drying, fresh medium was added to the 
top layer every 3 days. After 10-15 days colonies were stained with 0.005% crystal 
violet (w/v) and counted. 
 
8.3 XENOGRAFTS ASSAYS 
HCT116 cells resuspended in McCoy’s medium (106/100 µl) were injected 
subcutaneously into the flank of eight-week-old male nude mice (Harlan Laboratories). 
Tumor growth was monitored twice a week for 6 weeks. Tumor size was calculated by 
the formula ((L/2)x(W/2))xπ, where L and W are the longest and the shortest diameter 
in cm, respectively. All animal experiments were carried out in compliance with the 
institutions guidelines. 
 
8.4 SPHERE FORMATION ASSAYS  
80.000 cells with or without p38, C3G or double knock-down, were seeded in triplicate 
in 6 multiwell plates in DMEM advanced medium (Life Technologies, 12491-023) 
supplemented with antibiotics and the following complements: hFGF2 at 20 ng/ml 
(Almone labs, F-170) and insulin (1 mg/L), transferrin (0.55 mg/L) and sodium selenite  
(0.67 μg/L) (Life Technologies, 41400-045). Photographs were taken every 24 h and 
the number of spheres was counted under a phase-contrast microscope.  
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9. CONFOCAL MICROSCOPY ANALYSIS 
 
9.1 F-ACTIN STAINING 
F-actin staining was performed using rhodamine-conjugated phalloidin. Cells were 
cultured in sterile glass coverslips, previously coated with 2% gelatin in PBS, which 
were placed inside a 24 multiwell plate. After 24-48 h, the medium was removed and 
cells were fixed with 4% paraformaldehyde for 20 min at room temperature. After 
washing with PBS, cells were stained for 1 h with rhodamine phalloidin-TRITC 
(Invitrogen, R415. 300U) diluted 1:1000 in PBS 0.1% BSA. Then, glasses were washed 
twice with PBS and mounted in Vecta shield mounting medium to visualize the 
preparations in a Leica TCS-SL confocal microscope with a 63X objective. 
 
9.2  IMMUNOFLUORESCCENCE ANALYSIS OF E-CADHERIN AND ZO-1 
SUBCELLULAR LOCALIZATION 
The subcellular localization of E-cadherin and ZO-1 proteins was analyzed by confocal 
microscopy using the same antibodies used for western-blots. Cells were seeded on 
2% gelatin-coated glass coverslips. After 24-48 h, they were fixed with 4% 
paraformaldehyde at RT for 30 min. Additionally, to detect ZO-1, cells were 
permeabilized with 0.1% triton X-100 in 0.1% BSA-PBS for 20 min. Then, fixed cells 
were washed with PBS and incubated in blocking solution (2% BSA in PBS, 1h at RT), 
followed by an incubation with mouse anti-E-Cadherin or rabbit anti-ZO-1 (dilution 1:50) 
in 0.1% BSA PBS for 1 h at RT. After washing with PBS, cells were incubated for 1h at 
RT with FITC-labelled anti-mouse or anti-rabbit Alexa 594 (dilution 1:200) and DAPI 
1:1000 in 0.1% BSA PBS. After washing with PBS, cells were mounted in Vecta shield 
mounting medium and visualized in a Leica TCS-SL confocal microscope with a 63X  
objective. 
 
10. ANALYSIS OF TUMORS FROM XENOGRAFTS 
Tumors from xenografts assays were fixed with 4% PFA overnight at 4ºC, washed with 
PBS three times and left 1h in ethanol 50% at 4ºC. Then, they were kept in ethanol 
70% at 4ºC to preserve the samples until they were embedded in paraffin and cut in 
sections. Next, paraffin was removed from the sections for immunohistochemistry and 
immunofluorescence analyses as well as for tunel assays.  
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10.1  IMMUNOHISTOCHEMISTRY ANALYSIS 
First, samples were hydrated by incubation of the sections in the following way: xylene 
for 5 min (twice), ethanol 100% for 5 min (twice), ethanol 90% for 3 min, ethanol 80% 
for 3 min, ethanol 70% for 3 min and finally water for 3 min. Then, samples were 
transferred to a citrate buffer (10 mM, pH=6) and heated for 12 min. After cooling down 
to RT, the sections were washed with water for 5 min and with PBS for 5 min. Next, 
they were treated in the following way: ethanol 90% for 3 min, ethanol 100% for 3 min 
twice, 3% H2O2 in methanol 100%  for 20 min, ethanol 100% for 3 min, ethanol 90% for 
3 min in order to block endogenous peroxidase and afterwards, samples were washed 
with water for 5 min and twice with PBS for 5 min. Tissue samples were incubated in a 
blocking buffer (30 g/L bovine serum albumin in PBS and additionally, goat serum 
0.015% (Invitrogen, PCN5000)) for 30 min at RT. Then, samples were incubated with 
the primary antibody anti-SMA (DAKO, M0851) at 1:100 and ZO-1 (Life technologies, 
339100) at 1:50 in blocking buffer overnight at 4ºC. After washing 5 min with PBS, 
samples were incubated with the secondary antibody (anti-mouse IgG 1:2000 in 
blocking buffer) for 1 h at RT and then, washed with PBS for 5 min. Afterwards, they 
were incubated with the avidin/biotin reagent mix (Vectastain Elite ABC Kit, PK-6100) 
for 30 min at RT in the dark and washed again with PBS for 5 min. Next, one drop of 
hydrogen peroxide (in a buffer of pH=7.5) and two drops of the dAB reagent 
(Peroxidase Substrate Kit, SK-4100) diluted in distillated water were added to the 
samples and left for 1 min and removed by washing with water for 5 min.  
To carry out the hematoxylin staining, slides were placed in Harris (cytosolic) for 10 sec 
or Mayers (nuclear) hematoxylin for 5 min. The excess of hematoxylin was rinsed with 
water several times for 5 min. Finally, slides were dehydrated in the following way: 
incubation with 70% ethanol for 3 min, 80% ethanol for 3 min, 90% ethanol for 3 min, 
100% ethanol for 3 min (twice) and xylene 2 min (twice). The samples were then 
mounted using Vectamount H-5000 mounting medium and dried. 
 
10.2  IMMUNOFLUORESCENCE ANALYSIS 
Slides were hydrated in the following way: incubation with xylene for 10 min (twice), 
ethanol 100% for 3 min (twice), ethanol 90% for 3 min, ethanol 80% for 3 min, ethanol 
70% for 3 min and finally water for 10 min twice. They were transferred to a citrate 
buffer (10 mM, pH=6) and heated for 12 min. After cooling down to RT, the sections 
were washed with water for 5 min and with PBS for 5 min. Next, slides were incubated 
with 0.1% Triton X-100 in PBS for 5 min and washed with PBS for 5 min. Then, 
samples were incubated in blocking buffer (30 g/L bovine serum albumin in PBS and 
additionally, goat serum 0.015% (Invitrogen, PCN5000)) plus 200 μL of serum for 30 
min. Sections were then washed with PBS and incubated with the primary antibody E-
Cadherin (cell signaling, 3195S), CD14 (BD Pharmirgen, 553739) and MECA 32 (BD 
Pharmigen, 550563) at 1:50 in blocking buffer overnight at 4ºC. Afterwards, samples 
were washed first with 0.01% Tween-PBS for 5 min and then, with PBS for 5 min and 
incubated with the secondary antibody: Alexa fluor 488 Gota anti-rabbit (Life 
technologies, A11034) for E-Cadherin and Alexa Fluor 488 Goat anti-rat (Life 
technologies, A11006) for CD14 and MECA 32, for 1 h at RT. Next, samples were 
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washed again with 0.01% Tween-PBS for 5 min. Samples were mounted using 
Vectamount H-5000 mounting solution. 
 
10.3  TUNEL ASSAY 
First, sections were hydrated by treatment in the following way: xylene for 5 min 
(twice), ethanol 100% for 3 min (twice), ethanol 70% for 3 min, ethanol 50% for 3 min 
and finally, they were washed with water for 3 min (twice). Then, slides were washed 
with PBS and incubated with Proteinase K (Invitrogen, AM2546) in PBS (60 μg/μl) for 
15 min at RT. Proteinase K activity, was stopped by incubation with TBS for 5 min and 
samples were first washed with PBS for 5 min at RT and afterwards, with water for 3 
min (twice). Then, samples were treated with H2O2 3% (diluted in methanol) for 10 min 
in order to block endogenous peroxidase. Next, slides were washed with water for 3 
min (twice) and PBS for 3 min. TdT reaction was performed at 37ºC for 1 h, using a 
reaction mixture containing: TdT buffer and TdT enzyme (80 U/ml) (Fermentas Life 
Sciences, EP0162), 150 mM NaCl, 2 μM biotin 16-dUTP (Roche, 11093070910) and 
RNase free H2O. Slides were rinsed in PBS and incubated with the avidin/biotin 
enzyme mix (Vectastain Elite ABC Kit, PK-6100) 30 min at RT. Then, they were 
washed with PBS for 3 min, incubated with DAB peroxidase substrate (Sigma, D-4293) 
for 5-10 min at RT or until color is developed and washed with water to stop the 
reaction. Finally, slides were incubated with a methyl green solution (1% in water) for 5 
min and then, transferred directly to 100% ethanol to wash them twice. Samples were 
dehydrated in xylene for 1 min (twice) and dried. The samples were mounted using 
Cytoseal 60 Mounting Medium (Richard-Allan Scientific, 8310-4). 
 
11. STATISTICAL ANALYSIS 
Data have been represented as the mean value of 3-10 independent experiments 
±S.E.M. When comparisons were made between two experimental groups, unpaired 
Student's t-test was used. To compare more than two groups, analysis of variance 
(ANOVA) was performed. 
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1. p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION 
THROUGH METHYLATION OF DNA REGULATORY 
SEQUENCES. ROLE IN MIGRATION, INVASION AND TUMOR 
GROWTH 
As indicated in the group background section, Affymetrix microarrays analyses 
revealed that fibulin 3 mRNA levels were up-regulated in p38-deficient MEFs. This 
was also validated by RT-qPCR (M. Arechederra´s Thesis).  
p38 (Wagner and Nebreda 2009, del Barco Barrantes and Nebreda 2012) and Fibulin 
3 (Hu et al. 2009, Kim et al. 2012, Chen et al. 2014), are both involved in the regulation 
of migration and invasion of non-tumor and tumor cells. Moreover, fibulin 3 expression 
is deregulated in several tumors, including colorectal cancer (Tong et al. 2011, Obaya  
et al. 2012). Hence, we decided to characterize the regulation of fibulin 3 expression by 
p38 MAPK and to study if p38 could act through Fibulin 3 to regulate migration and 
invasion, as well as tumor growth in HCT116 cells.  
 
1.1 p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION IN HCT116 CELLS 
First, we quantified fibulin 3 mRNA expression by RT-qPCR in non-silenced and p38 
knock-down HCT116 cells in order to know if p38 was regulating fibulin 3 in these 
cells. As shown in figure 15A, there was an increase in fibulin 3 mRNA levels in 
HCT116 cells with permanent p38 knock-down as compared to non-silenced cells. 
Similarly, western-blot analysis using total cell extracts or mediums (to analyze both 
intracellular and secreted Fibulin 3) showed that the levels of the secreted and 
intracellular Fibulin 3 protein were higher in p38 knock-down HCT116 cells (Fig. 15B 
and 15C).  
Moreover, to further demonstrate that these changes in fibulin 3 expression were 
dependent on p38 MAPK, the effect of the selective p38/β inhibitor SB203580 was 
determined. As shown in figure 15D, treatment with SB203580 also up-regulated 
Fibulin 3 secretion in non-silenced HCT116 cells, while it had no effect on p38 knock-
down cells. These results confirmed that p38 is a negative regulator of fibulin 3 
expression. As SB203580 had no effect on p38 knock-down HCT116 cells, it is very 
likely that p38β is not a relevant regulator of fibulin3 expression as compared to p38.  
Therefore, all these data indicate that p38 MAPK is a negative regulator of fibulin 3 
expression in this human colon carcinoma cell line. 
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Figure 15-p38 MAPK is a negative regulator of fibulin 3 expression in HCT116 cells. HCT116 cells 
(non-silenced and p38 knock-down (shp38)) were maintained in the absence of serum for 24h and then, 
total RNA or proteins were isolated. (A) Analysis by RT-qPCR of fibulin 3 mRNA levels in HCT116 cells. 
Results represent the mean ± S.E.M. of RQ values (n=3-8). ***p<0.001 as compared with non-silenced 
cells. (B) Western-blot analysis of Fibulin 3 protein levels in the culture medium (secreted) or in cell 
extracts as indicated. β-actin was used to normalize cell extracts and p38 as a control of its expression.  
(C) Histograms show the mean ± S.E.M. of the densitometric analyses of the blots normalized with β-actin  
(n=3-8). *p<0.05, **p<0.01, ***p<0.001 as compared with non-silenced cells. (D) Effect of SB203580 (5 
M) on Fibulin 3 secretion to the culture medium referred to total protein levels. Fib3/β-actin ratios were 
calculated by densitometric analysis of the blots and expressed as a fold increase. 
 
 
1.2 p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION THROUGH 
METHYLATION OF DNA REGULATORY SEQUENCES 
Data from the literature indicated that Fibulin 3 expression could be regulated through 
DNA methylation. For example, Blackburn et al. in 2003, described important upstream 
regulatory motifs in fibulin 3 gene regulating its transcription in adult human and mouse 
retina. Furthermore, fibulin 3 expression is down-regulated in some tumors as a 
consequence of promoter methylation (Tong et al. 2011, Kim et al. 2012), which leads 
to changes in the invasive capacity (Kim et al. 2012). So, we wondered whether p38 
might down-regulate fibulin 3 expression through methylation of DNA regulatory 
sequences. 
To analyze it, we first studied the effect of the DNA methylation inhibitor, 5-aza-2´-
deoxicytidine (5A2dC). 5A2dC treatment induced an increase in the levels of the 
secreted Fibulin 3 protein in non-silenced HCT116 cells, while it had no effect in knock-
down HCT116 cells (Fig. 16A). Moreover, fibulin 3 mRNA levels were up-regulated in 
non-silenced HCT116 cells treated with 5A2dC (at 0.5 and 1 μM) up to the levels of 
p38 knock-down cells, where they remained unchanged (Fig. 16B). These results 
suggest that p38 might down-regulate fibulin 3 expression through a mechanism 
dependent on DNA hypermethylation. This p38-mediated DNA methylation was 
demonstrated in MEFs by other members of the group (M. Arecehederra´s thesis).  
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Figure 16-p38 down-regulates fibulin 3 expression through DNA methylation. HCT116 cells (non-
silenced and p38 knock-down) were maintained in the absence of serum for 24h, and then, total RNA or 
proteins were isolated. When indicated, cells were treated with 5-aza-2´-deoxicytidine (5A2dC) at 0,5M or 
1M for 48h (24h pretreatment plus 24h treatment in the absence of serum). (A) Western-blot analysis of 
Fibulin 3 protein levels in the culture medium. Fib3/total prot ratio was calculated by densitometric analysis 
of the blots referred to total proteins and expressed as a fold increase. (B) Analysis by RT-qPCR of fibulin 
3 mRNA levels. **p<0.01 compared as indicated. 
 
 
DNA methylation results from the activity of DNA methyltransferases (DNMTs) 
(Robertson 2001). Among DNMTs, DNMT3A/3B are de novo DNA methyltransferases, 
whose levels can be regulated by different mechanisms, being of relevance their post-
transcriptional regulation (Denis et al. 2011). In particular, binding of HuR protein to the 
3´UTR of dnmt3B mRNA, enhances its stability (Dai et al. 2012) and increases its 
protein levels in colorectal RKO cells (Lopez de Silanes et al. 2009). p38 MAPK can 
phosphorylate HuR, which enhances its binding to certain mRNAs such as p21 mRNA, 
increasing its protein levels (Lafarga et al. 2009). Thus, we hypothesized that p38 
MAPK could be regulating DNMT3A/3B protein levels through a HuR-dependent 
mechanism. So, we analyzed DNMT3A protein levels in non-silenced and p38 knock-
down HCT116 cells. We found a significant decrease in DNMT3A protein levels in 
p38 knock-down HCT116 cells as compared to their corresponding non-silenced cells 
(Fig. 17A).  
These results indicate that p38 MAPK positively regulates DNMT3A protein levels, 
which inversely correlates with Fibulin 3 levels, suggesting that DNMT3A would be 
responsible for the hypermethylation of fibulin 3 gene regulatory sequences and the 
subsequent down-regulation of Fibulin 3. To prove it, DNMT3A was re-introduced in 
p38 knock-down HCT116 cells by transfection of a dnmt3a construct, which led to a 
strong decrease in Fibulin 3 levels (Fig. 17B).   
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As HuR could be involved in dnmt3a mRNA stabilization, we first measured total HuR 
protein levels and we found a decrease in HuR protein levels in p38 knock-down 
HCT116 cells (Fig. 17C). This would be in agreement with the low DNMT3A protein 
levels. Hence, these results suggest that p38 MAPK might positively regulate 
DNMT3A protein levels through HuR-mediated stabilization, which could result in the 
hypermethylation of fibulin 3 gene regulatory sequences. 
In fact, this is the case in MEFs, where HuR knock-down prevents p38-dependent 
DNMT3A expression (M. Arechederra´s Thesis). 
Therefore, although we cannot exclude the possibility of the participation of other DNA 
methyltransferases, it is very likely that p38-HuR mediated DNMT3A expression is 
responsible for hypermethylation of fibulin 3 DNA regulatory sequences. 
 
 
 
 
Figure 17-DNMT3A expression correlates with Fibulin3 down-regulation. Regulation by p38. 
HCT116 cells were maintained in the absence of serum for 24h, and then, proteins were isolated. 
Western-blot analysis of DNMT3A (A) and HuR (C) protein levels in cell extracts. β-actin was used to 
normalize and p38 as a control of its expression. (B) Changes in Fibulin 3 protein levels upon DNMT3A 
expression in p38 knock-down HCT116 cells. Western-blot analysis of Fibulin 3 (secreted) and DNMT3A 
(in cell extracts) normalized with β-actin levels in cell extracts. DNMT3A/-actin, Fib3/-actin and HuR/-
actin ratios were calculated by densitometric analysis of the blots and expressed as a fold increase. 
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1.3 FIBULIN-3 KNOCK-DOWN INHIBITS MIGRATION AND INVASION OF HCT116 
CELLS 
Fibulin 3 is involved in the regulation of migration and invasion in different tumor cells, 
either promoting or inhibiting cell invasiveness depending on the tumor type (Hu et al. 
2009, Kim et al. 2012). Moreover, changes in fibulin 3 gene expression by promoter 
methylation were shown to occur in advanced stages of colorectal cancer, which 
correlates with the induction of metastasis (Tong et al. 2011). p38 also regulates cell 
migration and invasion (Nebreda and Porras 2000, Wagner and Nebreda 2009). So, 
we evaluated the function of Fibulin 3 in the processes of migration and invasion in 
HCT116 cells and whether it mediates p38 effects. To analyze it, permanent knock-
down of fibulin 3 gene was performed using a human fibulin 3 shRNA, selecting 
different clones. Secreted Fibulin 3 protein levels were decreased in both, non-silenced 
and p38 knock-down HCT116 cells upon fibulin 3 silencing (Fig. 18A). As shown in 
figure 18B and 18C, non-silenced HCT116 cells migrate faster than p38 knock-down 
cells and fibulin 3 knock-down impaired migration of parental cells and slightly reduced 
that of p38 knock-down cells, either in the absence or presence of HGF. Similarly, a 
transient fibulin 3 knock-down (Fig. 19A) using a second human fibulin 3 shRNA also 
prevented migration (Fig 19B).  
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Figure 18-Fibulin 3 knock-down inhibits migration of HCT116 cells expressing p38. HCT116 cells 
(non-silenced and p38 knock-down (shp38); with (shFib3) or without fibulin 3 knock-down) were 
maintained in 2% serum-supplemented medium, untreated or treated with HGF (40 ng/ml) when indicated. 
(A) Western-blot analysis of Fibulin 3 protein levels in the culture medium normalized with β-actin from cell 
extracts. p38 was used as a control of its expression. Fibulin 3/-actin ratio was calculated by 
densitometric analysis of the blots and expressed as a fold increase. (B and C) Wound healing assay. A 
wound was performed in confluent cells. Then, cells were allowed to migrate in the presence (HGF) or 
absence of HGF (control). (B) Representative images from phase contrast microscope after 0 and 72 h of 
migration. (C) Histograms show the mean ± S.E.M. of the percentage of wound closure at 24, 48 and 72 h 
(n=5-8). *p<0.05, **p<0.01, ***p<0.001 as compared with non-silenced cells. 
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Figure 19-Fibulin 3 knock-down inhibits migration of HCT116 cells expressing p38. HCT116 cells 
(non-silenced and p38 knock-down (shp38); with (sh2Fib3) or without fibulin 3 knock-down) were 
maintained in 2% serum-supplemented medium.  (A) Western-blot analysis of Fibulin 3 protein levels in the 
culture medium normalized with β-actin from cell extracts. p38 was used as a control of its expression. 
Fibulin 3/-actin ratio was calculated by densitometric analysis of the blots and expressed as a fold 
increase.  (B and C) Wound healing assay.  A wound was performed in confluent cells. Then, cells were 
allowed to migrate. (B) Representative images from phase contrast microscope after 0 and 48 h of 
migration. (C) Histogram shows the mean ± S.E.M. of the percentage of wound closure at 48 h (n=3). 
*p<0.05, **p<0.01 as compared with non-silenced cells. 
 
 
 
The effect of Fibulin 3 knock-down on the invasive capacity of HCT116 cells was also 
evaluated. Similar to migration assays, p38 know-down decreased basal and HGF-
induced invasion through matrigel and fibulin 3 silencing blocked basal and HGF-
induced invasion only in cells expressing p38 (Fig. 20A and 20B). 
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Figure 20-Effect of Fibulin 3 knock-down reduces invasion of HCT116 cells expressing p38. 
Invasion through matrigel of HCT116 cells (non-silenced and p38 knock-down (shp38); with (shFib3) or 
without fibulin 3 knock-down) using HGF as a chemoattractant. (A) Representative phase contrast 
microscope images of invading cells after staining with crystal violet. (B) Histograms show the mean ± 
S.E.M. of the number of invading cells expressed as the fold increase of control values (n=3-8). *p<0.05, 
**p<0.01 as compared with non-silenced cells. 
 
1.4 MECHANISMS INVOLVED IN THE REGULATION OF CELL MIGRATION AND 
INVASION BY FIBULIN 3 IN HCT116 CELLS. ROLE OF p38/β 
In order to analyze potential mediators of p38 and/or Fibulin 3 actions on invasion, the 
participation of MMPs was evaluated as they play a relevant role in extracellular matrix 
degradation during cell migration/invasion (Bourboulia and Stetler-Stevenson 2010, 
Kessenbrock et al. 2011). Hence, we initially evaluated MMP2 and MMP9 activities.  
MMP9 activity was highly decreased upon fibulin 3 knock-down in both non-silenced 
and p38 knock-down cells (Fig. 21A and 21B). p38 silencing also reduced MMP9 
activity, but to a lower extend (Fig. 21A and 21B), which correlated, at least partially, 
with invasion results. MMP2 activity was slightly reduced in fibulin 3 knock-down cells 
(Fig. 21A and 21B), suggesting its contribution to invasion as well.  
To evaluate the relevance of MMPs in the invasion of HCT116 cells, the effect of the 
broad spectrum MMP inhibitor, marimastat, was assessed. As shown in figures 22A 
and 22B, HGF-induced invasion was impaired by marimastat treatment. Therefore, 
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changes in the activity of others MMPs, together with MMP2 and 9 activities, would 
mediate the pro-invasive effect of Fibulin 3 in HCT116 cells.  
 
Figure 21-Effect of Fibulin 3 knock-down on MMP2 and 9 activities. Zymographic analysis of MMP2/9 
activities using gelatin as substrate and FBS as a control. (A) Representative zymogram. (B) Histograms 
show the mean value ± S.E.M. of the densitometric analysis of gelatinase areas (n=3). *p<0.05 as 
compared with non-silenced cells; 
+
p<0.05, 
+++
p<0.001 compared as indicated. 
 
 
 
Figure 22-Inhibition of MMPs prevents invasion of HCT116 cells. Invasion through matrigel of HCT116 
cells (non-silenced and p38 knock-down (shp38); with (shFib3) or without fibulin 3 knock-down) using 
HGF as a chemoattractant and the MMP inhibitor, marimastat (marim), when indicated. (A) Representative 
phase contrast microscope images of invading cells after staining with crystal violet. (B) Histogram shows 
the mean ± S.E.M. of the number of invading cells expressed as the fold increase of control values (n=3). 
*p<0.05, ***p<0.001 compared as indicated. 
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Even though Fibulin 3 levels were lower in non-silenced cells, as compared to p38 
knock-down HCT116 cells, its silencing inhibited migration and invasion in these cells. 
In fact, Fibulin 3 appears to be a positive regulator of cell migration and invasion, 
mainly in cells expressing p38. So, we analyzed the effect of fibulin 3 knock-down on 
p38 MAPKs activation. As shown in figure 23, we found that in non-silenced HCT116 
cells, HGF induced the activation of p38 MAPK and another isoform with a lower 
mobility (probably p38β), which was the only one activated in p38 knock-down cells. 
Interestingly, Fibulin 3 knock-down highly reduced the activation of both p38 MAPKs 
isoforms, which correlates with the decrease in migration and invasion.  
 
 
 
 
 
Figure 23-Effect of Fibulin 3 knock-down on p38 signaling pathway. Western-blot analysis of 
phospho-p38 MAPK levels from HCT116 cells (non-silenced, p38 knock-down (shp38); with (shFib3) or 
without fibulin 3 knock-down) normalized with extracts β-actin. p-p38/β-actin and p38/β-actin ratios were 
calculated by densitometric analysis of the blots and expressed as a fold increase. p38 was used as a 
control.  
 
 
Together these results indicate that Fibulin 3 promotes migration and invasion of 
HCT116 cells through a mechanism that appears to require p38 and/or p38β 
activation. At the same time, p38 limits Fibulin 3 expression, which could represent a 
negative feed-back loop. As expected, p38 mediates migration and invasion in these 
cells. MMPs would be mediators of Fibulin 3/p38 effects on these processes. 
 
1.5  ROLE OF FIBULIN 3 IN THE TUMORIGENIC CAPACITY OF HCT116 CELLS 
Once we knew the function of Fibulin 3 regulating migration and invasion of HCT116 
cells, we next wanted to determine the role of Fibulin 3 in the regulation of the 
tumorigenic capacity of these cells. First, we carried out anchorage dependent growth 
assays. As shown in figure 24A (left panel), fibulin 3 knock-down significantly reduced 
the number of foci in both parental and p38 knock-down cells, although the effect was 
more prominent in parental HCT116 cells. This effect was confirmed using a second 
human fibulin 3 shRNA to transiently knock-down fibulin 3 gene (figure 24B). Moreover, 
foci size was smaller in cells with Fibulin3 down-regulation (Fig. 24A, right panel). The 
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number of foci was also slightly reduced upon p38 knock-down, but differences were 
not statistically significant.  
 
 
 
 
Figure 24-Fibulin 3 knock-down inhibits focus formation. Anchorage dependent growth of HCT116 
cells (non-silenced and p38 knock-down (shp38); with (shFib3) (in A and C) or (sh2Fib3) (in B) or 
without fibulin 3 knock-down). Histograms show the mean ± S.E.M. of foci number (A and B) and the 
percentage of those with a size ≥50 pixels (B) (n=5). *p<0.05, **p<0.01, ***p<0.001 compared as 
indicated. (C) Representative images of foci from a plate (left) and individual foci (right) at 13 days. 
 
 
To further characterize the potential role of fibulin 3 in tumor growth, we also 
determined the ability of these cells to grow in soft-agar. The number of foci was 
significantly reduced upon either fibulin 3 or p38 knock-down (Fig. 25A), as well as 
foci size (Fig. 25B). To further confirm the function of p38 promoting cell growth in 
soft-agar, HCT116 cells were treated with SB203580 to inhibit p38/β. As shown in 
figure 25A, SB203580 treatment highly reduced anchorage independent cell growth 
only in cells expressing p38. Thus, SB203580 had no further effect when fibulin 3 or 
p38 were knocked-down. To demonstrate in vivo this pro-tumorigenic function of 
Fibulin 3 and p38 in HCT116 cells, we also carried out xenografts assays in nude 
mice. As shown in figures 26A and 26B, non-silenced HCT116 cells led to tumor 
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formation 14 days after injection and tumor size progressively increased over time. 
Tumor sizes were significantly decreased by fibulin 3 knock-down in non-silenced cells, 
but not in p38 knock-down cells, where the size of the tumors was highly reduced, 
independently of fibulin 3 silencing. These data are in agreement with data derived 
from soft-agar assays, although the effect of p38 knock-down is higher, probably due 
to differences in the microenviroment and/or the influence of the angiogenic processes. 
Therefore, these results indicate that Fibulin 3 promotes tumor growth in HCT116 cells 
through a mechanism dependent on p38. Moreover, in these cells p38 is a potent 
positive regulator of tumor growth.  
 
 
 
Figure 25- Fibulin 3 and p38 knock-down inhibit anchorage independent growth of HCT116 cells. 
Anchorage independent growth of HCT116 cells (non-silenced and p38 knock-down (shp38); with   
(shFib3) or without fibulin 3 knock-down) in soft agar was analyzed at 14 days. When indicated, cells were 
treated with SB203580 (5M). (A) Histogram shows the mean ± S.E.M. of the foci number expressed as 
the percentage of non-silenced cells (n=3). **p<0.01 as compared with non-silenced cells. (B) 
Representative images of several (upper panel) or individual foci (lower panel). 
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Figure 26- Fibulin 3 and p38 knock-down inhibit in vivo HCT116 cells tumor growth. Xenograft 
assay.  Immunodeficient mice were injected subcutaneously with HCT116 cells (non-silenced and p38 
knock-down (shp38); with (shFib3) or without fibulin 3 knock-down). Tumor size was calculated by the 
formula ((L/2)x(W/2))xπ,  where L and W are the longest and the shortest diameter in cm, respectively. (A) 
Graph shows the mean ± S.E.M. of tumor size at the indicated time points (n=6). *p<0.05, **p<0.01, 
***p<0.001 as compared with non-silenced cells. (B) Representative images of tumors. 
 
 
 
2. C3G REGULATES CELL ADHESION, MIGRATION AND 
INVASION THROUGH DOWN-REGULATION OF p38 MAPK 
ACTIVITY BY A MECHANISM NOT MEDIATED BY RAP1. 
INVOLVEMENT IN TUMOR GROWTH 
As it was mentioned in the introduction and the group background section, we have 
previously described a crosstalk between C3G and p38 MAPK to regulate apoptosis 
in CML (Maia et al. 2009) and MEFs (Gutierrez-Uzquiza et al. 2010). Both p38 MAPK 
(Rousseau et al. 2006, Cuenda and Rousseau 2007, Wagner and Nebreda 2009) and 
C3G (Ohba et al. 2001, Rufanova et al. 2009, Dayma and Radha 2011) regulate 
migration. p38 MAPK is also relevant for cell adhesion (Guo and Yang 2006, Zuluaga 
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et al. 2007), as well as C3G (Ohba et al. 2001, Voss et al. 2003, Guo and Yang 2006, 
Pannekoek et al. 2009).  
Moreover, our group in collaboration with Dr. Guerrero´s group found that C3G and 
p38 act through a common pathway to regulate cell adhesion in CML (Maia et al. 
2013). As previously indicated, C3G also regulates the tumorigenic and/or the 
migratory and invasive capacity of different cancer cells (Hirata et al. 2004, Gutierrez-
Berzal et al. 2006, Okino et al. 2006, Che et al. 2015). Additionally, in colon carcinoma, 
C3G gene was reported to be demethylated (Samuelsson et al. 2011), suggesting that 
it could play a role in this type of cancer. Based on all this, we wondered if C3G could 
act though p38 to control cell migration, invasion and tumor growth in colorectal 
cancer and whether Rap1, the main C3G target, could be mediating these effects. 
 
2.1 C3G INHIBITS CELL MIGRATION AND INVASION OF HCT116 CELLS 
THROUGH DOWN-REGULATION OF p38 ACTIVITY BY A MECHANISM NOT 
MEDIATED BY RAP1. FUNCTION IN CELL ADHESION  
Based on Oncomine database, C3G expression can be deregulated in colon 
carcinoma. Therefore, we analyzed C3G protein expression in different colorectal 
cancer cell lines with distinct invasive capacities: HCT116, SW480 and SW620 cells. 
As shown in figure 27, HCT116 cells, which has a lower invasive capacity, show higher 
levels of C3G, while SW480 and SW620 cells that are more invasive cells, express a 
very low level of C3G. Therefore, there was an inverse correlation between C3G 
protein levels and the invasive capacity of colon carcinoma cell lines. 
 
 
 
Figure 27-C3G levels in different colorectal cancer cell lines. Western-blot analysis of C3G levels 
HCT116, SW480 and SW620 cells normalized with β-actin. C3G/β-actin ratio was calculated by 
densitometric analysis of the blots and expressed as a fold increase. 
 
As C3G down-regulation correlates with an invasive phenotype in colon carcinoma, we 
have characterized the function of C3G in the regulation of the migratory and the 
invasive capacities of human HCT116 colon carcinoma cells and whether it acts 
through p38. To do it, we performed a permanent C3G knock-down in parental and 
p38-silenced cells, using a mixture of different shRNAs, selecting different clones. 
C3G protein levels significant decreased in both parental and p38 knock-down cells 
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after silencing (Fig. 28A). Moreover, in response to serum, a significant up-regulation of 
the levels of phospho-p38 MAPK, phospho-Akt and phospho-ERKs was observed 
upon C3G silencing (Fig. 28B). This indicates that C3G negatively regulates p38 
activity in HCT116 cells as it was previously found in MEFs (Gutierrez-Uzquiza et al. 
2010).  
 
 
 
 
 
 
Figure 28- Effect of C3G knock-down on different signaling pathways. HCT116 cells (non-silenced (-) 
and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were maintained in the 
absence of serum for the last 16 h. When indicated, cells were stimulated with serum (FBS) for 10 min.  
(A) Western-blot analysis of C3G levels. (B) Phospho-Akt, phospho-ERKs and phospho-p38 MAPK levels 
normalized with β-actin. p38 was used as a control of its expression. C3G/ β-actin, p38/ β-actin and p-
protein/β-actin ratios were calculated by densitometric analysis of the blots and expressed as a fold 
increase. 
 
 
Hence, we next determined the effect of C3G knock-down on migration and whether 
this effect was dependent on p38 activity. As shown in figures 29A and 29B, C3G 
silencing enhanced migration in HCT116 cells expressing p38, but not in those 
subjected to p38 depletion. Similarly, using another shRNA against C3G we also 
observed an increase in migration in cells expressing p38 (Fig. 29C). Moreover, 
inhibition of p38/β with SB203580 prevented the enhancement of migration induced 
by C3G knock-down in cells expressing p38 and decreased migration of non-silenced 
cells.  
RESULTS 
 
74 
 
 
 
 
Figure 29- C3G knock-down enhances migration of HCT116 cells through a mechanism dependent 
on p38. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) (in A and B) or 
(sh2C3G) (in C) or without C3G knock-down) were used. Wound healing assays. After doing the wound, 
cells were maintained in 2% of serum with or without the p38/β inhibitor, SB203580 (10μM)) and were 
allowed to migrate. (A) Representative images from phase contrast microscope after 0 and 48 h of 
migration. (B and C) Histograms shows the mean ± S.E.M. of the percentage of wound closure (n=5-8). 
*p<0.05, **p<0.01, ***p<0.001 versus non-silenced cells; 
++
p<0.01 compared as indicated. 
 
 
To assess if C3G was acting through its main target Rap1 in this context, Rap1 was 
knocked-down using two different shRNAs. Figure 30A shows that Rap1 levels were 
significantly reduced by both shRNAs, which led to a significant reduction in migration 
(Fig. 30B and 30C). This indicates that Rap1 does not mediate C3G effects on 
migration.  
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We also studied C3G function in the regulation of adhesion in HCT116 cells. As shown 
in figures 31A and 31B, C3G knock-down decreased adhesion of HCT116 cells, while 
p38 knock-down or p38 chemical inhibition (Fig. 31C) and Rap1 knock-down 
increased it. Thus, C3G knock-down cells expressing p38 showed the lowest 
adhesion, which is in agreement with its increased migration. All this indicates that C3G 
promotes adhesion through down-regulation of p38 activity, while Rap1 exerts an 
opposite effect.  
 
 
                 
Figure 30- C3G knock-down enhances migration of HCT116 cells through a mechanism not 
mediated by Rap1. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shRap1(1) and 
shRap1(2)) or without Rap1 knock-down) were used. (A) Western-blot analysis of Rap1 levels normalized 
with β-actin. Rap1/β-actin ratio was calculated by densitometric analysis of the blots and expressed as a 
fold increase. (B and C) Wound healing assay. After doing the wound, cells were maintained in 2% of 
serum and were allowed to migrate. (B) Representative images from phase contrast microscope after 0 
and 48 h of migration. (C) Histogram shows the mean ± S.E.M. of the percentage of wound closure (n=3). 
*p<0.05, **p<0.01, ***p<0.001 versus non-silenced cells. 
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Figure 31- Effect of C3G, p38 and Rap1 knock-down on adhesion. HCT116 cells (non-silenced (-) 
and p38 knock-down (shp38); with (shC3G) or without C3G knock-down; with (shRap1) or without Rap1 
knock-down) were used. Adhesion assay. Cells with (C) or without (B) the p38/β inhibitor, SB203580 
(10μM)) were seeded in a medium supplemented with 10% FBS and 1 h after, adhered cells were 
counted. (A) Representative images from phase contrast microscope. (B and C) Histograms show the 
mean ± S.E.M. of the number of adhered cells (n=3). *p<0.05, **p<0.01, ***p<0.001 versus non-silenced 
cells; +++p<0.001 compared as indicated. 
 
 
Next, we studied invasion of HCT116 cells through matrigel using HGF as 
chemoattractant. As shown in figures 32A and 32B, in C3G knock-down cells 
expressing p38, invasion was increased, but not in those where p38 was also 
silenced. Accordingly, inhibition of p38/ with SB203580 impaired it. Single p38 
knock-down also reduced invasion. 
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Figure 32- C3G silencing promotes invasion of HCT116 cells by a mechanism mediated by p38. 
HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-
down) were maintained in the absence of serum and in the presence or absence of the p38/β inhibitor, 
SB203580 (5μM). Invasion through matrigel using HGF as chemoattractant. (A) Representative images of 
invading cells after staining with crystal violet (phase contrast microscope). (B) Histogram showing the 
mean value ± S.E.M. of the percentage of invading cells (n=5). **p<0.01; ***p<0.001 versus non-silenced 
cells; 
++
p<0.01 compared as indicated.  
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We also studied if C3G could be acting through Rap1 to regulate invasion. However, 
Rap1 knock-down abrogates invasion (Fig. 33A and 33B). This indicates that C3G is 
not acting through a Rap1 dependent mechanism. 
 
          
       
 
Figure 33-C3G silencing promotes invasion of HCT116 cells by a mechanism not mediated by 
Rap1. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shRap1) or without Rap1 
knock-down) were maintained in the absence of serum. Invasion through matrigel using HGF as 
chemoattractant. (A) Representative images of invading cells after staining with crystal violet (phase 
contrast microscope). (B) Histogram showing the mean value ± S.E.M. of the percentage of invading cells  
(n=3). ***p<0.001 versus non-silenced cells. 
 
All these results indicate that C3G inhibits migration and invasion and promotes 
adhesion of HCT116 cells through down-regulation of p38 activity. In contrast, Rap1 
would play an opposite role, therefore C3G effects on these processes are not 
mediated by Rap1. 
 
2.2 ROLE OF MMPS AS MEDIATORS OF C3G EFFECTS ON CELL INVASION 
MMPs are important for extracellular matrix degradation during cell migration/invasion 
and play a key role in colorectal cancer progression (Conti and Thomas 2011). 
Therefore, we determined if they could be responsible of the pro-invasive effect of C3G 
knock-down in HCT116 cells mediated by p38.  
First, we analyzed the mRNA expression of various MMPs reported to be important for 
invasion of colon carcinoma cells such as MMP2, 9, 10 and 13 (Fig. 34). C3G silencing 
significantly reduced MMP10 mRNA levels, while it had no significant effect on the rest. 
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p38 knock-down decreased MMP 9 and 10 mRNA levels, as well as the double C3G 
and p38 knock-down, which also decreased MMP13 mRNA levels.  
Hence, these changes would explain the reduced invasion observed in cells depleted 
of p38 and in those with C3G/p38 silencing, but they do not support the C3G effect 
on invasion when p38 is expressed. Therefore, changes in MMPs activity might 
account for the changes in invasion. 
 
 
 
 
 
Figure 34-Effect of C3G and p38 knock-down on different MMPs expression.  HCT116 cells (non-
silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were used. 
Analysis by RT-qPCR of MMP2, 9, 10 and 13 mRNA levels. Histograms show the mean ± S.E.M. of RQ 
values (n=4). *p<0.05, ***p<0.001 as compared with non-silenced cells. 
 
 
Hence, we also analyzed MMP2 and MMP9 activities in HCT116 cells by zymography. 
As shown in figures 35A and 35B, MMP2 and 9 activities were higher in HCT116 cells 
expressing p38 than in those with p38 silencing. C3G knock-down further increased 
these activities, but only in cells expressing p38. These changes in MMP2/9 activities 
correlate with those in the invasive ability of these cells. Moreover, MMP2 and 9 
activities also decreased in cells with Rap1 silencing, regardless of the presence of 
p38.Therefore, the regulation of MMP2 and 9 activities by C3G, p38 and/or Rap1 
might represent a mechanism to control invasion. 
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Figure 35- Effect of C3G, p38 and Rap1 knock-down on MMP2/9 activities. HCT116 cells (non-
silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down; with (shRap1) or 
without Rap1 knock-down) were used. Zymographic analysis of MMP2/9 activities using gelatin as 
substrate and FBS as a control. (A and C) Representative zymograms. (B) Histogram showing the mean ± 
S.E.M. of the densitometric analyses of gelatinase areas expressed as fold increase of the control value 
(n=4). *p<0.05, **p<0.01 versus non-silenced cells.  
 
 
2.3 MECHANISMS INVOLVED IN THE REGULATION OF MIGRATION AND 
INVASION BY C3G AND p38 
Cell migration and invasion involve changes in the expression and/or subcellular 
localization of cell-cell contact proteins (Thiery et al. 2009, Lamouille et al. 2014) and 
the re-organization of F-actin cytoskeleton (Parsons et al. 2010). Moreover, induction of 
a migratory and invasive phenotype is often associated with epithelial-mesenchymal 
transition (EMT).  
An important protein present in adherent junctions is E-cadherin, playing a key role in 
cell-cell interactions. In fact, E-cadherin loss is a key event of many EMT processes 
(Tsanou et al. 2008, Pancione et al. 2012). C3G interacts with E-cadherin cytoplasmic 
domain, which participates in the maturation of E-cadherin-based cell-cell contacts 
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(Hogan et al. 2004, Kooistra et al. 2007). Thus, we studied E-cadherin as a potential 
mediator of C3G and/or p38 on migration and invasion. As shown in figure 36A, E-
cadherin protein levels substantially decreased in HCT116 cells subjected to C3G 
knock-down, with or without p38 depletion. Silencing of p38 also led to E-cadherin 
down-regulation, so that, the largest reduction in E-cadherin levels was observed in 
cells with C3G and p38 knock-down. Similarly, E-cadherin mRNA levels also 
decreased upon C3G and p38 Knock-down, but double knock-down had no further 
effect (Fig. 36B). This decrease in E-cadherin did not correlate with the migratory and 
invasive capacity of the cells. Hence, we then, analyzed changes in E-cadherin 
subcellular localization by confocal microscopy. In all cases, E-cadherin was mainly 
located in the membrane, although in the double knock-down it was partially 
internalized (Fig. 36C). 
 
 
 
 
Figure 36-Effect of C3G knock-down on E-cadherin expression and subcellular localization in 
HCT116 cells. Function of p38 MAPK. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); 
with (shC3G) or without C3G knock-down) were used. (A) Representative western-blot analysis of E-
cadherin levels normalized with β-actin. E-cadherin/β-actin ratio was calculated by densitometric analysis 
of the blots and expressed as a fold increase. (B) Analysis by RT-qPCR of E-cadherin mRNA levels. 
Histogram showing the mean ± S.E.M. of RQ values (n=5). **p<0.01, ***p<0.001 as compared with non-
silenced cells. (C) Representative confocal microscopy images of E-cadherin immuno-detection using a 
specific antibody and a FITC-labeled anti-mouse (green).  Nuclei were stained with DAPI. Scale bar=20μm 
 
 
 
We also analyzed the levels and localization of ZO-1 protein, a main component of tight 
junctions, which is crucial to maintain cell-cell contacts and is also regulated in EMT 
processes (Polette et al. 2007). Although no significant changes in total ZO-1 protein 
levels were observed upon C3G knock-down in cells expressing p38 (Fig. 37A), ZO-1 
was found to be internalized (Fig. 37C). In contrast, in p38 silenced HCT116 cells, 
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ZO-1 was mainly present in the membrane, as it was also observed in cells with the 
double C3G/p38 knock-down, where its total level was reduced (Fig. 37A and 37B).  
 
 
 
 
Figure 37-Effect of C3G knock-down on ZO-1 expression and subcellular localization in HCT116 
cells. Function of p38 MAPK.  HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with 
(shC3G) or without C3G knock-down) were used. (A) Representative western-blot analysis of ZO-1 levels 
normalized with β-actin (left panel). Histogram (right panel) showing the mean ± S.E.M. of the 
densitometric analysis of blots (n= 4). *p<0.05 as compared with non-silenced cells. (B) Representative 
confocal microscopy images of ZO-1 immunodetection using a specific antibody and anti-rabbit Alexa 594 
(red). Nuclei were stained with DAPI. Scale bar=20μm.  
 
 
These data suggest that cell-cell contacts, specially tight junctions, are partially 
disrupted in C3G knock-down HCT116 cells expressing p38, which would favor 
migration and invasion processes. 
EMT is involved in the generation of metastasis as it allows epithelial cells to acquire a 
migratory and invasive phenotype defined by the loss of epithelial-specific proteins, 
including tight- and adherens-junction proteins (Grunert et al. 2003). Therefore, the 
reduction in E-cadherin levels and ZO-1 internalization observed upon C3G knock-
down could be associated with an EMT process. Thus, we next determined the 
expression of the mesenchymal marker, N-cadherin. Its protein (Fig. 38A) and mRNA 
levels (Fig. 38B) increased upon C3G, p38 and double C3G/ p38 knock-down in 
HCT116 cells. These results suggest that C3G, p38 and C3G/p38 knock-down could 
induce an EMT process, which it is not correlated in all cases with migratory and 
invasive capacities of the cells. 
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Figure 38-Effect of C3G knock-down on N-cadherin expression in HCT116 cells. Function of p38 
MAPK. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G 
knock-down) were used. (A) Representative western-blot analysis of N-cadherin levels normalized with β-
actin and histogram showing the mean ± S.E.M. of the densitometric analyses of blots (n=4). (B) Analysis 
by RT-qPCR of N-cadherin mRNA levels. Histogram represents the mean ± S.E.M. of RQ values (n=5). 
*p<0.05, ***p<0.001 as compared with non-silenced cells. 
 
 
 
To gain a further insight into the potential function of C3G regulating EMT, we studied 
the expression of some transcription factors involved in this process. In particular, Snail 
1, Twist 1, Zeb 1 and Zeb 2 mRNA levels were quantified by RT-qPCR. Snail 1 and 
Zeb 1 mRNAs levels increased in C3G knock-down HCT116 cells expressing p38 
(Fig. 39). On the other hand, p38 knock-down induced a significant increase in Zeb 1 
and Zeb 2 mRNA levels, while double C3G/p38 silencing did not significantly modify 
these mRNA levels, although a tendency to increase them was observed (Fig. 39). 
These data suggest that C3G knock-down might be inducing EMT, which is correlated 
with the migratory and invasive properties of C3G depleted cells. However, p38 single 
knock-down might also have an effect inducing EMT, which does not correlate with the 
migratory and invasive properties of shp38 HCT116 cells. 
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Figure 39-Effect of C3G and p38 knock-down on the expression of transcription factors involved 
in EMT. HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G 
knock-down) were maintained in the absence of serum for 24 h and then, total RNA were isolated. 
Analysis by RT-qPCR of Snail 1, Twist 1, Zeb 1 and Zeb 2 mRNA levels. Results represent the mean ± 
S.E.M. of RQ values (n=4). *p<0.05, **p<0.01 as compared with non-silenced cells. 
 
 
 
Hence, we next studied F-actin cytoskeleton organization by confocal microscopy due 
to its relevance in migration. F-actin enriched structures including ruffles, filopodia and 
lamelipodia are usually present in migratory cells as a consequence of the actin re-
organization (Franz et al. 2002), which can be regulated by p38 (Huot et al. 1998, 
Okada et al. 2005, del Barco Barrantes and Nebreda 2012). 
As shown in figure 40, the presence of filopodia and lamelipodia was more noticeable 
in C3G knock-down HCT116 cells expressing p38 (see arrows), which would promote 
migration of these cells.  
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Figure 40-Effect of C3G knock-down on actin-organization in HCT116 cells. HCT116 cells (non-
silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were used. 
Representative confocal microscopy images of actin staining, using rhodamine conjugated phalloidin. 
Scale bar=20μm. Arrows indicates the presence of filopodia. 
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All these studies evidence a disruption of cell-to-cell contacts in C3G knock-down 
HCT116 cells expressing p38due to both ZO-1 internalization and partial E-cadherin 
loss. All this together with the actin cytoskeleton re-organization produced in these cells 
could explain the enhancement in migration and invasion.  
 
2.4 ROLE OF C3G IN THE REGULATION OF THE TUMORIGENIC CAPACITY OF 
HCT116 CELLS 
To study the function of C3G and p38 on the tumorigenic ability of HCT116 cells, we 
first carried out anchorage dependent growth assays. As shown in figure 41A, the 
assays revealed a reduction in the number of foci in C3G knock-down cells, which was 
more prominent in cells expressing p38. The number of foci was also reduced when 
p38 was silenced. These results suggest that both C3G and p38 promote foci 
formation probably through different pathways. Moreover, inhibition of p38 with 
SB203580 decreased the number of foci in non-silenced cells (Fig. 41A). In contrast, in 
C3G knock-down cells, the foci number was increased by SB203580 treatment, while 
having no effect on double C3G/p38 knock-down cells. This effect of p38/ inhibition 
might be a consequence of the increase in adhesion (Fig. 31C). We also studied the 
number of cells per focus and its morphology. As shown in figure 41B, both C3G and 
p38 knock-down decreased the number of cells per focus and SB203580 only 
reduced them in non-silenced cells. Moreover, the foci formed by C3G knock-down 
cells, especially those expressing p38, showed a decrease in cell-cell contacts, so 
that, cells were more disperse than those expressing C3G (Fig. 41C). 
We next asked if Rap1 was mediating C3G actions on foci formation. As shown in 
figures 42A and 42B, Rap1 knock-down led to a significant increase in the number of 
foci in p38 knock-down HCT116 cells, but not in cells expressing p38, even though 
there was a tendency to increase it. Thus, C3G and Rap1 knock-down have different 
effects on anchorage dependent growth of HCT116 cells. 
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Figure 41-C3G and p38 MAPK promote anchorage dependent growth of HCT116 cells. HCT116 
cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were 
used. When indicated, cells were treated with SB203580 (10μM) to inhibit p38/β. Anchorage dependent 
growth assay at 10 days. (A and B) Histograms show the mean ± S.E.M. of foci number (A) or the number 
of cells per focus (B) (n=5). ***p<0.001 versus non-silenced cells; 
++
p<0.01, 
+++
p<0.001 compared as 
indicated. (C) Representative images of foci from a plate (left) and individual foci (right).  
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Figure 42-Rap1 inhibits anchorage dependent growth of HCT116 cells. HCT116 cells (non-silenced (-) 
and p38 knock-down (shp38); with (shRap1) or without Rap1 knock-down) were used. Anchorage 
dependent growth of HCT116 cells at 10 days. (A) Histogram showing the mean ± S.E.M. of foci number 
(n=3). *p<0.05, **p<0.01 compared as indicated. (B) Representative images of foci from a plate. 
 
 
To further understand the role of C3G and p38 in tumor growth, we analyzed the 
effect of C3G and p38 knock-down on anchorage independent growth in soft-agar.  
As shown in figure 43A, the number of foci was highly reduced upon C3G Knock-down, 
p38 knock-down, double knock-down or p38 inhibition with SB203580. However, the 
largest reduction in the number of foci was observed in C3G depleted HCT116 cells 
expressing p38. Moreover, foci generated by non-silenced HCT116 cells are larger in 
size and double knock-down cells foci seemed to have less cells and more disperse 
(Fig. 43B). Moreover, cells from double knock-down foci did not look to be healthy and 
tend to move out of the focus. 
All these results suggest that C3G does not act through p38 to control anchorage 
independent growth in HCT116 cells.  
As shown in figure 44, foci number was increased upon Rap1 knock-down, mainly in 
p38 knock-down HCT116 cells. This indicates that Rap1 is not mediating C3G effects, 
but rather counteracting them. 
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Figure 43-C3G and p38 MAPK promote tumor growth in vitro of HCT116 cells. HCT116 cells (non-
silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were used. 
Anchorage independent growth at 14 days, in the absence or presence of SB203580 (10μM) as indicated. 
(A) Histogram shows the mean value ± S.E.M. of the foci number expressed as a fold increase of non-
silenced cells (n=4). **p<0.01, ***p<0.001 as compared with non-silenced cells. (B) Representative images 
of several (upper panel) or individual foci (lower panel). 
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Figure 44- Rap1 does not promote tumor growth in vitro of HCT116 cells. HCT116 cells (non-silenced 
(-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-down; with (shRap1) or without 
Rap1 knock-down) were used. Anchorage independent growth of HCT116 cells at 14 days. Histogram 
showing the mean value ± S.E.M. of the foci number expressed as a fold increase of non-silenced cells 
(n=3). *p<0.05, **p<0.01, ***p<0.001 as compared with non-silenced cells, or as indicated.  
 
 
 
Finally, we assessed the involvement of C3G on the tumorigenic activity of HCT116 
cells in nude mice. Upon subcutaneous inoculation of control HCT116 cells, tumors 
were readily visible at 14 days and progressively grew over time (Fig. 45A and 45B). 
Tumor sizes were significantly reduced in cells subject to either C3G or p38 knock-
down. Tumor growth was essentially undetectable in cells subject to double knock-
down. This potential collaboration between C3G and p38 promoting tumor growth was 
not observed in anchorage independent growth assays, where double knock-down 
HCT116 cells grew a little bit more than either C3G or p38 knock-down cells. 
All these results suggest that C3G and p38 MAPK are both promoting HCT116 cells 
foci formation and in vivo tumor growth, probably through independent mechanisms. 
  
RESULTS 
 
91 
 
 
 
 
Figure 45- C3G and p38 MAPK promote tumor growth in vivo of HCT116 cells.  Xenograft assay. 
Immunodeficient nude mice were injected subcutaneously with HCT116 cells (non-silenced (-) and p38 
knock-down (shp38); with (shC3G) or without C3G knock-down). Tumor size was calculated by the 
formula ((L/2)x(W/2))xπ, where L and W are the longest and the shortest diameter in cm, respectively. 
(A) Graph shows the mean value ± S.E.M. of tumor size at the indicated time points (n=6). ***p<0.001 
versus non-silenced cells. (B) Representative images of tumors in nude mice. 
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2.5 MECHANISMS INVOLVED IN THE REGULATION OF TUMOR GROWTH BY 
C3G AND p38 
The potential collaboration between C3G and p38 promoting tumor growth was not 
observed in anchorage independent growth assays, where double knock-down 
HCT116 cells grew more than either C3G or p38 knock-down cells. To explain this 
different effect of C3G and p38 knock-down on tumor growth in vitro and in vivo, we 
first studied the viability of HCT116 cells. We did not find significant differences in cell 
viability under basal conditions and we subjected the cells to some stimuli that could 
mimic some aspects of the in vivo tumor microenvironment. First, taking into account 
the elevated rate of oxidative metabolism that leads to the generation of high levels of 
reactive oxygen species (ROS), cells were exposed to oxidative stress. As shown in 
figure 46A, treatment with H2O2 significantly reduces cell viability in all cases, but its 
effect was more noticeable in single C3G or p38 knock-down cells and even more in 
those with double silencing.  
We also evaluated their ability to survive in suspension, and then, be able to attach. 
Cells suffer a particular type of cell death due to the absence of attachment to 
extracellular matrix (ECM) or upon cell adhesion to inappropriate location, called 
anoikis. Anoikis is a critical mechanism that prevents adherent-independent cell growth 
and attachment to an inappropriate matrix, thus avoiding the colonization of distant 
organs (Paoli et al. 2013). As shown in figure 46C, the number of adhered cells after 6 
h in suspension significantly decreased in C3G knock-down cells, regardless of the 
presence of p38. Moreover, the percentage of apoptotic cells under these conditions 
was increased, but mainly in double p38 and C3G knock-down cells (Fig. 46D). All 
this suggests that C3G-p38 depleted cells are more sensitive to the lack of 
attachment and they might dye under these conditions. 
This reduction in cell viability might explain the differences between in vitro and in vivo 
assays of tumor growth. Thus, although there was no significant decrease in the 
number of foci generated by double shp38-shC3G knock-down cells compared to 
non-silenced cells, their viability in response to different stimuli was significantly lower, 
which could explain the reduced in vivo tumor growth.  
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Figure 46-Effect of C3G and p38 knock-down on cell viability. HCT116 cells (non-silenced (-) and 
p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were used. (A) Viability assay. 
Cells were maintained in the absence of serum and treated with H2O2 2 mM for 4 h. Then, cells were fixed 
and stained with crystal violet. Histogram showing the mean value ± S.E.M. of the percentage of viable 
cells referred to untreated parental cells (100%) (n=4). ***p<0.001 versus non-silenced cells; ++p<0.01, 
+++p<0.001 compared as indicated. (B, C and D) Cell viability in suspension. Cells were maintained in 
suspension for 6 h and then, allowed to attach for 4 h. (B) Representative images of propidium iodide 
staining (fluorescence microscope), condensed nuclei are marked. (C) Histogram shows the mean value ± 
S.E.M. of the number of attached cells (n=3). *p<0.01 versus non silenced cells; +p<0.05 compared as 
indicated. (D) Histogram shows the mean value ± S.E.M. of the percentage of apoptotic cells (n=3). 
***p<0.001 versus non-silenced cells; 
+++
p<0.001 compared as indicated. 
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To further understand the potential mechanisms involved in the in vivo regulation of 
tumor growth, we analyzed the tumors from xenografts assays. Different 
immunofluorescence and immunohistochemistry analyses were performed to assess 
the morphology of tumor cells and the expression of proteins from cell-cell interactions, 
as well as the presence of apoptotic cells and stromal cells within the tumors. Both E-
cadherin (Fig. 47A) and ZO-1 (Fig. 47B) expression decreased in xenografts derived 
from C3G, p38 or C3G-p38 double silenced HCT116 cells. Additionally, E-cadherin 
was partially internalized in C3G knock-down cells expressing p38 (Fig. 47A), which 
would be in agreement with the migration and invasion data. These results suggest a 
disruption of adherent- and tight-junctions in cell-cell contacts upon C3G and/or p38 
knock-down that might impair tumor formation.  
 
 
 
 
Figure 47-Analysis of E-cadherin and ZO-1 in tumors derived from C3G, p38 and C3G-p38 knock-
down HCT116 cells. End point tumors generated from HCT116 cells (non-silenced (-) and p38 knock-
down (shp38); with (shC3G) or without C3G knock-down) were analyzed. (A) Immunofluorescence 
analysis of E-Cadherin (green) and (B) immunohistochemistry analysis of ZO-1 (brown) staining using 
specific primary antibodies.  
 
 
We also studied cell death within the tumors. As shown in figure 48A, tunel assay 
revealed the existence of a high number of dead cells in the inner part of all tumors. 
However, we found a significant increase in the number of tunel positive cells in tumors 
generated from C3G and p38 double knock-down HCT116 cells as compared with 
those produced by parental cells (Fig. 48B). This suggests that the double depletion of 
C3G and p38 induces apoptosis, resulting in the inhibition of tumor formation, which 
could explain the reduced size of the tumors generated by these cells. 
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Figure 48-Analysis of cell death in tumors derived from C3G, p38 and C3G-p38knock-down 
HCT116 cells. End point tumors generated from HCT116 cells (non-silenced (-) and p38 knock-down 
(shp38); with (shC3G) or without C3G knock-down) were analyzed. (A) Dead cells detected by tunel 
assay (black). (B) Histogram showing the mean value ± S.E.M. of the percentage of tunel positive areas 
per tumor. *p<0.05 versus non-silenced cells. 
 
 
To complete the analysis of the xenografts, we studied the presence of stromal cells 
within the tumors. As shown in figure 49A, fibroblast infiltration (-SMA positive cells) 
was increased in the tumors with either C3G and/or p38 silencing, meanwhile, 
macrophage infiltration (CD14 cells) was decreased in tumors generated by these cells 
(Fig. 49B). Moreover, the presence of vessels (MECA 32 positive cells) was increased 
upon silencing of p38 and this effect was independent of C3G in all tumors (Fig. 49C).  
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Figure 49- Analysis of infiltrated cells in tumors in tumors derived from C3G, p38 and C3G-p38 
knock-down HCT116 cells. End point tumors generated from HCT116 cells (non-silenced (-) and p38 
knock-down (shp38); with (shC3G) or without C3G knock-down) were analyzed. (A) 
Immunohistochemistry analysis of SMA (brown) and immunofluorescence analysis of (B) CD14 (green) 
and (C) MECA32 (green) staining using specific primary antibodies. 
 
 
In the tumor niche, colorectal cancer cells interact in a synergistic cross-talk with the 
host stromal microenvironment that supports tumor growth and metastasis (Gout and 
Huot 2008). So, differences between in vivo and in vitro assays could be also explained 
based on the interactions between stroma and tumor cells. TGFβ has a relevant role 
enhancing the effect of cancer-associated fibroblasts (CAFs) promoting colorectal 
cancer initiation (Calon et al. 2015). Other cytokines such as TNF or chemokines 
such as CXCL12 (SDF-1) also have a key role in stromal regulation (Kim 2012, 
Katanov et al. 2015). Thus, we next explored the effect of either C3G and/or p38 
knock-down on TGFβ, TGFβ receptor 1 (TGFβR1), CXCL12, its receptor, CXCR4, and 
TNF mRNA expression. We found that TGFβ1 mRNA level was significantly reduced 
upon C3G, p38 or double knock-down in HCT116 cells (Fig. 50), which correlates with 
the reduction in tumor sizes. TNF, CXCL12, TGFβR1 and CXCR4 mRNA levels were 
decreased in C3G-p38 double knock-down cells. Moreover, CXCL12 mRNA levels 
were also reduced upon single p38 silencing (Fig. 50). These results suggest that 
CXCL12 could play a role in p38-mediated pro-tumorigenic effect and TNF and 
CXCL12 in the concerted effect of C3G and p38 on tumor growth.  
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Figure 50-Effect of C3G and p38 knock-down on different stromal regulation factors expression. 
HCT116 cells (non-silenced (-) and p38 knock-down (shp38); with (shC3G) or without C3G knock-
down) were used. Analysis by RT-qPCR of TGFβ1, TGFβ1R, TNF, CXCL12 and CXCR4 mRNA levels in 
HCT116 cells. Results represent the mean ± S.E.M. of RQ values (n=4). *p<0.05, **p<0.01, ***p<0.001 as 
compared with non-silenced cells. 
 
 
 
As p38 and C3G seemed to have an important function controlling tumor growth, we 
studied the role of p38 and C3G in the regulation of the sphere formation capacity of 
HCT116 cells. As shown in figure 51, the number of spheres formed by p38 knock-
down HCT116 cells was significantly higher than that of parental or C3G silenced cells. 
Curiously, when both C3G and p38 were silenced, there was almost no sphere 
formation (Fig. 51), which suggests that C3G knock-down impairs the effect of p38 
depletion. Therefore, while p38 inhibits sphere formation, C3G would promote it. 
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Figure 51-Effect of C3G and p38 knock-down on sphere formation. HCT116 cells (non-silenced (-) 
and p38 knock-down (shp38); with (shC3G) or without C3G knock-down) were used. Sphere like growth 
assays. (A) Representative images of spheres taken with a phase contrast microscope and 
hematoxylin/eosin staining of the inside of a sphere formed by p38 knock-down HCT116 cells. (B) 
Histogram shows the mean value ± S.E.M. of the number of spheres at 72 h (n=3). **p<0.01 compared 
with non-silenced cells;
 +
p<0.05 compared as indicated. 
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1. p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION 
THROUGH DNA METHYLATION. ROLE IN MIGRATION, 
INVASION AND TUMOR GROWTH 
p38 MAPK can play a dual role in cancer acting either as a tumor suppressor or tumor 
promoter depending on the tumor stage and type of cancer (Wagner and Nebreda 
2009). However, the function of p38 MAPKs in cancer has not been fully characterized 
yet. At early stages of cancer progression, p38 MAPK can inhibit tumor initiation, for 
example, acting as a sensor of oxidative stress (Dolado et al. 2007), but at later stages, 
it can promote survival (Aguirre-Ghiso 2007, Schewe and Aguirre-Ghiso 2008), as well 
as migration and invasion leading to metastasis through regulation of cell motility, 
MMPs expression and/or activity (Wagner and Nebreda 2009, del Barco Barrantes and 
Nebreda 2012). Furthermore, in non-tumor cells, p38 promotes migration processes 
under different physiological and pathological conditions (Rousseau et al. 2006), which 
might be relevant during embryonic development or tissue regeneration. 
Our data uncover Fibulin 3 as a new target of p38 MAPK, which participates in the 
regulation of migration and invasion in the human HCT116 colon carcinoma cell line. 
Furthermore, we demonstrate that p38 down-regulates Fibulin 3 expression through 
DNA methylation. p38 might do so through the upregulation of DNMT3A protein 
levels, as DNMT3A protein levels highly decrease upon p38 knock-down, which 
correlates with a higher expression of Fibulin 3. In addition, the re-expresion of 
DNMT3A in p38-silenced HCT116 cells decreases Fibulin 3 levels, rescuing the effect 
of p38. Moreover, HuR would be involved in the p38-mediated up-regulation of 
DNMT3A through dnmt3a mRNA stabilization as it was demonstrated in MEFs by our 
group (M. Arechederra´s Thesis). This p38-HuR mediated upregulation of DNMT3A 
might be also operating in HCT116 cells based on the reduction of HuR protein levels 
upon p38knock-down. This would be also in agreement with the previously 
established stabilization of dnmt3b mRNA by the binding of HuR protein to its 3´UTR 
(Lopez de Silanes et al. 2009). Therefore, as dnmt3b is highly homologous to dnmt3a 
mRNA, it is reasonable that dnmt3a mRNA can be regulated in a similar way. Our data 
also agree with the reported function of p38 as a regulator of HuR. Thus, p38 was 
shown to stabilize p21 mRNA in response to γ-radiation through HuR phosphorylation, 
which leads to cytoplasmic accumulation of HuR and enhancement of its binding to the 
3´UTR of the mRNA (Lafarga et al. 2009). Similarly, p38 MAPK mediated cytoplasmic 
accumulation of HuR stabilizes survival motor neuron mRNA (Farooq et al. 2009). 
Other studies also support a role for this p38/HuR cascade in the control of the 
stability of other mRNAs, but they involve the participation of additional proteins. For 
example, p38 MAPK via MK2 also regulates the stability of TNF mRNA through 
regulation of HuR and tristetraprolin (TTP) (Tiedje et al. 2012). Hence, MK2 
phosphorylates the destabilizing factor, TTP, decreasing its affinity to the AU-rich 
element and its ability to replace HuR, which allows HuR-mediated initiation of TNF 
mRNA translation. Hyperphosphorylation of TTP via p38 MAPK is also involved in the 
up-regulation of IL-8 and VEGF in malignant gliomas (Suswam et al. 2008).  
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It is important to highlight the relevance of fibulin 3 gene silencing induced by 
hypermethylation of its regulatory sequences in cancer (Tong et al. 2011, Kimet al. 
2012). The down-regulation of fibulin 3 by hypermethylation of the promoter region is 
associated with poor prognosis in various tumors such as non-small cell lung 
carcinoma (Kim et al. 2012, 2013). However, it remains unknown which are the 
mechanisms controlling fibulin 3 gene hypermethylation. Therefore, the finding of p38 
MAPK as a novel regulator of fibulin 3 expression in a colorectal cancer model opens 
new possibilities to fully characterize the mechanisms underlying fibulin 3 actions in 
cancer. 
The group has also demonstrated this regulation in MEFs, where it was proved that 
p38-induced hyper-methylation of fibulin 3 gene regulatory sequences, leads to fibulin 
3 down-regulation (M. Arechederra´s Thesis). Hence, p38 MAPK down-regulates 
Fibulin 3 in HCT116 cells in a similar way as it does in MEFs (M. Arechederra´s 
Thesis). However, the role played by Fibulin 3 regulating migration and invasion is 
different in the two cell types. In HCT116 cells, Fibulin 3 promotes migration and 
invasion, while it inhibits these processes in MEFs. This agrees with previous data from 
the literature where Fibulin 3 was shown to act as either an activator or an inhibitor of 
migration and invasion. For example, in glioma and pancreatic adenocarcinoma, 
Fibulin 3 is overexpressed and promotes cell migration and invasion (Hu et al. 2009, 
Seeliger et al. 2009). In contrast, in non-small cell lung cancer cell lines Fibulin 3 is a 
negative regulator of invasiveness, so those cell lines where fibulin 3 is silenced by 
promoter methylation, became highly invasive (Kim et al. 2012). Activation of Wnt/β-
catenin signaling and MMP7 expression (Chen et al. 2014), as well as epithelial to 
mesenchymal transition (EMT) and shelf-renewal of lung cancer stem cells contributes 
to lung cancer invasion and metastasis induced by this down-regulation of Fibulin 3 
(Kim et al, 2013). In addition, Fibulin 3 is a negative regulator of invasiveness in 
nasopharyngeal carcinomas (Hwang et al. 2010). On the other hand, although fibulin-3 
down-regulation in colorectal cancer was correlated with lymph node metastasis and 
poor survival in a high percentage of patients (Tong et al. 2011), in the HCT116 colon 
carcinoma cell line we have demonstrated that fibulin 3 silencing inhibits migration, 
invasion and tumor growth. This raises the possibility that Fibulin 3 could play different 
roles in colon carcinoma depending on the tumor stage. 
During cell migration and invasion, MMPs are relevant for extracellular matrix 
degradation (Kessenbrock et al. 2011). We have found that MMPs are mediators of 
p38 and Fibulin 3 effects on invasion in HCT116 cells. In particular, there is a good 
correlation between MMP2/9 activities and the invasive capacity suggesting their 
involvement, which was further supported by the impairment of invasion by a broad 
spectrum MMP inhibitor. Moreover, p38 is a positive regulator of these MMPs, in 
agreement with data from the literature (Xu et al. 2006, Hou et al. 2009, Loesch et al. 
2010, Kessenbrock et al. 2011, del Barco Barrantes and Nebreda 2012, Ren et al. 
2013).  
Curiously, in our model, Fibulin 3 activates p38/β and its effect on migration and 
invasion appears to be dependent on this activation. Therefore, in HCT116 cells, 
Fibulin 3 favors cell migration and invasion mainly in cells expressing p38. So, the low 
level of Fibulin 3 produced by non-silenced HCT116 cells is enough to promote 
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migration and invasion acting through p38. In the A549 lung carcinoma cell line, p38 
is also activated by Fibulin 3, but its function has not been characterized (Xu et al. 
2014). In contrast, in MEFs, Fibulin 3 down-regulates p38 and p38β activation, which 
limits migration and invasion (M. Arechederra´s Thesis). Although there is not a straight 
forward explanation to the distinct regulation of p38 activation by Fibulin 3 in MEFs and 
HCT116 cells, there are a great number of differences between these two cell models 
that might account for this discrepancy. MEFs are non-tumor embryonic mesenchymal 
cells from a murine origin, while HCT116 cells are epithelial tumor cells from a human 
origin. These differences can support an opposite response mainly based on the 
following reasons: (i) epithelial and mesenchymal cells express different proteins (i.e. 
E-cadherin and N-cadherin, respectively) and (ii) HCT116, as other tumor cells, present 
several genetic alterations. Thus, it should be highlighted that the colon carcinoma 
HCT116 cell line bears a mutation in codon 13 of the ras gene, which leads to the up-
regulation of a number of signaling pathways such as Ras/ERKs, PI3K/Akt or even p38 
MAPKs. In addition, TGF1 and 2 are expressed by these cells, which would 
dysregulate additional pathways and genes expression.   
It is also noticeable the role played by p38 promoting tumor growth of HCT116 cells in 
vitro and in vivo. This is in contrast with its pro-apoptotic function, previously identified 
in HCT116 cells treated with cisplatin (Bragado et al. 2007) and with its tumor 
suppressor role in other tumor cell lines. For example, there is good evidence that 
p38 can function as a tumor suppressor in several mouse models of cancer (Hui et al. 
2007, Ventura et al. 2007, Sakurai et al. 2008, Wakeman, Schneider et al. 2012), but it 
should be noted that all these studies have been performed by genetic deletion of p38 
before tumor initiation (Gupta et al. 2015). In other tumors and in agreement with our 
results, increased levels of phosphorylated p38 have been correlated with malignancy 
(Wagner and Nebreda, 2009) such as in head and neck carcinoma (Leelahavanichkul 
et al. 2014), where p38 promotes tumor growth in vitro and in vivo. In addition, in a 
mouse model of colitis-associated tumor induction, p38 deficiency decreases cell 
proliferation and survival of colon tumors (Gupta el al. 2014). According to this, 
pharmacological p38 inhibition reduces tumor growth in patient-derived xenografts 
(Gupta el al., 205). However, initially, p38 suppresses colitis-associated tumor 
initiation maintaining an intact epithelial barrier (Gupta el al. 2014).  
In conclusion, we have described that p38 down-regulates fibulin 3 expression in 
HCT116 cells through DNA methylation. p38 might do so through the up-regulation of 
DNMT3A. In addition, we have identified Fibulin 3 as a positive regulator of cell 
migration, invasion and tumor growth acting through a mechanism dependent on p38, 
which acts as a potent inducer of tumor growth.  
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Figure 52-p38 MAPK down-regulates Fibulin 3 expression regulating cell migration, invasion and 
tumor growth in HCT116 cells. Scheme showing that p38 decreases Fibulin 3 expression in HCT116 
cells, which contributes to the regulation of migration, invasion and tumor growth. p38 acting through 
HuR would up-regulate DNMT3A, leading to fibulin 3 promoter methylation and silencing of the gene. 
Fibulin 3 promotes migration, invasion and tumor growth through p38/β activation, so that, its down-
regulation by p38 would represent a negative feed-back loop. 
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2. C3G REGULATES CELL ADHESION, MIGRATION AND 
INVASION THROUGH DOWN-REGULATION OF p38 MAPK 
ACTIVITY BY A MECHANISM NOT MEDIATED BY RAP1. 
INVOLVEMENT IN TUMOR GROWTH 
Our group has previously described in MEFs and CML cells a new functional cross-talk 
between C3G and p38 MAPK that regulates apoptosis, so that, C3G through down-
regulation of p38 MAPK activity controls cell death (Maia et al. 2009, Gutierrez-
Uzquiza et al. 2010). Depending on the cell type, Rap1 is a mediator of C3G actions 
(Maia et al. 2009) or not (Gutierrez-Uzquiza et al. 2010). Moreover, in CML both 
proteins participate in the same signaling pathway regulating cell adhesion (Maia et al. 
2013). In the present work, we have explored whether C3G and p38 could also act in 
a common pathway to regulate cell migration, invasion and tumor growth of HCT116 
cells and if C3G effects could be mediated by Rap1. 
Previous data from the literature showed that p38 MAPK plays a role in different 
aspects of cell migration and invasion (Rousseau et al. 2006, Wagner and Nebreda 
2009, del Barco Barrantes and Nebreda 2012).  C3G plays also a relevant role in cell 
migration, although its precise function has not been well characterized. C3G 
deficiency in MEFs enhances migration (Ohba et al. 2001) and accordingly, C3G 
overexpression decreased cell migration of highly invasive breast carcinoma cells 
(Dayma and Radha 2011). In contrast, its overexpression results in increased migration 
of glomerulal epithelial cells in glomerulonephritis (Rufanova et al. 2009). In agreement 
with this, C3G is required for a correct migration of sympathetic preganglionic (Yip et al. 
2012) and cortical neurons (Voss et al. 2008) and C3G/Rap1 pathway also mediates 
IGF-1-induced migration of MCF-7 breast cancer cells (Guvakova et al. 2014). 
Therefore, all these data indicate that C3G can play opposite functions in the control of 
cell motility, which might be dependent on the cell type, stimulus and/or other factors. 
In this study, we have demonstrated that in HCT116 colon carcinoma cells, C3G 
inhibits migration and invasion through down-regulation of p38 activity. In fact, C3G 
silencing enhanced migration/invasion in cells expressing p38, but not in those where 
p38 is silenced. Therefore, the previously identified C3G/p38 cascade that regulates 
cell death (Maia et al. 2009, Gutierrez-Uzquiza et al. 2010) would be also regulating 
cell migration and invasion in HCT116 cells. Data from our group indicates that this 
cascade would be also controlling these processes in MEFs (M. Arechederra´s Thesis). 
Our results also indicate that Rap1 does not mediate C3G actions on migration and 
invasion in HCT116 cells, which fits well with previous data showing that Rap1 basal 
activity remains unaltered in C3G knock-out cells (Ohba et al. 2001). This also agrees 
with our previous results showing that C3G regulated apoptosis in MEFs acting through 
p38, but independently of Rap1 (Gutierrez-Uzquiza et al. 2010). In contrast, in K562 
Rap1 is a component of the C3G/p38 cascade controlling cell death in CML cells 
(Maia et al. 2009). Indeed, C3G effects are not necessarily dependent on its GEF 
activity (Guerrero et al. 1998, Shivakrupaet al. 2003, Guerrero et al. 2004, Martin-
Encabo et al. 2007), but rather rely on specific protein-protein interactions in some 
contexts. 
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In relation to this, it is important to highlight that there are several Rap1 GEFs, different 
from C3G, able to activate Rap1 (Hattori and Minato 2003, Schultess et al. 2005, Stork 
and Dillon 2005, Pannekoek et al. 2009). Hence, depending on the cell type and the 
stimulus, specific GEFs are activated leading to Rap1 activation. 
Our findings indicate that Rap1 contributes to cell migration and invasion, which agrees 
with data from the literature, where Rap1 promotes these processes in different 
models. For example, Rap1 mediates migration, invasiveness and in vivo 
dissemination of B-cell lymphoma cells (Lin et al. 2010), invasion of renal (Kim et al. 
2012) and prostate cancer cells (Bailey et al. 2009) and migration of breast cancer cells 
(McSherry et al. 2011). Accordingly, optimal cell migration has been associated with 
cycles of Rap1 activation (Takahashi et al. 2013). 
Rap1 activates p38 in MEFs in response to different stimuli (Gutierrez-Uzquiza et al. 
2010). We have seen here that in HCT116 cells, the promigratory effect of p38 is 
impaired upon Rap1 knock-down. Thus, it is likely that Rap1 could act through p38in 
the context of migration. Although Rap1 can regulate p38 MAPK, there are 
contradictory results in the literature. For example, Rap1 is known to activate p38 in 
response to FGF-2 in endothelial cells (Yan et al. 2008). However, Rap1 has an 
inhibitory effect on p38 MAPK activation upon IL-1 stimulation (Palsson et al. 2000, 
McDermott and O'Neill 2002) and it acts in parallel with p38 MAPK to induce 
chemotaxis in monocytes treated with LPS (lipopolysaccharide) (Yi et al. 2012). 
Our results support a role for p38 in the actions of C3G on migration and invasion, as 
C3G knock-down enhances these processes acting through p38. Our group (M. 
Arechederra´s Thesis) and other authors (del Barco Barrantes and Nebreda 2012) 
have previously shown that p38 plays a role in different aspects of cell migration, 
invasion and metastasis, favoring tumor progression (del Barco Barrantes and Nebreda 
2012). p38 mediates migration in HeLa cells and MEFs through the regulation of the 
actin cytoskeleton by MK2 (Rousseau et al. 2006). In addition, in HGF/Met-activated 
cortical neurons, the Rac1/p38 cascade is crucial for migration (Segarra et al. 2006) 
and activation of p38 can also induce cytoskeletal remodeling and a migratory 
response in tumor cells by increasing Hsp27 phosphorylation (Laferriere et al. 2001). In 
this line, our results indicate that C3G acting through p38 regulate actin organization 
in HCT116 cells. Thus, in C3G silenced cells p38 promotes the formation of filopodia 
and other migratory structures. In addition, the induced internalization of ZO-1 and the 
partial loss of E-cadherin would disrupt cell-cell interactions, which would favor cell 
migration. This is also supported by in vivo data derived from xenografts analysis, 
which showed a reduction in ZO-1 and E-cadherin expression and a partial 
internalization of E-cadherin.  
According to our results, many studies have shown an overall decrease in the 
expression of E-cadherin in colorectal tumor cells (Schuhmacher et al. 1999, Rosivatz 
et al. 2004). Moreover, loss of E-cadherin has been associated with an invasive and 
aggressive phenotype of colorectal cancer cells (Tsanou et al. 2008). ZO-1 is also 
frequently down-regulated in primary CRC, although re-expressed in liver-metastases 
(Kaihara et al. 2003). Moreover, low expression of E-cadherin and high expression of 
N-cadherin are correlated with local infiltration, vascular invasion and tumor 
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dedifferentiation (Ye et al. 2015). This increased expression of N-cadherin, together 
with the low E-cadherin expression was observed in C3G knock-down cell. Additionally, 
data derived from the analysis of transcription factors involved in EMT suggest a 
possible induction of EMT upon C3G silencing that might promote invasion. 
Nevertheless, some of these changes in N-cadherin, E-cadherin and EMT transcription 
factors were also observed in single p38 and double C3G-p38 silenced cells, even 
though they are less migratory and invasive. This might be explained by their reduced 
capacity to form filopodia and other migratory structures.  
Several studies have shown the implication of MMP2 and/or MMP9 in cell migration 
and invasion (Kessenbrock et al. 2011). Moreover, p38 MAPK promotes these 
processes in a number of tumors (Wagner and Nebreda 2009). In melanoma cells 
(Estrada et al. 2009) or ovarian cancer cells (Zhou et al. 2007), p38 MAPK does so 
through regulation of MMP9. p38 also mediates tumor cell invasion in hepatocellular 
carcinoma, head and neck squamous carcinoma, glioblastoma and pancreatic cancer 
cell lines (Wagner and Nebreda 2009). Accordingly, p38 induces MMP1, MMP2, 
MMP9 and MMP13 expression in bladder, breast, liver, skin, keratinocytes and 
prostate cancer (del Barco Barrantes and Nebreda 2012). Our results also indicate that 
C3G, acting through p38 regulates MMP2 and MMP9 activities in HCT116 colon 
carcinoma cells, which correlates with its effect on cell migration and invasion. 
Similarly, in the previous section of this memory, MMP2 and MMP9 were shown to be 
regulated by p38Fibulin 3 and mediated invasion of HCT116 cells. This fits with our 
previous observations that p38 is a positive regulator of MMP2 and MMP9 activities in 
MEFs (M. Arechederra´s Thesis). 
The role of Rap1 in the control of MMP2/9 activities is different from that of C3G, which 
indicate that Rap1 is not the mediator of C3G actions on cell invasion. Results from our 
group (M. Arechederra´s Thesis) also indicate that in MEFs, Rap1, in the presence of 
p38, leads to MMP2 and MMP9 activation, which agrees with the role of Rap1 
inducing MMP9 secretion and invasion in head and neck squamous carcinoma cells 
(Mitra et al. 2008). In contrast to our results, recent published data suggest that C3G, 
acting through Rap1, might promote invasion of epithelial ovarian cancer cells through 
the induction of MMP2 and 9 secretion (Che et al. 2015).  
Our studies using HCT116 colon carcinoma cells also revealed a positive role for both 
p38 and C3G in promoting anchorage-independent growth in soft agar as well as 
tumor growth in nude mice. Our data support the concept that C3G does not regulate 
tumor growth through down-regulation of p38 activity, which differs from the 
mechanism used to regulate the migratory and invasive responses. Additionally, our 
data indicate that Rap1 does not mediate these C3G-driven effects. Accordingly, 
results derived from our in vivo studies revealed that C3G and p38 double knock-
down led to a larger reduction in tumor size than each individual knock-down. However, 
this was not observed in anchorage dependent or independent growth assays, where 
the number of foci was higher in the double knock-down than in that of C3G knock-
down, although there were less cells per focus. One plausible explanation for this 
discrepancy may be that in an in vivo context, other mechanisms may influence the 
C3G response. In fact, an enhanced cell death is produced in these tumors, which 
might impair tumor development. This possibility is also supported by the low viability 
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detected in vitro when silenced cells are submitted to oxidative stress or to a lack of 
attachment. Therefore, it is very likely that C3G, p38 or double C3G-p38 silencing 
can inhibit tumor growth through the reduction of cell viability. The low adhesion of 
single C3G silenced cells and the lack of interaction between them might also impair 
tumor growth in vivo and in vitro (anchorage-dependent growth). In fact, the low 
adhesion of C3G knock-down cells correlates with a low number of foci and p38 
inhibition with SB203580 reverts both effects. It is also important to mention that p38 
was previously shown to promote in vivo cell proliferation and survival of human colon 
carcinoma cells (Gupta et al. 2015), leading to tumor growth. This is in agreement with 
our results that support a role for p38 in cell viability in response to oxidative stress.   
Additionally, the tumor stroma could be influencing in vivo tumor growth. Tumor stroma 
plays an essential role in the development of colorectal cancer (Kalluri and Zeisberg 
2006), regulating both the initiation and progression of cancer through mechanisms 
that involved the secretion of cytokines and growth factors and/or the expression of 
their receptors (Gout and Huot 2008). In particular, TGFβ generated by colon cancer 
cells acts on cancer associated fibroblasts, present in the stroma, which contributes to 
tumor growth by increasing the frequency of tumor initiation cells (Calon et al. 2015). 
Notably, we found a remarkable reduction in the expression of TGFβ mRNA in C3G, 
p38 or double knock-down HCT116 cells, which suggests that TGFβ might play a role 
in C3G and/or p38-mediated-colon carcinoma tumor growth, as well as its receptor. 
We also found a significant decreased in TNF mRNA levels in tumors generated by 
double C3G-p38 knock-down HCT116 cells, which correlates with a decrease in 
tumor size. This is in agreement with other studies supporting a pro-tumoral role of 
TNF in CRC (De Simone et al. 2015). Moreover, CXCL12 (SDF-1)/CXCR4 pathway 
seems to play an important role in the progression of CRC and generation of liver 
metastasis (Kim et al. 2012, Kollmar et al. 2007). In this line, our studies has shown a 
decreased expression of CXCL12 and CXCR4 in double C3G-p38 knock-down cells, 
associated with the generation of small tumors in nude mice and a low invasive 
capacity. Furthermore, the reduction in CXCL12 mRNA levels in p38 knock-down 
cells, agrees with the p38-mediated SDF-1 expression in human lung stem cells (Ruiz 
et al. 2014). 
It may be also possible that other cytokines, chemokines and growth factors could be 
contributing to this response as well. 
Cancer stem cells play critical roles in CRC initiation and progression, including the 
generation of metastasis (Huang and Wicha 2008, Cherciu et al. 2014). We have found 
that p38 knock-down in HCT116 cells promotes sphere formation, which suggests 
that these cells would be able to initiate tumor growth acting as cancer stem cells 
(CSCs). Hence, although we have also demonstrated here that p38 depletion initially 
inhibits in vivo and in vitro tumor growth, the potential generation of CSCs might allow 
tumor initiation and progression over time. In contrast, C3G knock-down reversed this 
effect of p38, suggesting that C3G silencing impairs the generation of CSC. Future 
studies are required to further understand the precise role played by C3G and p38 in 
the regulation of stemness and cancer stem cells. 
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To conclude, our data demonstrate that C3G down-regulation promotes migration and 
invasion in HCT116 colon carcinoma cells through a mechanism that requires p38 
activation, but not mediated by Rap1. In contrast, down-regulation of Rap1 impairs 
migration and invasion. On the other hand, C3G and p38 promote growth of HCT116 
cells in vitro and in vivo most likely through different mechanisms. The effect of C3G 
might be dependent on its pro-adhesive and pro-survival role that would allow cell 
attachment and subsequent proliferation and/or survival of the cells. p38 might 
promote cell survival and/or proliferation as previously demonstrated (Gupta et al. 
2014). Furthermore, the regulation of the interactions of tumor cells with the stroma by 
C3G and p38 might contribute to induce tumor growth in vivo. 
 
 
Figure 53-Role of C3G/p38 cascade in the control of cell migration, invasion and tumor growth of 
HCT116 cells. Diagram showing that C3G inhibits cell migration and invasion through down-regulation of 
p38 activity by a mechanism not mediated by Rap1, which promotes these processes. Partial loss of E-
cadherin, ZO-1 internalization and F-actin cytoskeleton remodeling may mediate p38 and/or C3G actions 
on migration and invasion. MMP2/9 contribute to p38-induced invasion. In contrast, both C3G and p38 
promote tumor growth probably through independent pathways, inducing cell survival.  
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3. GENERAL DISCUSSION 
In the two parts of this Thesis, and in agreement with other groups (Gupta et al. 2014; 
Gupta et al. 2015), our results strongly indicate that p38 acts as a promoter of tumor 
growth in colon carcinoma. We have also described that p38 induces 
migration/invasion of human colon carcinoma HCT116 cells, identifying Fibulin 3 as a 
new effector of p38. Additionally, our results uncover C3G as a negative regulator of 
migration and invasion that acts through p38. In contrast, both C3G and p38 
promote tumor growth. 
In the first part of this study, we have shown that Fibulin 3 is a new target of p38 in 
human colon carcinoma HCT116 cells, which acts as a positive regulator of migration, 
invasion and tumor growth through a mechanism dependent on p38. Curiously, p38 
down-regulates Fibulin 3 expression through DNA methylation, which would lead to a 
decrease in cell migration, invasion and tumor growth. This might represent a negative 
feed-back loop to limit p38 effects. Therefore, our findings support a pro-tumorigenic 
role of Fibulin 3 in colorectal cancer, which requires p38, but it is also regulated by it. 
Based on the partial reduction in tumor size upon fibulin 3 knock-down, it might 
collaborate with other genes to induce tumor growth as it happens in lung carcinoma 
(Kim et al. 2012, Kim et al. 2014). Fibulin 3 would represent a potential new 
therapeutical target, opening new perspectives for colon cancer treatment. However, 
as previous data from the literature has associated fibulin-3 down-regulation in CRC 
with lymph node metastasis and poor survival (Tong et al. 2011), it would be important 
to further characterize how Fibulin 3 expression is regulated during CRC progression 
and its function in each step. 
In the second part of the study, we have demonstrated that C3G inhibits cell migration 
and invasion through down-regulation of p38 activity in HCT116 cells. Hence, the 
C3G/p38 cascade, previously identified by our group as a regulator of cell death 
(Maia et al. 2009, Gutierrez-Uzquiza et al. 2010), is also involved in the control of cell 
migration and invasion in HCT116 cells, as well as in MEFs (M. Arechederra´s Thesis). 
These results are in agreement with the increased migration observed in C3G-/- MEFs 
(Ohba et al. 2001) and with the reduced migration of breast carcinoma cells 
overexpressing C3G (Dayma and Radha 2011). Furthermore, we have found that Rap1 
does mediate the effects of C3G on migration and invasion of HCT116 cells, but rather 
icounteracts them. F-acting cytoskeleton remodeling is involved in the regulation of 
migration and invasion by C3G, as it has been also demonstrated in other studies (Sasi 
et al. 2015). However, we have additionally demonstrated that this function of C3G is 
dependent on p38 and is associated with a decrease in E-cadherin and ZO-1 
internalization. 
Our results have also uncovered a pro-tumoral role of C3G in colorectal cancer that 
appears to be dependent on its pro-adhesive and pro-survival function, but it is not 
mediated by down-regulation of p38 activity. 
Therefore, we have demonstrated that C3G/p38 cascade controls cell migration and 
invasion in colorectal cancer, characterizing some of the mechanisms involved. p38 
and C3G also regulate tumor growth in colorectal cancer by independent mechanisms. 
Furthermore, we have identified Fibulin 3 as a new mediator of p38 MAPK actions in 
this model. In consequence, our results open new perspectives for future studies to find 
new targets for cancer therapies. 
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Figure 54- Crosstalk between p38, Fibulin 3 and C3G in the regulation of migration, invasion and 
tumor growth in HCT116 cells.  p38 MAPK promotes cell migration, invasion and tumor growth. Fibulin 
3 also regulates these processes through p38 activation, which in term leads to down-regulation of fibulin 
3 expression, generating a negative feed-back loop. On the other hand, C3G inhibits migration and 
invasion through down-regulation of p38 MAPK activity through a Rap1 independent mechanism  
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1. p38 down-regulates Fibulin 3 expression by promoting DNA methylation 
through up-regulation of DNMT3A protein levels in the human colon carcinoma 
HCT116 cell line. 
 
2. Fibulin 3 promotes cell migration and invasion through mechanisms involving 
p38/β, as well as MMP2 and MMP9 activation. 
 
3. Fibulin 3 contributes to in vitro and in vivo tumor growth of HCT116 cells when 
p38 is expressed. 
 
4. p38 mediates migration and invasion, which is correlated with MMP2 and 
MMP9 activation. Moreover, inhibition of MMPs impairs invasion.  
 
5. p38 promotes in vitro and in vivo tumor growth of HCT116 cells. 
 
6. C3G protein levels are inversely correlated with the invasive capacity of 
different human colon carcinoma cell lines. 
 
7. C3G inhibits migration and invasion of HCT116 cells through down-regulation of 
p38 MAPK activity. 
 
8. Rap1 does not mediate, but rather counteracts, C3G inhibitory effect on 
HCT116 cells migration and invasion.  
 
9. C3G promotes cell adhesion, while p38 and Rap1 negatively regulate it.  
 
10. C3G knock-down enhances migration acting through p38, which involves ZO-
1 internalization, loss of E-cadherin and F-actin cytoskeleton re-organization. 
 
11. C3G promotes in vitro and in vivo tumor growth of HCT116 cells through a 
mechanism that does not involve down-regulation of p38 activity. In contrast, 
both proteins contribute to tumor growth by favouring cell survival. 
 
12. TFGβ1 mRNA levels decrease upon C3G, p38 and double C3G-p38 knock-
down in HCT116 cells, which correlates with inhibition of in vivo tumor growth. 
 
13. p38 knock-down enhances sphere formation in HCT116 cells. 
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CONCLUDING REMARKS 
Fibulin 3 acting through p38 promotes migration, invasion and tumor growth. 
However, p38 limits these effects of Fibulin 3 inducing its silencing by promoting DNA 
methylation, which generates a negative feed-back loop that would limit Fibulin 3 
effects. On the other hand, C3G inhibits cell migration and invasion through the 
negative regulation of p38 activity via Rap1 independent mechanisms. In contrast, 
C3G does not regulate tumor growth through inhibition of p38, but rather collaborate 
with it to induce tumor growth, probably acting through different pathways. 
. 
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ROLE OF C3G AND p38 IN THE REGULATION OF 
MIGRATION, INVASION AND TUMORAL GROWTH IN 
COLON CARCINOMA. FUNCTION OF FIBULIN 3 
 
1. INTRODUCTION 
Colorectal cancer (CRC) represents the third most common cancer type and the 
second leading cause of cancer-related death in the western world. CRC results from 
the accumulation of both acquired genetic and epigenetic changes that transform 
normal glandular epithelium into adenocarcinoma (Lao and Grady 2011), affecting 
several genes such as Apc, K-ras, dcc/Smad4 and p53 or DNA mismatch repair genes 
(Pancione et al. 2012). 
p38 MAPKs are a subfamily of Serine-Threonine kinases activated by different stimuli 
that control fundamental cellular processes such as cell growth, proliferation, 
differentiation, migration and apoptosis (Dhillon et al. 2007, Nebreda and Porras 2000, 
Wagner and Nebreda 2009). There are four p38 MAPKs isoforms in mammals: , β, δ 
and γ. p38 MAPK is ubiquitously expressed and is the most abundant isoform 
(Cuenda and Rousseau 2007). p38 is involved in the regulation of many cellular 
functions, among them, cell migration and invasion. In cancer, it can act as either a 
promoter or a suppressor of tumor growth, playing different roles during tumor 
progression (del Barco Barrantes and Nebreda 2012). 
C3G is a guanine nucleotide exchange factor (GEF) mainly for the Ras family 
members: Rap1 (Gotoh et al. 1995) and R-Ras (Gotoh et al. 1997), but it can also act 
through GEF independent mechanisms. C3G regulates several cellular functions such 
as cell death, adhesion, migration and invasion (Radha et al. 2011).  
In collaboration with Dr. Carmen Guerrero’s group (Centro del Investigación del Cáncer 
de Salamanca), our group has found a new functional relationship between C3G and 
p38 MAPK involved in the regulation of cell death in MEFs (Gutierrez-Uzquiza et al. 
2010) and in the chronic myeloid leukemia (CML) K562 cell line (Maia et al. 2009). 
Moreover, C3G and p38 act through a common regulatory pathway to control cell 
adhesion in K562 cells regulating focal adhesion proteins (Maia et al. 2013). 
Fibulins are a family of extracellular matrix secreted glycoproteins with at least seven 
members (Argraves et al. 1990, de Vega et al. 2009). Fibulins have both anti- and pro-
oncogenic effects and their expression can be deregulated in some human cancers, 
correlating with tumor progression (Obaya et al. 2012). In particular, Fibulin 3 is 
involved in the regulation of cell migration and invasion during tumor progression and 
can have a pro- or anti-tumoral effects. For example, Fibulin 3 plays a pro-tumoral role 
in glioma (Hu et al. 2009, Nandhu et al. 2014) and pancreatic adenocarcinomas 
(Camaj et al. 2009). In contrast, Fibulin 3 acts as a tumor suppressor in lung cancer   
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(Kim et al. 2012, Chen et al. 2014) and nasopharyngeal carcinoma (Hwang et al. 
2010). 
 
2. OBJECTIVES/AIMS 
1. To determine if p38 MAPK regulates fibulin 3 expression, how it does it and 
the role of Fibulin 3 as a potential mediator of p38 actions on cell migration, 
invasion and tumor growth. 
 
2. To analyze whether C3G could act through p38 MAPK to regulate migration, 
invasion and tumor growth, identifying the mechanisms involved. 
 
3. RESULTS 
1. p38 MAPK DOWN-REGULATES FIBULIN 3 EXPRESSION THROUGH 
METHYLATION OF DNA REGULATORY SEQUENCES. ROLE IN MIGRATION, 
INVASION AND TUMOR GROWTH 
 
p38 MAPK down-regulates fibulin 3 expression 
Based on our group data derived from Affymetrix microarrays showing that fibulin 3 
mRNA expression was down-regulated by p38 in MEFs, we have characterized the 
role played by p38 in the regulation of Fibulin 3 in the human colon carcinoma 
HCT116 cell line.  
We found that p38 MAPK is a negative regulator of Fibulin 3 expression in HCT116 
cells. It was known that Fibulin 3 expression was mainly regulated at the transcriptional 
level through methylation of regulatory sequences (Blackburnet al. 2003, Kim et al. 
2012). Thus, we studied whether p38 might down-regulate Fibulin 3 expression 
through DNA methylation. Treatment with 5-aza-2´-deoxicytidine (5A2dC) suggests 
that p38 represses fibulin 3 expression through hypermethylation of DNA. 
Furthermore, we have found that the DNA methylase, DNMT3A, which is up-regulated 
in cells expressing p38 MAPK, might be mediating this methylation.  The p38-
mediated up-regulation of the RNA-binding protein, HuR, would stabilize dnmt3a 
mRNA leading to an increase in DNMT3A protein levels. . 
Fibulin-3 knock-down inhibits migration and invasion of HCT116 cells 
Our results derived from the analysis of the effect of fibulin 3 knock-down indicate that 
Fibulin 3 promotes migration and invasion of human colon carcinoma HCT116 cells 
through a mechanism that appears to require p38/ activation. As expected, p38 
mediates migration and invasion in these cells. Our data also suggest that MMP2 and 9 
might be involved in the regulation of cell invasion by Fibulin 3/p38. 
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Role of Fibulin 3 in the tumorigenic capacity of HCT116 cells 
We have also studied the involvement of Fibulin 3 and p38 in the regulation of tumor 
growth by in vitro and in vivo (xenografts in nude mice) assays. We have found that 
Fibulin 3 promotes tumor growth of HCT116 cells through a mechanism dependent on 
p38. Moreover, p38 is a potent positive regulator of tumor growth in this tumor 
model. 
2. C3G REGULATES CELL ADHESION, MIGRATION AND INVASION THROUGH 
DOWN-REGULATION OF p38 MAPK ACTIVITY BY A MECHANISM NOT 
MEDIATED BY RAP1. INVOLVEMENT IN TUMOR GROWTH  
Our group has previously described that C3G through down-regulation of p38 MAPK 
activity was able to control apoptosis (Gutierrez-Uzquiza et al. 2010). Thus, we have 
also explored if the C3G/p38 cascade might be involved in the regulation of migration 
and invasion processes in HCT116 cells. 
 
C3G inhibits cell migration and invasion of HCT116 cells through down-regulation of 
p38 activity by a mechanism not mediated by Rap1. Function in cell adhesion 
Based on Oncomine database, C3G expression can be deregulated in colon 
carcinoma. Hence, we have analyzed C3G protein expression in different colorectal 
cancer lines with distinct invasive capacities and we have found that there was an 
inverse correlation between C3G protein levels and their invasive capacity. We have 
also demonstrated that C3G knock-down promotes cell migration and invasion through 
the up-regulation of p38 activity by a mechanism not mediated by Rap1 in the human 
colon carcinoma HCT116 cell line. Moreover, C3G promotes adhesion through down-
regulation of p38 activity, while Rap1 exerts an opposite effect. 
MMP2/9 might be involved in the regulation of migration and invasion processes by 
C3G/p38. Furthermore, changes in the expression of E-Cadherin and ZO-1 and their 
subcellular localization, together with F-actin re-organization might be responsible for 
the effects of C3G and p38 on these processes. 
Role of C3G in the regulation of the tumorigenic capacity of HCT116 cells 
Our results also indicate that both C3G and p38 MAPK promote in vitro and in vivo 
tumor growth of HCT116 cells, probably through independent mechanisms. Based on 
the reduction in cell viability in the absence of C3G and/or p38 expression, C3G 
and/or p38 would be favoring survival leading to tumor growth. TGFβ and other 
cytokines and/or chemokines might contribute to mediate the actions of C3G and/or 
p38 on tumor growth. 
Finally, we have found that p38 knock-down enhances sphere formation in HCT116 
cells. 
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4. DISCUSSION 
In the first part of this Thesis project, we uncover Fibulin 3 as a new target of p38 
MAPK in the human colon carcinoma HCT116 cell line. Furthermore, we demonstrate 
that p38 down-regulates fibulin 3 expression through induction of DNA methylation by 
DNMT3A. p38 might do so through the upregulation of HuR, which would stabilize 
dnmt3a mRNA, leading to an increase in DNMT3A protein levels.  The down-regulation 
of fibulin 3 by hypermethylation of the promoter region has been previously found in 
non-small cell lung carcinoma and colorectal cancer (Kim et al. 2012, Tong et al. 2011). 
However, the mechanisms underlying Fibulin 3 actions in cancer are still poorly 
understood and the finding of p38 MAPK as a novel regulator of fibulin 3 expression 
in a colorectal cancer model is important to further understand its role in tumor 
progression. In addition, Fibulin 3 was shown to act as either an activator of migration 
and invasion (Hu et al. 2009, Seeliger et al. 2009) or an inhibitor of these processes 
(Kim et al. 2012). In our study, we have identified Fibulin 3 as a positive regulator of 
cell migration, invasion and tumor growth acting through a mechanism dependent on 
p38, which also acts enhancing tumor growth of HCT116 cells.  
In the second part of our study, we show that C3G regulates migration and invasion in 
HCT116 cells through down-regulation of p38 activity in a similar way it controls cell 
death in MEFs and chronic myeloid leukemia cells (Gutierrez-Uzquiza et al. 2010, Maia 
et al. 2009). However, these actions of C3G are not mediated by Rap1. In fact, Rap1 
plays an opposite effect. This is in agreement with the increased migration observed in 
C3G-/- MEFs (Ohba et al. 2001) and the reduced migration found in breast carcinoma 
cells with C3G over-expression (Dayma and Radha 2011). Rap1 might be promoting 
cell migration and invasion through p38 activation. This positive role of Rap1 in 
invasion and migration was previously shown in other studies (Kim et al. 2012, Lin et 
al. 2010, McSherry et al. 2011). Our data also indicate that C3G acting through p38 
regulates F-actin remodeling, which together with changes in E-cadherin expression 
and ZO-1 subcellular localization would mediate their effects on migration and invasion. 
Moreover, C3G and p38 promote tumor growth of HCT116 cells in vitro and in vivo 
most likely through different mechanisms. This effect of C3G might be dependent on its 
role favoring cell adhesion and survival. p38, in agreement with previous findings 
(Gupta et al. 2015), might also induce cell survival. Additionally, C3G and p38 through 
regulation of the stroma, might also contribute to induce in vivo tumor growth. 
 
5. MAIN CONCLUSION 
p38 silences fibulin 3 expression through the induction of DNA methylation in human 
colon carcinoma HCT116 cells. This would represent a negative feed-back loop to limit 
its pro-migratory and invasive effect that is mediated by mechanisms involving 
p38activation. Moreover, Fibulin 3 promotes tumor growth acting through p38, which 
plays a pro-tumorigenic role. On the other hand, C3G inhibits cell migration and 
invasion through the negative regulation of p38 activity by a mechanism not 
dependent on Rap1. However, both C3G and p38 collaborate to induce tumor growth, 
probably acting through different pathways.   
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PAPEL DE C3G Y p38 EN LA REGULACIÓN DE LA 
MIGRACIÓN, INVASIÓN Y CRECIMIENTO TUMORAL EN 
CARCINOMA DE COLON. FUNCIÓN DE FIBULINA 3  
 
1. INTRODUCCIÓN 
El cáncer colorectal (CCR) es el tercer tipo de cáncer más común y la segunda causa 
de muerte por cáncer en el mundo occidental. El CCR aparece como resultado de la 
acumulación de alteraciones genéticas y epigenéticas que transforman el epitelio 
glandular normal en un adenocarcinoma (Lao and Grady 2011), afectando a diversos 
genes como Apc, K-ras, dcc/Smad4 y p53 o genes reparadores de apareamientos 
incorrectos en el DNA (Pancione et al. 2012).  
Las p38 MAPKs son una subfamilia de Serina/Treonina quinasas activadas por 
distintos estímulos que controlan procesos celulares fundamentales como el 
crecimiento celular, la proliferación celular, la diferenciación celular, la migración 
celular o la apoptosis (Dhillon et al. 2007, Nebreda and Porras 2000, Wagner and 
Nebreda 2009). Existen cuatro isoformas de p38 MAPKs en humanos: , β, δ y γ. 
p38 MAPK se expresa de forma ubicua y es la isoforma más abundante (Cuenda and 
Rousseau 2007). p38 está implicada en la regulación de muchas funciones celulares, 
entre ellas, cabe destacar la regulación de la migración e invasión celular en distintos 
tipos celulares. En cáncer puede actuar, tanto promoviendo como inhibiendo el 
crecimiento tumoral, desempeñando distintos papeles durante la progresión tumoral 
(del Barco Barrantes and Nebreda 2012). 
C3G es un factor activador del intercambio de nucleótidos de guanina (GEF), 
principalmente, para los miembros de la familia de Ras: Rap1 (Gotoh et al. 1995) y R-
Ras (Gotoh et al. 1997). Además, puede actuar por mecanismos independientes de su 
actividad catalítica como GEF. C3G regula diversas funciones celulares como por 
ejemplo la muerte celular, la adhesión, la migración y la invasión (Radha et al. 2011).  
En colaboración con el grupo de la Doctora Carmen Guerrero (Centro de Investigación 
del Cáncer de Salamanca), nuestro grupo ha descrito una nueva interacción funcional 
entre C3G y p38 MAPK que está implicada en la regulación de la muerte celular en 
MEFs (Gutierrez-Uzquiza et al. 2010) y en las células de leucemia mieloide crónica 
K562 (Maia et al. 2009). Así mismo, C3G y p38 actúan a través de una cascada 
común favoreciendo la adhesión celular en células K562, regulando proteínas de las 
adhesiones focales  (Maia et al. 2013). 
Las fibulinas son una familia de proteínas de la matriz extracelular que son secretadas 
como glicoproteínas al medio. Consta de, al menos, siete miembros descritos  
(Argraves et al. 1990, de Vega et al. 2009). Las fibulinas desempeñan papeles tanto 
pro- como anti-tumorales y su expresión está desregulada en algunos cánceres 
humanos, lo que se correlaciona con la progresión tumoral y la generación de 
metástasis (Obaya et al. 2012). En particular, la Fibulina 3 está implicada en la 
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regulación de la migración e invasión durante la progresión tumoral y puede ejercer un 
papel pro- o anti-tumoral. Por ejemplo, la Fibulina 3 ejerce una función pro-tumoral en 
glioma (Hu et al. 2009, Nandhu et al. 2014) y adenocarcinoma pancreático (Camaj et 
al. 2009), mientras que desempeña una función como supresor tumoral en el cáncer 
de pulmón (Kim et al. 2012, Chen et al. 2014) y el carcinoma nasofaríngeo (Hwang et 
al. 2010). 
 
2. OBJETIVOS  
1. Determinar si la p38 MAPK regula la expresión de fibulina 3, cómo lo hace y 
el papel de Fibulina 3 como potencial mediador de los efectos de p38 sobre la 
migración, la invasión y el crecimiento tumoral.  
 
2. Analizar si C3G podría actuar a través de p38 MAPK para regular la 
migración, la invasión y el crecimiento tumoral. 
 
3. RESULTADOS 
1. p38 MAPK REGULA NEGATIVAMENTE LA EXPRESIÓN DE FIBULINA 3 
MEDIANTE METILACIÓN DE SECUENCIAS REGULATORIAS DEL ADN. PAPEL 
EN LA MIGRACION CELULAR, LA INVASIÓN CELULAR Y EL CRECIMIENTO 
TUMORAL 
p38 MAPK regula negativamente la expresión de fibulina 3 
Basándonos en datos previos del grupo derivados de análisis de expresión génica 
mediante microarrays de Affymetrix que mostraban que la expresión de fibulina 3 
estaba reprimida por p38 en MEFs, hemos caracterizado el papel de p38 en la 
regulación de la expresión de fibulina 3 en la línea celular humana de carcinoma de 
colon HCT116. 
Hemos visto que p38 MAPK regula negativamente la expresión de fibulina 3 en estas 
células. Se había descrito que la expresión de fibulina 3 se regulaba principalmente a 
nivel transcripcional mediante metilación de secuencias reguladoras (Blackburn et al. 
2003, Kim et al. 2012). Por ello, estudiamos si p38 podría estar inhibiendo la 
expresión de fibulina 3 mediante metilación del DNA. Los resultados obtenidos tras el 
tratamiento de las células con 5-aza-2´-deoxicytidine (5A2dC) sugieren que p38 
reprime la expresión de fibulina 3 mediante hipermetilación del DNA. Además, 
encontramos que la DNA metilasa, DNMT3A, cuyos niveles están incrementados 
cuando se expresa p38, podría estar mediando esta metilación. El aumento de los 
niveles de la proteína de unión a RNA, HuR, inducido por p38MAPK podría favorecer 
la estabilización del RNAm de dnmt3a, lo que daría lugar a un incremento en los 
niveles proteicos de la DNMT3A. 
El silenciamiento de fibulina 3 inhibe la migración y la invasión en células HCT116  
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Nuestros resultados derivados del análisis del efecto del silenciamiento de fibulina 3 
indican que la Fibulina 3 promueve la migración y la invasión en la línea celular 
humana de cáncer colorectal HCT116 mediante un mecanismo que parece requerir la 
activación de p38 y/o p38β. Como cabía esperar, p38 media la migración y la 
invasión en estas células. Nuestros resultados también sugieren que las 
metaloproteasas MMP2 y 9 podrían estar implicadas en la regulación de la invasión 
celular por Fibulina 3/p38. 
Papel de Fibulina 3 en la capacidad tumorigénica de las células HCT116 
Además hemos estudiado la implicación de Fibulina 3 y de p38 en la regulación del 
crecimiento tumoral mediante ensayos in vitro e in vivo (xenotransplantes). Hemos 
visto que la Fibulina 3 promueve el crecimiento tumoral de las células HCT116 a través 
de un mecanismo dependiente de p38. Además, en este modelo tumoral, p38 es un 
potente activador del crecimiento tumoral. 
 
2. C3G REGULA LA ADHESIÓN, MIGRACIÓN E INVASIÓN CELULAR A 
TRAVÉS DE LA REGULACIÓN NEGATIVA DE LA ACTIVIDAD DE p38 MAPK 
MEDIANTE UN MECANISMO NO MEDIADO POR RAP1. IMPLICACIÓN EN EL 
CRECIMIENTO TUMORAL 
Nuestro grupo ha demostrado previamente que C3G a través de la regulación negativa 
de la actividad de p38 MAPK controla la apoptosis (Gutierrez-Uzquiza et al. 2010). En 
base a esto, hemos estudiado si esta cascada C3G/p38 podría estar también 
implicada en la regulación de los procesos de migración e invasión celular en las 
células HCT116. 
 
C3G inhibe la migración y la invasión de las células HCT116 mediante la regulación 
negativa de la actividad de p38 en un mecanismo no mediado por Rap1. Función en 
la regulación de la adhesión celular 
De acuerdo a la información de la base de datos Oncomine, la expresión de C3G 
puede estar desregulada en carcinoma de colon. Basándonos en ello, hemos 
analizado la expresión de C3G en diferentes líneas de cáncer colorectal con diferente 
capacidad invasiva y hemos visto que existe una correlación inversa entre los niveles 
de C3G y la capacidad invasiva de estas líneas celulares. Además, hemos demostrado 
que el silenciamiento de C3G promueve la migración y la invasión a través del 
aumento de la actividad de p38 mediante un mecanismo no mediado por Rap1 en la 
línea humana de carcinoma de colon HCT116. Así mismo, C3G promueve la adhesión 
celular mediante la inhibición de la actividad de p38, mientras que Rap1 ejerce  un 
efecto opuesto.  
MMP2 y 9 podrían estar implicadas en la regulación de la migración e invasión por 
C3G/p38. Además, los cambios en la expresión de E-Cadherina y ZO-1, así como de 
su localización subcelular, junto con la reorganización del citoesqueleto de F-actina, 
podrían ser responsables de los efectos de C3G y p38 en estos procesos celulares. 
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Papel de C3G en la regulación de la capacidad tumorigénica de las células HCT116 
Nuestros resultados sugieren que tanto C3G como p38 MAPK promueven el 
crecimiento tumoral de las células HCT116 in vitro e in vivo, probablemente mediante 
mecanismos independientes. En base a la reducción de la viabilidad celular al silenciar 
la expresión de C3G y/o p38, C3G y/o p38 favorecerían la supervivencia de estas 
células, lo que daría lugar al crecimiento tumoral. El TGFβ y otras citoquinas y/o 
quimoquinas podrían contribuir a mediar las acciones de C3G y/o p38 sobre el 
crecimiento tumoral. 
Por último, hemos encontrado que el silenciamiento de p38 aumenta la formación de 
esferas en la línea celular HCT116.  
 
4. DISCUSIÓN 
En la primera parte de esta Tesis, hemos identificado a la Fibulina 3 como una nueva 
diana de p38 MAPK en la línea celular humana de cáncer colorectal HCT116. 
Además, hemos demostrado que p38 regula negativamente la expresión de fibulina 3 
mediante la inducción de la metilación del DNA por la DNA metilasa, DNMT3A. p38 
ejercería dicho efecto aumentando los niveles de HuR, lo que daría lugar a la 
estabilización del RNAm de la dnmt3a. La regulación negativa de la expresión de 
fibulina 3 mediante hipermetilación de la región promotora ha sido previamente 
descrita en cáncer de pulmón de célula no pequeña y cáncer colorectal (Kim et al. 
2012, Tong et al. 2011). Sin embargo, los mecanismos que subyacen a las acciones 
de la Fibulina 3 en cáncer, aún no se conocen bien. Por tanto, el hecho de identificar a 
la p38 MAPK como un nuevo regulador de la expresión de fibulina 3 en el modelo de 
cáncer colorectal es importante para entender mejor el papel que juega la Fibulina 3 
en la progresión tumoral. Además, se había demostrado que la Fibulina 3 puede 
actuar tanto como activador de los procesos de migración e invasión (Hu et al. 2009, 
Seeliger et al. 2009) o como inhibidor (Kim et al. 2012). En nuestro estudio, hemos 
identificado a la Fibulina 3 como un regulador positivo de la migración, la invasión y el 
crecimiento tumoral actuando a través de mecanismos dependientes de p38, que, a 
su vez, actúa favoreciendo el crecimiento tumoral de las células HCT116. 
En la segunda parte de este estudio, hemos demostrado que C3G regula la migración 
y la invasión celular en las células HCT116 a través de la inhibición de la p38 MAPK, 
al igual que controla la muerte celular en MEFs y en células de leucemia mieloide 
crónica (Gutierrez-Uzquiza et al. 2010, Maia et al. 2009). Sin embargo, estas acciones 
de C3G no están mediadas por Rap1. De hecho, Rap1 juega un papel opuesto. Estos 
resultados están de acuerdo con el aumento de migración descrito en MEFs C3G-/- 
(Ohba et al. 2001) y la reducción en la migración encontrada en células de carcinoma 
de mama con sobre-expresión de C3G (Dayma and Radha 2011). Rap1 favorecería la 
migración y la invasión celular a través de la activación de p38. Este papel de Rap1 
como promotor de estos procesos, también ha sido descrito en otros estudios (Kim et 
al. 2012, Lin et al. 2010, McSherry et al. 2011). Nuestros datos también indican que 
C3G actuando a través de p38 regula la remodelación del citoesqueleto de F-actina. 
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Esto unido a los que cambios que induce en la expresión de E-Cadherina y la 
localización subcelular de ZO-1 mediarían sus efectos sobre la migración y la invasión. 
Además, C3G y p38 promueven el crecimiento tumoral de las células HCT116 in vitro 
e in vivo,  probablemente a través de mecanismos distintos. Este efecto de C3G sería 
dependiente de su papel como activador de la adhesión y la supervivencia celular. 
p38, también induciría la supervivencia de estas células, lo que estaría de acuerdo 
con datos previos de la literatura (Gupta et al. 2015). Adicionalmente, C3G y p38 
podrían estar implicados en la regulación del estroma en el nicho tumoral, lo que 
contribuiría a la inducción del crecimiento tumoral in vivo. 
 
5. CONCLUSIÓN FINAL 
La p38 MAPK reprime la expresión de fibulina 3 a través de la inducción de la 
metilación del DNA en las células humanas de carcinoma de colon HCT116. Esto 
podría representar un mecanismo de retro-inhibición para limitar su efecto pro-
migratorio e invasivo, que está mediado por mecanismos que implican la activación de  
p38. Además, la Fibulina 3 promueve el crecimiento tumoral actuando a través de la 
p38, la cual, juega un papel pro-tumoral.  Por otro lado, C3G inhibe la migración y la 
invasión a través de la regulación negativa de la actividad de p38 por un mecanismo 
no mediado por Rap1. Sin embargo, tanto C3G como p38 colaboran para inducir el 
crecimiento tumoral, probablemente actuando a través de diferentes rutas.
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APPENDIX 
p38MAPK Down-regulates Fibulin 3 Expression through
Methylation of Gene Regulatory Sequences
ROLE INMIGRATION AND INVASION*
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Background: p38MAPK regulates migration/invasion.
Results: p38 induces hypermethylation of Fibulin 3 gene regulatory sequences leading to Fibulin 3 down-regulation. This
contributes to regulate migration and invasion in MEFs and HCT116 cells.
Conclusion: p38 down-regulates fibulin 3 expression through promotermethylation to control p38-mediatedmigration and
invasion.
Significance: To understand the function of new p38 targets in migration/invasion and tumorigenesis.
p38 MAPKs regulate migration and invasion. However, the
mechanisms involved are only partially known. We had previ-
ously identified fibulin 3, which plays a role in migration, inva-
sion, and tumorigenesis, as a gene regulated by p38. We have
characterized in detail how p38 MAPK regulates fibulin 3
expression and its role. We describe here for the first time that
p38, p38, and p38 down-regulate fibulin 3 expression. p38
has a stronger effect, and it does so throughhypermethylation of
CpG sites in the regulatory sequences of the gene. This would be
mediated by theDNAmethylase, DNMT3A,which is down-reg-
ulated in cells lacking p38, but once re-introduced represses
Fibulin 3 expression. p38 through HuR stabilizes dnmt3a
mRNA leading to an increase inDNMT3Aprotein levels.More-
over, by knocking-down fibulin 3, we have found that Fibulin 3
inhibits migration and invasion inMEFs bymechanisms involv-
ing p38/ inhibition. Hence, p38 pro-migratory/invasive
effect might be, at least in part, mediated by fibulin 3 down-
regulation inMEFs. In contrast, in HCT116 cells, Fibulin 3 pro-
motes migration and invasion through amechanism dependent
on p38 and/or p38 activation. Furthermore, Fibulin 3 pro-
motes in vitro and in vivo tumor growth of HCT116 cells
through a mechanism dependent on p38, which surprisingly
acts as a potent inducer of tumor growth.At the same time, p38
limits fibulin 3 expression, which might represent a negative
feed-back loop.
p38 MAPKs5 are a subfamily of MAPKs activated by several
stimuli, which are involved in the regulation of themain cellular
functions, including migration and invasion (1–2). There are
four isoforms of p38 MAPKs: p38, p38, p38, and p38,
which can have both overlapping and specific functions (1).
p38 and p38 show a high grade of homology and are ubiqui-
tously expressed, while p38 and p38 have more restricted
expression patterns and some specialized functions (2).
p38 is essential for embryonic development (3–4), being
expressed at high levels (5). It regulates different cellular func-
tions. For example, it can inhibit proliferation (6–8) and adhe-
sion (9) and promote differentiation (7, 10), apoptosis (11–13),
migration (14), and invasion (15–16). In addition, it can also
activate proliferation (17–18) or survival (19–21). In fact, it is
now clear that p38 can play dual roles depending on the stim-
ulus, cellular context, or other additional factors (8). This is also
true for cancer, where p38 behaves as either a tumor suppres-
sor or promoter depending on the type of cancer and the tumor
stage (8). In a number of tumors, p38 inhibits tumor initiation
because of its role in cell cycle arrest and in the induction of
apoptosis (13). However, at later stages, it can promote survival
(19–20), migration, and invasion leading to metastasis (8, 16).
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